

## BCG vaccine

## Section

Recommendations for all immunization programmes  
All vaccines should comply with the WHO requirements for biological substances.

## Indications

Need for immunization against tuberculosis

## Japanese encephalitis vaccine

## Section

Recommendations for certain regions  
All vaccines should comply with the WHO requirements for biological substances.

## Indications

Need for immunization against certain single viral diseases

## Medicines for COVID-19

## Section

Medicines for COVID-19  
Refer to WHO living guidelines

## Indications

COVID-19

## Abacavir

## Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors  
Oral > Solid: 300 mg tablet (as sulfate)

## Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Abacavir + lamivudine

## Section

Fixed-dose combinations of antiretrovirals  
Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)

## Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Abacavir + lamivudine + lopinavir + ritonavir

## Section

Fixed-dose combinations of antiretrovirals  
Oral > Solid: 30 mg + 15 mg + 40 mg + 10 mg capsule containing oral granules

## Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Abemaciclib

### Section

Targeted therapies

### Indications

Therapeutic equivalent to palbociclib for

Other specified malignant neoplasms of breast

## Abiraterone

### Section

Hormones and antihormones

Oral > Solid: 250 mg; 500 mg

### Indications

Malignant neoplasms of prostate

## Acamprosate calcium

### Section

Medicines for alcohol use disorders

Oral > Solid > tablet: 333 mg

### Indications

Disorders due to use of alcohol

## Acetazolamide

### Section

Ophthalmological preparations > Miotics and antiglaucoma medicines

Oral > Solid: 250 mg

### Indications

Primary open-angle glaucoma

## Acetic acid

### Section

Ear, nose and throat medicines [c]

Local > Otological > drops: 2% in alcohol

### Indications

Infectious diseases of external ear

## Acetylcysteine

### Section

Antidotes and other substances used in poisonings > Specific

Parenteral > General injections > IV: 200 mg per mL in 10 mL ampoule

Oral > Liquid: 10%; 20%

### Indications

Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs

Acute or subacute hepatic failure

## Acetylsalicylic acid

| Section                                                                                                                                         | Indications                                                                                                                      |
|-------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|
| Antimigraine medicines > For treatment of acute attack<br>Oral > Solid: 300 to 500 mg                                                           | Migraine                                                                                                                         |
| Anti-platelet medicines<br>Oral > Solid: 100 mg                                                                                                 | Acute myocardial infarction<br>Cerebral ischaemic stroke                                                                         |
| Medicines for juvenile joint diseases<br>Oral > Solid: 100 to 500 mg<br>Local > Rectal > Suppository: 50 to 150 mg                              | Acute rheumatic fever without mention of heart involvement<br>Mucocutaneous lymph node syndrome<br>Juvenile idiopathic arthritis |
| Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs)<br>Oral > Solid: 100 to 500 mg<br>Local > Rectal > Suppository: 50 to 150 mg | Pain                                                                                                                             |

## Acetylsalicylic acid + atorvastatin + ramipril

| Section                                                                                                                                                                                                                                                   | Indications                                                                                                        |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|
| Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease<br>Oral > Solid > tablet: 100 mg + 20 mg + 2.5 mg; 100 mg + 20 mg + 5 mg; 100 mg + 20 mg + 10 mg; 100 mg + 40 mg + 2.5 mg; 100 mg + 40 mg + 5 mg; 100 mg + 40 mg + 10 mg | Atherosclerotic chronic arterial occlusive disease<br>Chronic ischaemic heart disease<br>Cerebral ischaemic stroke |

## Acetylsalicylic acid + simvastatin + ramipril + atenolol + hydrochlorothiazide

| Section                                                                                                                                            | Indications                                                                                                        |
|----------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|
| Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease<br>Oral > Solid > tablet: 100 mg + 20 mg + 5 mg + 50 mg + 12.5 mg | Atherosclerotic chronic arterial occlusive disease<br>Chronic ischaemic heart disease<br>Cerebral ischaemic stroke |

## Aciclovir

| Section                                                                                                                                                                                                                                                                                          | Indications                                                                                                        |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|
| Antitherpes medicines<br>Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt)<br>Oral > Liquid: 200 mg per 5 mL<br>Oral > Solid: 200 mg tablet<br><br>Ophthalmological preparations > Anti-infective agents<br>Local > Ophthalmological > Ointment: 3% w/w | <div>Zoster</div> <div>Varicella</div> <div>Herpes simplex infections</div><br><div>Herpes simplex keratitis</div> |

## Acclidinium

| Section                                                               | Indications                                                                                          |
|-----------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| Antiasthmatic and medicines for chronic obstructive pulmonary disease | Therapeutic equivalent to tiotropium bromide for<br><div>Chronic obstructive pulmonary disease</div> |

## Activated charcoal

| Section                                                                                  | Indications                                                                               |
|------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
| Antidotes and other substances used in poisonings > Non-specific<br>Oral > Other: powder | <div>Unspecified injury, poisoning or certain other consequences of external causes</div> |

## Adalimumab

| Section                                                                                                                                                                                                                                                                                                                 | Indications                                                                                                                                  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| Immunomodulators for non-malignant disease<br>Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL<br><br>Medicines for juvenile joint diseases<br>Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL | <div>Axial spondyloarthritis</div> <div>Crohn disease site</div> <div>Rheumatoid arthritis</div><br><div>Juvenile idiopathic arthritis</div> |

## Afatinib

| Section            | Indications                                                                                                   |
|--------------------|---------------------------------------------------------------------------------------------------------------|
| Targeted therapies | Therapeutic equivalent to erlotinib for<br><div>Other specified malignant neoplasms of bronchus or lung</div> |

## Albendazole

| Section                                                                                                                                  | Indications                                                                                                                                           |
|------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Intestinal anthelmintics</b><br>Oral > Solid > tablet: 400 mg (chewable, scored)<br>Oral > Solid > tablet: 400 mg (chewable, scored)) | <div>Echinococcosis</div> <div>Ascariasis</div> <div>Enterobiasis</div> <div>Trichuriasis</div> <div>Hookworm diseases</div> <div>Cysticercosis</div> |
| <b>Cysticidal medicines</b><br>Oral > Solid > tablet: 400 mg (chewable, scored); 200 mg (chewable)                                       | <div>Other specified echinococcosis</div> <div>Cysticercosis of central nervous system</div>                                                          |
| <b>Antifilarials</b><br>Oral > Solid > tablet: 400 mg (chewable, scored)                                                                 | <div>Filariasis</div>                                                                                                                                 |

## Alcohol based hand rub

| Section                                                                                        | Indications                  |
|------------------------------------------------------------------------------------------------|------------------------------|
| <b>Disinfectants</b><br>Local > Topical > Solution: 80% v/v ethanol; 75% v/v isopropyl alcohol | <div>Denatured alcohol</div> |

## Alcuronium

| Section                                                                                                                                                                | Indications                 |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|
| <b>Muscle relaxants (peripherally-acting) and cholinesterase inhibitors</b><br>Parenteral > General injections > IV: 5 mg per mL in 2 mL ampoule (alcuronium chloride) | <div>Muscle relaxants</div> |

## Alfacalcidol

| Section                                                                                                         | Indications                                                                                                    |
|-----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|
| <b>Medicines for endocrine disorders</b><br>Oral > Liquid: 2 µg per mL<br>Oral > Solid > capsule: 0.25 µg; 1 µg | <div>Chronic kidney disease, stage unspecified</div> <div>Disorders of vitamin D metabolism or transport</div> |

## All-trans retinoic acid

| Section                                                  | Indications                                                             |
|----------------------------------------------------------|-------------------------------------------------------------------------|
| <b>Targeted therapies</b><br>Oral > Solid: 10 mg capsule | <div>Acute myeloid leukaemia with recurrent genetic abnormalities</div> |

## Allopurinol

### Section

Medicines used to treat gout

Oral > Solid: 100 mg

Supportive medicines

Oral > Solid: 100 mg; 300 mg

### Indications

Gout

Tumour lysis syndrome

## Alteplase

### Section

Thrombolytic medicines

Parenteral > General injections > IV: 10 mg in vial powder for injection; 20 mg in vial powder for injection; 50 mg in vial powder for injection

### Indications

Cerebral ischaemic stroke

## Amidotrizoate

### Section

Diagnostic agents > Radiocontrast media

Parenteral > General injections > unspecified: 140 to 420 mg iodine per mL in 20 mL ampoule (as sodium or meglumine salt)

### Indications

Amidotrizoate

## Amikacin

### Section

Ophthalmological preparations > Anti-infective agents

Antituberculosis medicines

Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

Access group antibiotics

Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)

Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

### Indications

Therapeutic equivalent to [gentamicin](#) for

Other specified conjunctivitis

Therapeutic equivalent to [gentamicin](#) for

Infectious blepharitis

Multi-drug resistant *Mycobacterium tuberculosis*

### First choice

Neutropenia (high-risk)

co-prescribed with [cefotaxime](#)

Acute pyelonephritis (severe)

co-prescribed with [cefotaxime](#)

Inflammatory and other diseases of prostate (severe)

co-prescribed with [ceftriaxone](#)

Acute pyelonephritis (severe)

co-prescribed with [ceftriaxone](#)

Inflammatory and other diseases of prostate (severe)

### Second choice

co-prescribed with [cloxacillin](#)

Sepsis without septic shock

## Amiloride

### Section

Diuretics

Oral > Solid: 5 mg (hydrochloride)

### Indications

Oedema

Ascites

## Amiodarone

### Section

Antiarrhythmic medicines

Parenteral > General injections > IV: 50 mg per mL in 3 ampoule (hydrochloride)

Oral > Solid: 100 mg (hydrochloride); 200 mg (hydrochloride); 400 mg (hydrochloride)

### Indications

Cardiac arrhythmia

## Amitriptyline

| Section                                                                                     | Indications          |
|---------------------------------------------------------------------------------------------|----------------------|
| Medicines for other common symptoms in palliative care<br>Oral > Solid: 25 mg; 10 mg; 75 mg | Palliative care      |
| Medicines for depressive disorders<br>Oral > Solid: 25 mg; 75 mg                            | Depressive disorders |

## Amlodipine

| Section                                                                             | Indications            |
|-------------------------------------------------------------------------------------|------------------------|
| Antihypertensive medicines<br>Oral > Solid: 5 mg (as maleate, mesylate or besylate) | Essential hypertension |

## Amodiaquine

| Section                                                                                                               | Indications                                                             |
|-----------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| Antimalarial medicines > For curative treatment<br>Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride) | Malaria due to Plasmodium falciparum<br>Malaria due to Plasmodium vivax |

## Amodiaquine + sulfadoxine + pyrimethamine

| Section                                                                                                                                                                                                                                     | Indications |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| Antimalarial medicines > For chemoprevention<br>Oral > Solid: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] dispersible tablets in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] dispersible tablets in co-package | Malaria     |

## Amoxicillin

### Section

#### Access group antibiotics

Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid

Oral > Solid: 250 mg (anhydrous) capsule or tablet; 500 mg (anhydrous) capsule or tablet

Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid

Oral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate)

Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection

Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)

Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)

### Indications

#### First choice

Acute sinusitis

Acute otitis media

Acute pharyngitis

Acute malnutrition in infants, children or adolescents (complicated) [children]

Acute malnutrition in infants, children or adolescents (uncomplicated) [children]

Chronic obstructive pulmonary disease with acute exacerbation

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

co-prescribed with [gentamicin](#)

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with [gentamicin](#)

Sepsis without septic shock

#### Second choice

Bacterial meningitis

#### Other indications

Bacterial infection of unspecified site

Infectious cystitis

## Amoxicillin + clavulanic acid

### Section

#### Access group antibiotics

Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection

Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Oral > Liquid: 250 mg + 62.5 mg per 5 mL powder for oral liquid; 125 mg + 31.25 mg per 5 mL powder for oral liquid

Oral > Solid: 500 mg + 125 mg tablet

Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) powder for oral liquid

Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)

Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)

Oral > Liquid: 125 mg + 31.25 mg powder for oral liquid; 250 mg + 62.5 mg powder for oral liquid

#### Antituberculosis medicines

Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg per 5 mL (as potassium salt) powder for oral liquid

Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)

### Indications

#### First choice

Peritoneal abscess (mild-moderate)

Neutropenia (low-risk)

Bacterial cellulitis, erysipelas or lymphangitis

Acute sinusitis

Peritonitis (mild-moderate)

Infectious cystitis

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

Chronic obstructive pulmonary disease with acute exacerbation

#### Second choice

Other specified prophylactic measures

Acute otitis media

Osteomyelitis or osteitis

Bacterial infection of joint

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

co-prescribed with clarithromycin

Bacterial pneumonia (Community-acquired pneumonia - severe)

#### Other indications

Bacterial infection of unspecified site

Multi-drug resistant Mycobacterium tuberculosis

## Amphotericin B

### Section

#### Antifungal medicines

Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)

#### Antileishmaniasis medicines

Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)

### Indications

Blastomycosis

Cryptococcosis

Candidosis

Coccidioidomycosis

Histoplasmosis

Sporotrichosis

Aspergillosis

Visceral leishmaniasis

## Ampicillin

### Section

#### Access group antibiotics

Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection

Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension

Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)

### Indications

#### First choice

co-prescribed with gentamicin

Peritoneal abscess (severe)

co-prescribed with gentamicin

Sepsis without septic shock

co-prescribed with gentamicin

Peritoneal abscess (mild-moderate)

co-prescribed with gentamicin

Peritonitis (severe)

co-prescribed with gentamicin

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescribed with gentamicin

Peritonitis (mild-moderate)

co-prescribed with gentamicin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

#### Second choice

Bacterial meningitis

#### Other indications

Bacterial infection of unspecified site

## Anakinra

### Section

Medicines for juvenile joint diseases

Parenteral > General injections > SC: 100 mg per 0.67 mL in pre-filled syringe

### Indications

Juvenile systemic arthritis

## Anastrozole

### Section

Hormones and antihormones

Oral > Solid: 1 mg tablet

### Indications

Other specified malignant neoplasms of breast

Malignant neoplasms of breast

## Anidulafungin

### Section

Antifungal medicines

### Indications

Therapeutic equivalent to micafungin for

Systemic or invasive candidosis

## Ansuvimab

### Section

Medicines for Ebola virus disease

Parenteral > General injections > IV: 400 mg powder for injection

### Indications

Ebola virus disease

## Anti-d immunoglobulin

### Section

Human immunoglobulins

Parenteral > General injections > IV: 250 µg in single-dose vial

Parenteral > General injections > IM: 250 µg in single-dose vial

### Indications

Maternal care for red cell antibodies

Rh incompatibility reaction

## Anti-rabies immunoglobulin

### Section

Human immunoglobulins

Parenteral > General injections > IM: 150 IU per mL in vial

Parenteral > Locoregional injections > Other: 150 IU per mL in vial

### Indications

Rabies

## Anti-rabies virus monoclonal antibodies

| Section                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Indications            |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|
| <a href="#">Immunologicals</a> > <a href="#">Sera, immunoglobulins and monoclonal antibodies</a><br>Parenteral > <a href="#">Locoregional injections</a> > <a href="#">Intradermal</a> : 40 IU per mL in 1.25 mL vial (human); 40 IU per mL in 2.5 mL vial (human); 100 IU per mL in 2.5 mL vial (human); 300 IU per mL in 10 mL vial (murine); 600 IU per mL in 1 mL vial (murine); 600 IU per mL in 2.5 mL vial (murine); 600 IU per mL in 5 mL vial (murine) | <a href="#">Rabies</a> |

## Anti-tetanus immunoglobulin

| Section                                                                                                                        | Indications             |
|--------------------------------------------------------------------------------------------------------------------------------|-------------------------|
| <a href="#">Human immunoglobulins</a><br>Parenteral > <a href="#">General injections</a> > <a href="#">IM</a> : 500 IU in vial | <a href="#">Tetanus</a> |

## Antirabies hyperimmune serum

| Section                                                                                                                                                                                                     | Indications            |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|
| <a href="#">Immunologicals</a> > <a href="#">Sera, immunoglobulins and monoclonal antibodies</a><br>Parenteral > <a href="#">General injections</a> > <a href="#">unspecified</a> : 1000 IU in 5 mL ampoule | <a href="#">Rabies</a> |

## Antivenom immunoglobulin

| Section                                                                                                                                                                    | Indications                                                                                                                       |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|
| <a href="#">Immunologicals</a> > <a href="#">Sera, immunoglobulins and monoclonal antibodies</a><br>Parenteral > <a href="#">General injections</a> > <a href="#">IV</a> : | <a href="#">Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified</a> |

## Antivenom sera

| Section                                                                                                                                                                    | Indications                                                                                                                       |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|
| <a href="#">Immunologicals</a> > <a href="#">Sera, immunoglobulins and monoclonal antibodies</a><br>Parenteral > <a href="#">General injections</a> > <a href="#">IV</a> : | <a href="#">Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified</a> |

## Apixaban

| Section                                         | Indications                                                                                                                                                                                                                                           |
|-------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <a href="#">Medicines affecting coagulation</a> | <a href="#">Therapeutic equivalent to <a href="#">dabigatran</a> for</a><br><a href="#">Venous thromboembolism</a><br><a href="#">Therapeutic equivalent to <a href="#">dabigatran</a> for</a><br><a href="#">Other specified atrial fibrillation</a> |

## Aprepitant

| Section                                                                                                                     | Indications        |
|-----------------------------------------------------------------------------------------------------------------------------|--------------------|
| Antiemetic medicines<br>Oral > Liquid: 125 mg powder for oral suspension (in sachet)<br>Oral > Solid: 80 mg; 125 mg; 165 mg | Nausea or vomiting |

## Aripiprazole

| Section                           | Indications                                                                                     |
|-----------------------------------|-------------------------------------------------------------------------------------------------|
| Medicines for psychotic disorders | Therapeutic equivalent to risperidone for<br>Schizophrenia or other primary psychotic disorders |

## Arsenic trioxide

| Section                                                                                                                                                           | Indications                                                  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|
| Cytotoxic medicines<br>Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion | Acute myeloid leukaemia with recurrent genetic abnormalities |

## Artemether

| Section                                                                                                                                | Indications                                                             |
|----------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| Antimalarial medicines > For curative treatment<br>Parenteral > General injections > IM: 80 mg per mL in 1 mL ampoule (oily injection) | Malaria due to Plasmodium falciparum<br>Malaria due to Plasmodium vivax |

## Artemether + lumefantrine

| Section                                                                                                                   | Indications                                                             |
|---------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| Antimalarial medicines > For curative treatment<br>Oral > Solid: 20 mg + 120 mg tablet; 20 mg + 120 mg dispersible tablet | Malaria due to Plasmodium falciparum<br>Malaria due to Plasmodium vivax |

## Artesunate

| Section                                                                                                                                                                                                                                                                                                           | Indications                                                             |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| Antimalarial medicines > For curative treatment<br>Parenteral > General injections > IV: 60 mg in ampoule containing anhydrous artesunic acid with a separate ampoule of 5% sodium bicarbonate solution<br>Oral > Solid: 50 mg tablet<br>Local > Rectal > Other: 50 mg capsules; 200 mg capsules; 100 mg capsules | Malaria due to Plasmodium falciparum<br>Malaria due to Plasmodium vivax |

## Artesunate + amodiaquine

### Section

Antimalarial medicines > For curative treatment

Oral > Solid: 25 mg + 67.5 mg tablet; 50 mg + 135 mg tablet; 100 mg + 270 mg tablet

### Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

## Artesunate + mefloquine

### Section

Antimalarial medicines > For curative treatment

Oral > Solid: 25 mg + 55 mg tablet; 100 mg + 220 mg tablet

### Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

## Artesunate + pyronaridine tetraphosphate

### Section

Antimalarial medicines > For curative treatment

Oral > Solid: 60 mg + 180 mg tablet; 20 mg + 60 mg granules

### Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

## Ascorbic acid

### Section

Vitamins and minerals

Oral > Solid: 50 mg

### Indications

Scurvy

## Asparaginase

### Section

Cytotoxic medicines

Powder for injection: 10 000 IU in vial.

Parenteral > General injections > unspecified: 10000 IU in vial powder for injection

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Lymphoid leukaemia, not elsewhere classified

## Atazanavir

### Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Atazanavir + ritonavir

### Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Atenolol

### Section

Antianginal medicines

Oral > Solid: 50 mg; 100 mg

Antihypertensive medicines

Oral > Solid: 50 mg; 100 mg

### Indications

Angina pectoris

Essential hypertension

Therapeutic equivalent to [bisoprolol](#) for

Essential hypertension

## Atezolizumab

### Section

Immunomodulators

Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion

### Indications

Other specified malignant neoplasms of bronchus or lung

Therapeutic equivalent to [pembrolizumab](#) for

Other specified malignant neoplasms of bronchus or lung

## Atoltivimab + maftivimab + odesivimab

### Section

Medicines for Ebola virus disease

Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial

### Indications

Ebola virus disease

## Atorvastatin

### Section

Lipid-lowering agents

### Indications

Therapeutic equivalent to [simvastatin](#) for

Mixed hyperlipidaemia

Therapeutic equivalent to [simvastatin](#) for

Coronary atherosclerosis

## Atorvastatin + perindopril + amlodipine

| Section                                                                                                                                                                                           | Indications                                                                                                                                   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease<br>Oral > Solid > tablet: 20 mg + 5 mg + 5 mg; 20 mg + 10 mg + 10 mg; 40 mg + 5 mg + 5 mg; 40 mg + 10 mg + 10 mg | <div>Atherosclerotic chronic arterial occlusive disease</div> <div>Chronic ischaemic heart disease</div> <div>Cerebral ischaemic stroke</div> |

## Atracurium

| Section                                                                                                                               | Indications                                                                                                                 |
|---------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|
| Muscle relaxants (peripherally-acting) and cholinesterase inhibitors<br>Parenteral > General injections > IV: 10 mg per mL (besylate) | <div>Muscle relaxants</div> <div>Therapeutic equivalent to <a href="#">vecuronium</a> for</div> <div>Muscle relaxants</div> |

## Atropine

| Section                                                                                                                                                  | Indications                                                                                      |
|----------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| Antidotes and other substances used in poisonings > Specific<br>Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)   | <div>Exposure to or harmful effects of undetermined intent of pesticides</div>                   |
| Preoperative medication and sedation for short-term procedures<br>Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate) | <div>Parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics</div>            |
| Diagnostic agents > Ophthalmic medicines                                                                                                                 | <div>Therapeutic equivalent to <a href="#">tropicamide</a> for</div> <div>Cycloplegic drug</div> |
| Ophthalmological preparations > Mydriatics<br>Local > Ophthalmological > Solution (eye drops): 0.1% (sulfate); 0.5% (sulfate); 1% (sulfate)              | <div>Anterior uveitis</div>                                                                      |

## Axicabtagene ciloleucel

| Section                                                                                                                                                | Indications                               |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|
| Antineoplastics and supportive medicines<br>Cell suspension for infusion: $2 \times 10^6$ anti-CD19 CAR-positive viable T-cells per kg of body weight. | <div>Diffuse large B-cell lymphomas</div> |

## Azacitidine

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 100 mg in vial powder for injection

### Indications

Myeloid leukaemia

## Azathioprine

### Section

#### Disease-modifying anti-rheumatic drugs (DMARDs)

Oral > Solid: 50 mg

#### Immunomodulators for non-malignant disease

Oral > Solid: 50 mg

Parenteral > General injections > IV: 100 mg in vial powder for injection (as sodium salt); 50 mg in vial powder for injection (as sodium salt)

Oral > Liquid: 10 mg per mL

Oral > Solid > tablet: 50 mg (scored); 25 mg

### Indications

Rheumatoid arthritis, serology unspecified

Psoriatic arthritis

Relapsing-remitting multiple sclerosis

Failure or rejection of transplanted organs or tissues

## Azithromycin

### Section

#### Ophthalmological preparations > Anti-infective agents

Local > Ophthalmological > Solution (eye drops): 1.5% eye drops

#### Watch group antibiotics

Oral > Liquid: 200 mg per 5 mL oral liquid

Oral > Solid: 250 mg (anhydrous) capsule; 500 mg (anhydrous) capsule

Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid

Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)

Oral > Solid > dosage form: 500 mg (anhydrous); 250 mg (anhydrous)

### Indications

Trachoma

#### First choice

Typhoid fever

Trachoma

Chlamydia trachomatis

Yaws

Paratyphoid fever

co-prescribed with ceftriaxone

Gonococcal infection

#### Second choice

Infectious gastroenteritis or colitis without specification of infectious agent

co-prescribed with cefixime

Gonococcal infection

## Aztreonam

### Section

Reserve group antibiotics

Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection

### Indications

Other specified bacterial diseases

## Barium sulfate

### Section

Diagnostic agents > Radiocontrast media

Oral > Liquid: Aqueous suspension

### Indications

Barium sulfate with suspending agents

## Beclometasone

### Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Respiratory > Inhalation > aerosol: 50 µg per dose (dipropionate); 250 µg per dose (dipropionatae)

### Indications

Therapeutic equivalent to budesonide for

Asthma

Asthma

## Beclometasone + formoterol

### Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

### Indications

Therapeutic equivalent to budesonide + formoterol for

Asthma

## Bedaquiline

### Section

Antituberculosis medicines

Oral > Solid: 100 mg tablet; 20 mg tablet

### Indications

Multi-drug resistant Mycobacterium tuberculosis

## Bendamustine

### Section

Cytotoxic medicines

Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL

### Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Follicular lymphoma

## Benzathine benzylpenicillin

### Section

#### Access group antibiotics

Parenteral > General injections > IM: 900 mg in vial benzylpenicillin powder for injection (= 1.2 million IU); 1.44 g in vial benzylpenicillin powder for injection (= 2.4 million IU)

### Indications

#### First choice

Syphilis

Congenital syphilis [children]

#### Other indications

Bacterial infection of unspecified site

## Benznidazole

### Section

#### American trypanosomiasis

Oral > Solid > tablet: 100 mg (scored); 50 mg (scored); 12.5 mg

### Indications

Chagas disease

## Benzoic acid + salicylic acid

### Section

#### Dermatological medicines > Antifungal medicines

Local > Topical > Cream: 6% + 3%

Local > Topical > Ointment: 6% + 3%

### Indications

Fungal infection of the skin

## Benzoyl peroxide

### Section

#### Dermatological medicines > Medicines affecting skin differentiation and proliferation

Local > Topical > Cream: 5%

Local > Topical > Lotion: 5%

### Indications

Acne

## Benzyl benzoate

### Section

#### Dermatological medicines > Scabicides and pediculicides

Local > Topical > Lotion: 25%

### Indications

Pthiriasis

Pediculosis corporis

Pediculosis capitis

Scabies

## Benzylpenicillin

### Section

#### Access group antibiotics

Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)

Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)

### Indications

#### First choice

Congenital syphilis [children]

Syphilis

co-prescribed with gentamicin

Sepsis without septic shock

co-prescribed with gentamicin

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescribed with gentamicin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

#### Second choice

Bacterial meningitis

#### Other indications

Bacterial infection of unspecified site

## Betamethasone

### Section

#### Dermatological medicines > Anti-inflammatory and antipruritic medicines

Local > Topical > Cream: 0.1% (as valerate)

Local > Topical > Ointment: 0.1% (as valerate)

### Indications

Pruritus due to skin disorder

Psoriasis of unspecified type

Dermatitis or eczema

Lichen planus

## Bevacizumab

### Section

#### Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations

Parenteral > Locoregional injections > Intravitreal: 25 mg per mL

### Indications

Age related macular degeneration

## Bicalutamide

### Section

#### Hormones and antihormones

Oral > Solid: 50 mg

### Indications

Malignant neoplasms of prostate

## Binimetinib

### Section

Targeted therapies

### Indications

Therapeutic equivalent to [trametinib](#) for

Other specified melanoma of skin

## Biperiden

### Section

Medicines for parkinsonism

Parenteral > General injections > IV: 5 mg per mL in 1 mL ampoule (lactate)

Oral > Solid: 2 mg tablet (hydrochloride)

### Indications

Parkinson disease

## Bisacodyl

### Section

Laxatives

### Indications

Therapeutic equivalent to [senna](#) for

Constipation

## Bisoprolol

### Section

Antianginal medicines

Oral > Solid: 1.25 mg; 5 mg

Medicines used in heart failure

Oral > Solid: 1.25 mg; 5 mg

Antihypertensive medicines

Oral > Solid: 1.25 mg; 5 mg

Antiarrhythmic medicines

Oral > Solid: 1.25 mg; 5 mg

### Indications

Angina pectoris

Heart failure

Essential hypertension

Cardiac arrhythmia

## Bleomycin

| Section                                                                                                                                                                          | Indications                                                                                                                                                                                                                                                        |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Cytotoxic medicines<br>Parenteral > General injections > unspecified: 15 mg in vial (as sulfate)<br>Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate) | <div>Unspecified malignant neoplasms of ill-defined or unspecified sites</div> <div>Kaposi sarcoma of unspecified primary site</div> <div>Hodgkin lymphoma</div> <div>Other specified malignant neoplasms of the ovary</div> <div>Germ cell tumour of testis</div> |

## Bortezomib

| Section                                                                                                  | Indications                    |
|----------------------------------------------------------------------------------------------------------|--------------------------------|
| Targeted therapies<br>Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection | <div>Plasma cell myeloma</div> |

## Bromocriptine

| Section                                                 | Indications                                                                                                         |
|---------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| Antiseizure medicines<br>Oral > Solid: 2.5 mg; 5 mg     | <div>Parkinson disease</div>                                                                                        |
| Medicines for disorders of the pituitary hormone system | <div>Therapeutic equivalent to cabergoline for</div> <div>Other specified benign neoplasm of endocrine glands</div> |

## Budesonide

| Section                                                                                                                                       | Indications                  |
|-----------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|
| Antiasthmatic and medicines for chronic obstructive pulmonary disease<br>Respiratory > Inhalation > aerosol: 100 µg per dose; 200 µg per dose | <div>Asthma</div>            |
| Ear, nose and throat medicines [c]<br>Local > Nasal > Spray: 100 µg per dose                                                                  | <div>Allergic rhinitis</div> |

## Budesonide + formoterol

| Section                                                                                                                                                        | Indications       |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| Antiasthmatic and medicines for chronic obstructive pulmonary disease<br>Respiratory > Inhalation > dry powder: 100 µg + 6 µg per dose; 200 µg + 6 µg per dose | <div>Asthma</div> |

## Budesonide + salmeterol

### Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

### Indications

Therapeutic equivalent to [budesonide + formoterol](#) for

Asthma

## Bumetanide

### Section

Medicines used in heart failure

### Indications

Therapeutic equivalent to [furosemide](#) for

Heart failure

Diuretics

Therapeutic equivalent to [furosemide](#) for

Anuria or oliguria

Therapeutic equivalent to [furosemide](#) for

Oedema

## Bupivacaine

### Section

Local anaesthetics

Parenteral > Locoregional injections > Spinal anaesthesia: 0.5% in 4 mL ampoule (hydrochloride) + 7.5% glucose solution

Parenteral > General injections > unspecified: 0.25% in vial (hydrochloride); 0.5% in vial (hydrochloride)

### Indications

Local anaesthetics

## Buprenorphine

### Section

Medicines for opioid use disorders

### Indications

Therapeutic equivalent to [methadone](#) for

Opioid dependence

## Bupropion

### Section

Medicines for nicotine use disorders

Oral > Solid: 150 mg sustained-release (hydrochloride)

### Indications

Nicotine dependence

## C1 esterase inhibitor

### Section

Plasma-derived medicines

Parenteral > General injections > IV: 500 IU in vial powder for injection

### Indications

Hereditary angioedema

## Cabergoline

### Section

Antiseizure medicines

Oral > Solid: 0.5 mg

Medicines for disorders of the pituitary hormone system

Oral > Solid > tablet: 0.5 mg; 1 mg

### Indications

Parkinson disease

Other specified benign neoplasm of endocrine glands

## Caffeine citrate

### Section

Medicines administered to the neonate [c]

Parenteral > General injections > IV: 20 mg per mL (equivalent to 10 mg caffeine base per mL)

Oral > Liquid: 20 mg per mL (equivalent to 10 mg caffeine base per mL)

### Indications

Apnoea of newborn

## Calamine

### Section

Dermatological medicines > Anti-inflammatory and antipruritic medicines

Local > Topical > Lotion:

### Indications

Pruritus

## Calcipotriol

### Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Local > Topical > Cream: 50 µg per mL (0.005%)

Local > Topical > Lotion: 50 µg per mL (0.005%)

Local > Topical > Ointment: 50 µg per mL (0.005%)

### Indications

Psoriasis of unspecified type

## Calcitriol

### Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Medicines for endocrine disorders

Oral > Solid > capsule: 0.25 µg; 0.5 µg

### Indications

Therapeutic equivalent to calcipotriol for

Psoriasis of unspecified type

Chronic kidney disease, stage unspecified

Disorders of vitamin D metabolism or transport

## Calcium

### Section

Vitamins and minerals

Oral > Solid: 500 mg (elemental calcium)

### Indications

Calcium deficiency

## Calcium folinate (leucovorin calcium)

### Section

Cytotoxic medicines

Oral > Solid: 15 mg tablet

Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule

Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule

Oral > Solid > tablet: 15 mg; 5 mg; 25 mg

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant neoplasm metastasis in large intestine

Malignant trophoblastic neoplasms of placenta

Burkitt lymphoma including Burkitt leukaemia

Osteosarcoma of bone and articular cartilage of unspecified sites

Malignant neoplasms of rectum

Malignant neoplasms of colon

## Calcium gluconate

### Section

Antidotes and other substances used in poisonings > Specific

Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

Vitamins and minerals

Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

### Indications

Hypermagnesaemia

Tetany due to acute calcium deficiency

## Canagliflozin

### Section

Oral hypoglycaemic agents

### Indications

Therapeutic equivalent to empagliflozin for

Type 2 diabetes mellitus

## Capecitabine

### Section

Cytotoxic medicines

Oral > Solid: 150 mg tablet; 500 mg tablet

### Indications

Malignant neoplasms of colon

Other specified malignant neoplasms of breast

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of rectum

## Capreomycin

### Section

Antituberculosis medicines

Parenteral > General injections > IV: 1000 mg powder for injection (vial)

### Indications

Multi-drug resistant Mycobacterium tuberculosis

## Captopril

### Section

Medicines used in heart failure

Oral > Solid: 25 mg

### Indications

Heart failure

## Carbachol

### Section

Ophthalmological preparations > Miotics and antiglaucoma medicines

### Indications

Therapeutic equivalent to pilocarpine for

Acute angle closure with pupillary block

Therapeutic equivalent to pilocarpine for

Ocular hypertension

Therapeutic equivalent to pilocarpine for

Primary open-angle glaucoma

## Carbamazepine

### Section

#### Antiseizure medicines

Oral > Liquid: 100 mg per 5 mL

Oral > Solid > tablet: 200 mg (scored); 100 mg (scored); 100 mg (chewable); 200 mg (chewable); 400 mg (scored)

#### Medicines for bipolar disorders

Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 400 mg

### Indications

Epilepsy or seizures

Bipolar or related disorders

## Carbetocin

### Section

#### Uterotonics

Parenteral > General injections > IV: 100 µg per mL (heat stable)

### Indications

Postpartum haemorrhage

## Carbimazole

### Section

#### Thyroid hormones and antithyroid medicines

### Indications

Therapeutic equivalent to methimazole for

Thyrotoxicosis

## Carboplatin

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL

### Indications

Other specified gliomas of brain

Other specified carcinomas of ovary

Retinoblastoma

Other specified malignant neoplasms of bronchus or lung

Malignant neoplasms of nasopharynx

Malignant neoplasms of kidney, except renal pelvis

Malignant neoplasms of breast

Osteosarcoma of bone and articular cartilage of unspecified sites

Malignant neoplasms of lip, oral cavity or pharynx

Malignant neoplasms of cervix uteri

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

## Carmellose

### Section

Ophthalmological preparations

### Indications

Therapeutic equivalent to [hypromellose](#) for

Keratoconjunctivitis sicca

## Carvedilol

### Section

Antianginal medicines

### Indications

Therapeutic equivalent to [bisoprolol](#) for

Angina pectoris

Medicines used in heart failure

Therapeutic equivalent to [bisoprolol](#) for

Heart failure

Antihypertensive medicines

Therapeutic equivalent to [bisoprolol](#) for

Essential hypertension

Antiarrhythmic medicines

Therapeutic equivalent to [bisoprolol](#) for

Cardiac arrhythmia

## Caspofungin

### Section

Antifungal medicines

### Indications

Therapeutic equivalent to [micafungin](#) for

Systemic or invasive candidosis

## Cefalexin

### Section

[Access group antibiotics](#)

Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid

Oral > Solid: 250 mg (as monohydrate)

Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)

Oral > Solid > dispersible tablet: 125 mg; 250 mg

### Indications

#### First choice

Bacterial cellulitis, erysipelas or lymphangitis

#### Second choice

Acute pharyngitis

Chronic obstructive pulmonary disease with acute exacerbation

#### Other indications

Bacterial infection of unspecified site

## Cefazolin

### Section

#### Access group antibiotics

Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection

### Indications

#### First choice

Other specified prophylactic measures

co-prescribed with [metronidazole](#)

Other specified prophylactic measures

#### Second choice

Osteomyelitis or osteitis

Bacterial infection of joint

#### Other indications

Surgical site infection

## Cefepime

### Section

#### Watch group antibiotics

Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection

### Indications

Other specified bacterial diseases

## Cefixime

### Section

#### Watch group antibiotics

Oral > Liquid: 100 mg per 5 mL powder for oral liquid

Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)

### Indications

#### Second choice

Infectious gastroenteritis or colitis without specification of infectious agent

co-prescribed with [azithromycin](#)

Gonococcal infection

## Cefotaxime

### Section

#### Watch group antibiotics

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

### Indications

#### First choice

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

Other specified pneumonia (Hospital-acquired pneumonia)

Bacterial meningitis

co-prescribed with amikacin

Inflammatory and other diseases of prostate (severe)

co-prescribed with amikacin

Acute pyelonephritis (severe)

co-prescribed with clarithromycin

Bacterial pneumonia (Community-acquired pneumonia - severe)

co-prescribed with metronidazole

Peritoneal abscess (mild-moderate)

co-prescribed with metronidazole

Peritonitis (mild-moderate)

co-prescribed with metronidazole

Peritonitis (severe)

co-prescribed with metronidazole

Peritoneal abscess (severe)

#### Second choice

Acute pyelonephritis (mild to moderate)

Osteomyelitis or osteitis

Bacterial infection of joint

Sepsis without septic shock

Inflammatory and other diseases of prostate (mild to moderate)

#### Other indications

Bacterial infection of unspecified site

## Ceftaroline

### Section

#### Reserve group antibiotics

Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection

### Indications

Other specified bacterial diseases

## Ceftazidime

### Section

#### Watch group antibiotics

Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection

### Indications

#### First choice

co-prescribed with [vancomycin](#)

Endophthalmitis

#### Other indications

[Pseudomonas aeruginosa](#) resistant to other antibiotic

## Ceftazidime + avibactam

### Section

#### Reserve group antibiotics

Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection

### Indications

Carbapenem-resistant [Pseudomonas aeruginosa](#)

Carbapenem resistant Enterobacterales

## Ceftolozane + tazobactam

### Section

#### Reserve group antibiotics

Parenteral > General injections > IV: 1 g + 0.5 g powder for injection

### Indications

Carbapenem-resistant [Pseudomonas aeruginosa](#)

## Ceftriaxone

### Section

#### Watch group antibiotics

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 2 g in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)

### Indications

#### First choice

Other specified pneumonia (Hospital-acquired pneumonia)

Paratyphoid fever

Typhoid fever

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

Bacterial meningitis

co-prescribed with [amikacin](#)

Inflammatory and other diseases of prostate (severe)

co-prescribed with [amikacin](#)

Acute pyelonephritis (severe)

co-prescribed with [azithromycin](#)

Gonococcal infection

co-prescribed with [clarithromycin](#)

Bacterial pneumonia (Community-acquired pneumonia - severe)

co-prescribed with metronidazole

Peritonitis (severe)

co-prescribed with metronidazole

Peritonitis (mild-moderate)

co-prescribed with metronidazole

Peritoneal abscess (mild-moderate)

co-prescribed with metronidazole

Necrotising fasciitis

co-prescribed with metronidazole

Peritoneal abscess (severe)

co-prescribed with vancomycin

Endophthalmitis

#### Second choice

Acute pyelonephritis (mild to moderate)

Osteomyelitis or osteitis

Inflammatory and other diseases of prostate (mild to moderate)

Bacterial infection of joint

Sepsis without septic shock

Infectious gastroenteritis or colitis without specification of infectious agent

#### Other indications

Bacterial infection of unspecified site

## Cefuroxime

### Section

#### Watch group antibiotics

Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection

### Indications

#### Second choice

Other specified prophylactic measures

## Cemiplimab

### Section

#### Immunomodulators

### Indications

Therapeutic equivalent to pembrolizumab for

Other specified malignant neoplasms of bronchus or lung

## Certolizumab pegol

| Section                                    | Indications                                                                                                                                                                                                                                                                                               |
|--------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Immunomodulators for non-malignant disease | Therapeutic equivalent to <a href="#">adalimumab</a> for<br><a href="#">Axial spondyloarthritis</a><br>Therapeutic equivalent to <a href="#">adalimumab</a> for<br><a href="#">Crohn disease site</a><br>Therapeutic equivalent to <a href="#">adalimumab</a> for<br><a href="#">Rheumatoid arthritis</a> |
| Medicines for juvenile joint diseases      | Therapeutic equivalent to <a href="#">adalimumab</a> for<br><a href="#">Juvenile idiopathic arthritis</a>                                                                                                                                                                                                 |

## Cetirizine

| Section                                         | Indications                                                                                                                             |
|-------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| Antiallergics and medicines used in anaphylaxis | Therapeutic equivalent to <a href="#">loratadine</a> for<br><a href="#">Allergic or hypersensitivity conditions of unspecified type</a> |

## Chlorambucil

| Section                                          | Indications                                                                                                                                                        |
|--------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Cytotoxic medicines<br>Oral > Solid: 2 mg tablet | <a href="#">Unspecified malignant neoplasms of ill-defined or unspecified sites</a><br><a href="#">Chronic lymphocytic leukaemia or small lymphocytic lymphoma</a> |

## Chloramphenicol

| Section                                                                                                                                                                                                                                                                                                              | Indications                                                                                                                                             |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|
| <a href="#">Access group antibiotics</a><br>Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)<br>Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection<br>Oral > Liquid: 150 mg per 5 mL (as palmitate)<br>Oral > Solid: 250 mg capsule | <b>Second choice</b><br><a href="#">Bacterial meningitis</a><br><br><b>Other indications</b><br><a href="#">Bacterial infection of unspecified site</a> |

## Chlorhexidine

| Section                                                                                                                                                                                                                                                                                                                                          | Indications                                               |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------|
| <a href="#">Medicines administered to the neonate [c]</a><br>Local > Topical > Solution: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)<br><br>Local > Topical > Gel: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)<br><br><a href="#">Antiseptics</a><br>Local > Topical > Solution: 5% (digluconate) for dilution | <div>Omphalitis of newborn</div> <div>Chlorhexidine</div> |

## Chlorine base compound

| Section                                                                                                                                                                                                                                    | Indications                                       |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------|
| <a href="#">Disinfectants</a><br>Local > Topical > Powder: 0.1% available chlorine for solution<br><br>Local > Topical > Liquid: 0.1% available chlorine for solution<br><br>Local > Topical > Solid: 0.1% available chlorine for solution | <div>Disinfectant, not elsewhere classified</div> |

## Chloroquine

| Section                                                                                                                                                                                                                                                                                                                                                      | Indications                                                                                                                                                                         |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <a href="#">Antimalarial medicines &gt; For chemoprevention</a><br>Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)<br><br>Oral > Solid: 150 mg tablet (as phosphate or sulfate)                                                                                                                                                                | <div>Malaria due to Plasmodium falciparum</div> <div>Malaria due to Plasmodium vivax</div> <div>Malaria due to Plasmodium ovale</div> <div>Malaria due to Plasmodium malariae</div> |
| <a href="#">Antimalarial medicines &gt; For curative treatment</a><br>Parenteral > General injections > IV: 40 mg per mL in 5 mL ampoule (as hydrochloride, phosphate or sulfate)<br><br>Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)<br><br>Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate) | <div>Malaria due to Plasmodium falciparum</div> <div>Malaria due to Plasmodium vivax</div>                                                                                          |
| <a href="#">Disease-modifying anti-rheumatic drugs (DMARDs)</a><br>Oral > Solid: 100 mg tablet (as phosphate or sulfate); 150 mg tablet (as phosphate or sulfate)                                                                                                                                                                                            | <div>Rheumatoid arthritis</div>                                                                                                                                                     |

## Chlorothiazide

### Section

Antihypertensive medicines

Medicines used in heart failure

### Indications

Therapeutic equivalent to hydrochlorothiazide for

Essential hypertension

Therapeutic equivalent to hydrochlorothiazide for

Heart failure

## Chloroxylonol

### Section

Disinfectants

Local > Topical > Solution: 4.8%

### Indications

Phenol disinfectant, not elsewhere classified

## Chlorpromazine

### Section

Medicines for psychotic disorders

Oral > Liquid: 25 mg per 5 mL (hydrochloride)

Oral > Solid: 100 mg (hydrochloride); 10 mg (hydrochloride); 25 mg (hydrochloride); 50 mg (hydrochloride)

Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (hydrochloride)

Oral > Solid: 100 mg (hydrochloride)

### Indications

Schizophrenia or other primary psychotic disorders

Therapeutic equivalent to haloperidol for

Schizophrenia or other primary psychotic disorders

## Chlortalidone

### Section

Antihypertensive medicines

Medicines used in heart failure

### Indications

Therapeutic equivalent to hydrochlorothiazide for

Essential hypertension

Therapeutic equivalent to hydrochlorothiazide for

Heart failure

## Chlortetracycline

### Section

Ophthalmological preparations > Anti-infective agents

### Indications

Therapeutic equivalent to tetracycline for

Other specified conjunctivitis

Therapeutic equivalent to tetracycline for

Infectious keratitis

Therapeutic equivalent to tetracycline for

Infectious blepharitis

Therapeutic equivalent to tetracycline for

Trachoma

## Cholera vaccine

### Section

Recommendations for some high-risk populations

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against cholera alone

## Ciclesonide

### Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

### Indications

Therapeutic equivalent to budesonide for

Asthma

## Ciclosporin

### Section

Immunomodulators for non-malignant disease

Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection

Oral > Liquid: 100 mg per mL

Oral > Solid > capsule: 25 mg

### Indications

Failure or rejection of transplanted organs or tissues

## Cimetidine

### Section

Antiulcer medicines

Oral > Solid: 200 mg

Parenteral > General injections > unspecified: 200 mg in 2 mL ampoule

### Indications

Peptic ulcer, site unspecified

Gastro-oesophageal reflux disease

## Ciprofloxacin

### Section

#### Watch group antibiotics

Parenteral > General injections > IV: 2 mg per mL (as hyclate)

Oral > Liquid: 250 mg per 5 mL (anhydrous)

Oral > Solid: 250 mg (as hydrochloride)

Oral > Solid: 250 mg (as hydrochloride); 500 mg (as hydrochloride)

Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)

#### Ear, nose and throat medicines [c]

Local > Otological > drops: 0.3% (as hydrochloride)

### Indications

#### First choice

Paratyphoid fever

Typhoid fever

Acute pyelonephritis (mild to moderate)

Neutropenia (low-risk)

Infectious gastroenteritis or colitis without specification of infectious agent

Inflammatory and other diseases of prostate (mild to moderate)

#### Second choice

Cholera [children]

Cholera

co-prescribed with metronidazole

Peritoneal abscess (mild-moderate)

co-prescribed with metronidazole

Peritonitis (mild-moderate)

#### Other indications

Bacterial infection of unspecified site

Infectious diseases of external ear

## Cisplatin

### Section

#### Cytotoxic medicines

Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection

Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified gliomas of brain

Other specified malignant neoplasms of the ovary

Other specified malignant neoplasms of bronchus or lung

Malignant neoplasms of nasopharynx

Germ cell tumour of testis

Osteosarcoma of bone and articular cartilage of unspecified sites

Malignant neoplasms of lip, oral cavity or pharynx

Malignant neoplasms of cervix uteri

## Cladribine

### Section

#### Medicines for multiple sclerosis

Oral > Solid > tablet: 10 mg

#### Cytotoxic medicines

Parenteral > General injections > IV: 1 mg per mL in 10 mL vial; 2 mg per mL in 5 mL vial

### Indications

Multiple sclerosis

Langerhans cell histiocytosis

## Clarithromycin

### Section

#### Watch group antibiotics

Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid

Parenteral > General injections > unspecified: 500 mg in vial powder for injection

Oral > Solid > dosage form: 500 mg; 250 mg

Oral > Solid: 500 mg

### Indications

#### First choice

co-prescribed with cefotaxime

Bacterial pneumonia (Community-acquired pneumonia - severe)

co-prescribed with ceftriaxone

Bacterial pneumonia (Community-acquired pneumonia - severe)

#### Second choice

Acute pharyngitis

co-prescribed with amoxicillin + clavulanic acid

Bacterial pneumonia (Community-acquired pneumonia - severe)

## Clindamycin

### Section

#### Access group antibiotics

Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)

Oral > Solid: 150 mg (as hydrochloride) capsule

Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection

Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)

Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride)

Oral > Solid: 150 mg (as hydrochloride)

### Indications

#### First choice

co-prescribed with piperacillin + tazobactam

Necrotising fasciitis

#### Second choice

Osteomyelitis or osteitis

Bacterial infection of joint

#### Other indications

Bacterial infection of unspecified site

## Clofazimine

| Section                                                   | Indications                                     |
|-----------------------------------------------------------|-------------------------------------------------|
| Antituberculosis medicines<br>Oral > Solid: 100 mg; 50 mg | Multi-drug resistant Mycobacterium tuberculosis |
| Antileprosy medicines<br>Oral > Solid: 100 mg; 50 mg      | Leprosy                                         |

## Clomifene

| Section                                             | Indications                                                           |
|-----------------------------------------------------|-----------------------------------------------------------------------|
| Ovulation inducers<br>Oral > Solid: 50 mg (citrate) | Female infertility without specification whether primary or secondary |

## Clomipramine

| Section                                                                                                    | Indications                   |
|------------------------------------------------------------------------------------------------------------|-------------------------------|
| Medicines for obsessive compulsive disorders<br>Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride) | Obsessive-compulsive disorder |

## Clonazepam

| Section                                       | Indications                   |
|-----------------------------------------------|-------------------------------|
| Antiseizure medicines<br>Oral > Solid: 500 µg | Generalised myoclonic seizure |

## Clopidogrel

| Section                                                | Indications                                                                        |
|--------------------------------------------------------|------------------------------------------------------------------------------------|
| Anti-platelet medicines<br>Oral > Solid: 75 mg; 300 mg | Acute ischaemic heart disease<br>Presence of coronary angioplasty implant or graft |

## Clotrimazole

| Section                                                                                                                            | Indications             |
|------------------------------------------------------------------------------------------------------------------------------------|-------------------------|
| Antifungal medicines<br>Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet | Vulvovaginal candidosis |

## Cloxacillin

### Section

#### Access group antibiotics

Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid

Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule

Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection

Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid

Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection

Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt)

### Indications

#### First choice

Bacterial cellulitis, erysipelas or lymphangitis

Bacterial infection of joint

Osteomyelitis or osteitis

#### Second choice

co-prescribed with amikacin

Sepsis without septic shock

#### Other indications

Bacterial infection of unspecified site

## Clozapine

### Section

#### Medicines for psychotic disorders

Oral > Solid: 25 mg; 50 mg; 100 mg; 200 mg

### Indications

Schizophrenia or other primary psychotic disorders

## Coagulation factor IX

### Section

#### Blood coagulation factors

Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection

### Indications

Coagulation defects, purpura or other haemorrhagic or related conditions

Haemophilia B

## Coagulation factor IX complex

### Section

#### Blood coagulation factors

### Indications

Therapeutic equivalent to coagulation factor IX for

Coagulation defects, purpura or other haemorrhagic or related conditions

Therapeutic equivalent to coagulation factor IX for

Haemophilia B

## Coagulation factor VIII

### Section

Blood coagulation factors

Parenteral > General injections > IV: 500 IU in vial powder for injection;  
250 IU in vial powder for injection; 1000 IU in vial powder for injection

### Indications

Haemophilia A

## Coal tar

### Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Local > Topical > Solution: 5%

### Indications

Psoriasis of unspecified type

## Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate

### Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 150 mg + 150 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide

### Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 150 mg + 150 mg + 200 mg + 10 mg

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Cobimetinib

### Section

Targeted therapies

### Indications

Therapeutic equivalent to trametinib for

Other specified melanoma of skin

## Codeine

### Section

Opioid analgesics

Oral > Solid: 30 mg tablet (codeine phosphate)

Antitussives

Oral > Solid: 10 mg tablet (codeine phosphate)

Medicines for diarrhoea

Oral > Solid: 30 mg tablet (codeine phosphate)

### Indications

Pain

Cough

Diarrhoea

## Colchicine

### Section

Medicines used to treat gout

Oral > Solid: 0.5 mg

### Indications

Gout

## Colecalciferol

### Section

Vitamins and minerals

Oral > Liquid: 400 IU per mL

Oral > Solid: 400 IU; 1000 IU

### Indications

Calcium deficiency

Vitamin D deficiency

Therapeutic equivalent to [ergocalciferol](#) for

Vitamin D deficiency

Therapeutic equivalent to [ergocalciferol](#) for

Calcium deficiency

## Colistin (injection)

### Section

Reserve group antibiotics

Parenteral > General injections > unspecified: 1 million IU in vial (as colistemetate sodium)

Parenteral > General injections > unspecified: 1 million IU in vial (as colistemetate sodium) (equivalent to 34 mg colistin base activity)

### Indications

Other specified bacterial diseases

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

## Compound sodium lactate solution

### Section

Solutions correcting water, electrolyte and acid-base disturbances >

Parenteral

Parenteral > General injections > IV: injectable solution

### Indications

Other specified disorders of fluid, electrolyte or acid-base balance

Hypovolaemic shock

## Condoms

### Section

Barrier methods

-

### Indications

Contact with health services for contraceptive management

## Copper-containing intrauterine device

### Section

Intrauterine devices

-

### Indications

Contact with health services for insertion of contraceptive device

## Crizotinib

### Section

Targeted therapies

Oral > Solid: 200 mg; 250 mg

Oral > Solid > capsule: 200 mg; 250 mg

### Indications

Other specified malignant neoplasms of bronchus or lung

Anaplastic large cell lymphoma, ALK-positive

## Cryoprecipitate (pathogen-reduced)

### Section

Blood and blood components

Injection: frozen liquid in bag or lyophilized powder in vial containing:

> 50 IU Factor VIII

> 100 IU vWF

> 140 mg clottable fibrinogen per unit

### Indications

Coagulation defects, purpura or other haemorrhagic or related conditions

Von Willebrand disease

Obstetric haemorrhage

## Cyanocobalamin

### Section

Antianaemia medicines

.

### Indications

Anaemias or other erythrocyte disorders

## Cyclizine

### Section

Medicines for other common symptoms in palliative care

Oral > Solid: 50 mg tablet

Parenteral > General injections > unspecified: 50 mg per mL

### Indications

Palliative care

## Cyclopentolate

| Section                                    | Indications                                                   |
|--------------------------------------------|---------------------------------------------------------------|
| Diagnostic agents > Ophthalmic medicines   | Therapeutic equivalent to tropicamide for<br>Cycloplegic drug |
| Ophthalmological preparations > Mydriatics | Therapeutic equivalent to atropine for<br>Anterior uveitis    |

## Cyclophosphamide

| Section                                                                                                                                                                                                                                                                                                                                                     | Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Cytotoxic medicines<br>Oral > Solid: 25 mg tablet<br>Parenteral > General injections > unspecified: 500 mg in vial powder for injection<br>Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection<br>Oral > Solid: 25 mg; 50 mg<br>Oral > Solid: 25 mg; 50 mg tablet | Unspecified malignant neoplasms of ill-defined or unspecified sites<br>Burkitt lymphoma including Burkitt leukaemia<br>Malignant neoplasms of breast<br>Ewing sarcoma of bone and articular cartilage of unspecified sites<br>Lymphoid leukaemia, not elsewhere classified<br>Chronic lymphocytic leukaemia or small lymphocytic lymphoma<br>Diffuse large B-cell lymphomas<br>Plasma cell myeloma<br>Other specified gliomas of brain<br>Other specified malignant neoplasms of breast<br>Malignant trophoblastic neoplasms of placenta<br>Follicular lymphoma<br>Malignant neoplasms of kidney, except renal pelvis<br>Rhabdomyosarcoma primary site<br>Hodgkin lymphoma<br>Anaplastic large cell lymphoma, ALK-negative<br>Anaplastic large cell lymphoma, ALK-positive |

## Cycloserine

| Section                                                    | Indications                                     |
|------------------------------------------------------------|-------------------------------------------------|
| Antituberculosis medicines<br>Oral > Solid: 250 mg; 125 mg | Multi-drug resistant Mycobacterium tuberculosis |

## Cytarabine

### Section

#### Cytotoxic medicines

Parenteral > General injections > unspecified: 100 mg in vial powder for injection

Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Lymphoid leukaemia, not elsewhere classified

Myeloid leukaemia

Acute myeloid leukaemia with recurrent genetic abnormalities

Burkitt lymphoma including Burkitt leukaemia

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Langerhans cell histiocytosis

## Dabigatran

### Section

#### Medicines affecting coagulation

Oral > Solid: 110 mg; 150 mg

### Indications

Venous thromboembolism

Other specified atrial fibrillation

## Dabrafenib

### Section

#### Targeted therapies

Oral > Solid: 50 mg; 75 mg

### Indications

Other specified melanoma of skin

## Dacarbazine

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection

### Indications

Hodgkin lymphoma

## Daclatasvir

### Section

#### Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

Oral > Solid: 30 mg tablet (as hydrochloride); 60 mg tablet (as hydrochloride)

### Indications

Chronic hepatitis C

## Daclatasvir + sofosbuvir

### Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

Oral > Solid: 60 mg + 400 mg

### Indications

Chronic hepatitis C

## Dactinomycin

### Section

Cytotoxic medicines

Parenteral > General injections > IV: 500 µg in vial powder for injection

### Indications

Malignant trophoblastic neoplasms of placenta

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant neoplasms of kidney, except renal pelvis

Rhabdomyosarcoma primary site

Ewing sarcoma of bone and articular cartilage of unspecified sites

## Dalteparin

### Section

Medicines affecting coagulation

### Indications

Therapeutic equivalent to [enoxaparin](#) for

Acute ischaemic heart disease

Therapeutic equivalent to [enoxaparin](#) for

Venous thromboembolism

## Dapagliflozin

### Section

Oral hypoglycaemic agents

### Indications

Therapeutic equivalent to [empagliflozin](#) for

Type 2 diabetes mellitus

## Dapsone

### Section

Antileprosy medicines

Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet

### Indications

Leprosy

## Daptomycin

### Section

Reserve group antibiotics

Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection

### Indications

Other specified bacterial diseases

## Daratumumab

### Section

Immunomodulators

Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL

### Indications

Plasma cell myeloma

## Darbepoetin alfa

### Section

Antianaemia medicines

### Indications

Therapeutic equivalent to erythropoiesis-stimulating agents for

Anaemia due to chronic disease

## Darunavir

### Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Dasabuvir

### Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

Oral > Solid: 250 mg tablet

### Indications

Chronic hepatitis C

## Dasatinib

### Section

Targeted therapies

Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet

### Indications

Chronic myeloid leukaemia, not elsewhere classified

## Daunorubicin

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)

### Indications

Lymphoid leukaemia, not elsewhere classified

Myeloid leukaemia

Acute myeloid leukaemia with recurrent genetic abnormalities

## Deferasirox

### Section

#### Other medicines for haemoglobinopathies

Oral > Solid > dispersible tablet: 100 mg; 125 mg; 250 mg; 400 mg; 500 mg

Oral > Solid > tablet: 90 mg; 180 mg; 360 mg

### Indications

Therapeutic equivalent to deferoxamine for

Thalassaemias

Other specified sickle cell disorders or other haemoglobinopathies

Thalassaemias

## Deferoxamine

### Section

#### Antidotes and other substances used in poisonings > Specific

Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)

#### Other medicines for haemoglobinopathies

Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)

### Indications

Harmful effects of drugs, medicaments or biological substances, not elsewhere classified

Thalassaemias

Other specified sickle cell disorders or other haemoglobinopathies

## Delafloxacin

### Section

#### Watch group antibiotics

Parenteral > General injections > IV: 300 mg lyophilized powder for injection

Oral > Solid: 450 mg

### Indications

Methicillin resistant *Staphylococcus aureus*

## Delamanid

### Section

#### Antituberculosis medicines

Oral > Solid: 50 mg tablet; 25 mg tablet (dispersible)

### Indications

Multi-drug resistant *Mycobacterium tuberculosis*

## Dengue vaccine

### Section

#### Recommendations for some high-risk populations

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against certain single viral diseases

## Desmopressin

### Section

#### Medicines affecting coagulation

Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate)

Local > Nasal > Spray: 10 µg per dose (acetate)

### Indications

Haemophilia A

Von Willebrand disease

## Dexamethasone

### Section

#### Other medicines administered to the mother

Parenteral > General injections > unspecified: 4 mg per mL (dexamethasone phosphate (as sodium))

#### Hormones and antihormones

Oral > Solid: 4 mg

Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)

Oral > Liquid: 2 mg per 5 mL

Oral > Solid: 2 mg; 4 mg

#### Antiallergics and medicines used in anaphylaxis

Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)

#### Medicines for other common symptoms in palliative care

Oral > Liquid: 2 mg per 5 mL

Oral > Solid: 2 mg; 4 mg

Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)

#### Antiemetic medicines

Oral > Liquid: 0.5 mg per 5 mL; 2 mg per 5 mL

Oral > Solid: 0.5 mg; 0.75 mg; 1.5 mg; 4 mg

Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)

### Indications

Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy

Plasma cell myeloma

Lymphoid leukaemia, not elsewhere classified

Burkitt lymphoma including Burkitt leukaemia

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Allergic or hypersensitivity conditions of unspecified type

Palliative care

Nausea or vomiting

## Dextran 40

### Section

Plasma substitutes

.

### Indications

Hypovolaemia

## Dextran 70

### Section

Plasma substitutes

Parenteral > General injections > IV: 6% injectable solution

### Indications

Hypovolaemia

## Diaphragms

### Section

Barrier methods

-

### Indications

Contact with health services for contraceptive management

## Diazepam

### Section

Antiseizure medicines

Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system

Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube

Medicines for other common symptoms in palliative care

Oral > Liquid: 2 mg per 5 mL

Oral > Solid: 5 mg; 10 mg

Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system

Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube

Parenteral > General injections > unspecified: 5 mg per mL

Medicines for anxiety disorders

Oral > Solid: 5 mg (scored); 2 mg (scored)

### Indications

Therapeutic equivalent to lorazepam for

Status epilepticus

Status epilepticus

Palliative care

Anxiety

## Diazoxide

| Section                                                                                                | Indications                                                  |
|--------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|
| <p>Medicines for hypoglycaemia</p> <p>Oral &gt; Liquid: 50 mg per mL</p> <p>Oral &gt; Solid: 50 mg</p> | <p>Persistent hyperinsulinaemic hypoglycaemia of infancy</p> |

## Didanosine

| Section                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Indications                                                                                                                |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|
| <p>Antiretrovirals &gt; Nucleoside/Nucleotide reverse transcriptase inhibitors</p> <p>Oral &gt; Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution</p> <p>Oral &gt; Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule</p> | <p>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</p> |

## Diethylcarbamazine

| Section                                                                                                            | Indications                 |
|--------------------------------------------------------------------------------------------------------------------|-----------------------------|
| <p>Antifilarials</p> <p>Oral &gt; Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate)</p> | <p>Lymphatic filariasis</p> |

## Digitoxin

| Section                                                                                                                                                | Indications          |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| <p>Medicines used in heart failure</p> <p>Parenteral &gt; General injections &gt; IV: 0.2 mg in 1 mL ampoule</p> <p>Oral &gt; Solid: 50 µg; 100 µg</p> | <p>Heart failure</p> |

## Digoxin

### Section

#### Antiarrhythmic medicines

Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule

Oral > Liquid: 50 µg per mL

Oral > Solid: 62.5 µg; 250 µg

#### Medicines used in heart failure

Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule; 100 µg per mL in 1 mL ampoule

Oral > Liquid: 50 µg per mL

Oral > Solid > tablet: 62.5 µg; 250 µg; 125 µg

### Indications

Cardiac arrhythmia

Heart failure

## Dihydroartemisinin + piperazine phosphate

### Section

#### Antimalarial medicines > For curative treatment

Oral > Solid: 40 mg + 320 mg tablet; 20 mg + 160 mg tablet

### Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

## Dihydroergocryptine mesylate

### Section

#### Antiseizure medicines

Oral > Solid:

### Indications

Parkinson disease

## Diloxanide

### Section

#### Antiamoebic and anti giardiasis medicines

Oral > Solid: 500 mg (furoate)

### Indications

Amoebiasis

## Dimercaprol

### Section

#### Antidotes and other substances used in poisonings > Specific

Parenteral > General injections > IM: 50 mg per mL in 2 mL ampoule

### Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

## Diphtheria antitoxin

### Section

#### Immunologicals > Sera, immunoglobulins and monoclonal antibodies

Parenteral > General injections > IM: 10000 IU in vial; 20000 IU in vial

### Indications

Need for immunization against diphtheria alone

## Diphtheria vaccine

### Section

Recommendations for all immunization programmes

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against diphtheria alone

## Diphtheria-pertussis-tetanus vaccine

### Section

Recommendations for all immunization programmes

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against diphtheria-tetanus-pertussis, combined

## Diphtheria-tetanus vaccine

### Section

Recommendations for all immunization programmes

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against combinations of infectious diseases

## Docetaxel

### Section

Cytotoxic medicines

Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL

### Indications

Other specified malignant neoplasms of breast

Malignant neoplasms of breast

Malignant neoplasms of prostate

Unspecified malignant neoplasms of ill-defined or unspecified sites

## Docusate sodium

### Section

Medicines for other common symptoms in palliative care

Oral > Liquid: 50 mg per 5 mL oral liquid

Oral > Solid: 100 mg capsule

### Indications

Palliative care

## Dolasetron

| Section                                                | Indications                                                     |
|--------------------------------------------------------|-----------------------------------------------------------------|
| Medicines for other common symptoms in palliative care | Therapeutic equivalent to ondansetron for<br>Palliative care    |
| Antiemetic medicines                                   | Therapeutic equivalent to ondansetron for<br>Nausea or vomiting |

## Dolutegravir

| Section                                                                                                  | Indications                                                                                                               |
|----------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|
| Antiretrovirals > Integrase inhibitors<br>Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored) | Human immunodeficiency virus disease<br>without mention of associated disease or<br>condition, clinical stage unspecified |

## Dolutegravir + lamivudine + tenofovir

| Section                                                                                                                                                       | Indications                                                                                                               |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|
| Fixed-dose combinations of antiretrovirals<br>Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil) | Human immunodeficiency virus disease<br>without mention of associated disease or<br>condition, clinical stage unspecified |

## Donepezil

| Section                                                                                                                                                                                                                                         | Indications                       |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|
| Medicines for diseases of the nervous system<br>Oral > Liquid: 1 mg per mL (hydrochloride)<br>Oral > Solid > tablet: 5 mg (hydrochloride); 10 mg (hydrochloride); 5 mg (hydrochloride) (orodispersible); 10 mg (hydrochloride) (orodispersible) | Dementia due to Alzheimer disease |

## Dopamine

| Section                                                                                                            | Indications                        |
|--------------------------------------------------------------------------------------------------------------------|------------------------------------|
| Medicines used in heart failure<br>Parenteral > General injections > IV: 40 mg per mL in 5 mL vial (hydrochloride) | Heart failure<br>Cardiogenic shock |

## Doxorubicin

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)

Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)

Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Rhabdomyosarcoma primary site

Follicular lymphoma

Burkitt lymphoma including Burkitt leukaemia

Ewing sarcoma of bone and articular cartilage of unspecified sites

Malignant neoplasms of breast

Lymphoid leukaemia, not elsewhere classified

Other specified malignant neoplasms of breast

Diffuse large B-cell lymphomas

Plasma cell myeloma

Malignant neoplasms of kidney, except renal pelvis

Osteosarcoma of bone and articular cartilage of unspecified sites

Kaposi sarcoma of unspecified primary site

Hodgkin lymphoma

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

## Doxorubicin (as pegylated liposomal)

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)

### Indications

Kaposi sarcoma of unspecified primary site

## Doxycycline

### Section

#### Access group antibiotics

Oral > Solid: 100 mg (as hyclate)

Parenteral > General injections > unspecified: 100 mg in vial powder for injection

Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)

Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)

Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium)

Oral > Solid: 50 mg (as hyclate); 100 mg (as hyclate)

Oral > Solid > dispersible tablet: 100 mg (as monohydrate)

#### Antimalarial medicines > For curative treatment

Oral > Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate)

#### Antimalarial medicines > For chemoprevention

Oral > Solid: 100 mg (hydrochloride or hyclate)

### Indications

#### First choice

Cholera

Chlamydia trachomatis

#### Second choice

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

Cholera [children]

Chronic obstructive pulmonary disease with acute exacerbation

#### Other indications

Bacterial infection of unspecified site

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium falciparum

## Durvalumab

### Section

#### Immunomodulators

Parenteral > General injections > IV: 120 mg per 2.4 mL in vial; 500 mg per 10 mL in vial

### Indications

Other specified malignant neoplasms of bronchus or lung

## Edoxaban

### Section

#### Medicines affecting coagulation

### Indications

Therapeutic equivalent to dabigatran for

Venous thromboembolism

Therapeutic equivalent to dabigatran for

Other specified atrial fibrillation

## Efavirenz

### Section

#### Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors

Oral > Solid: 600 mg tablet

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Efavirenz + emtricitabine + tenofovir

### Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Efavirenz + lamivudine + tenofovir

### Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Therapeutic equivalent to efavirenz + emtricitabine + tenofovir for

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Eflornithine

### Section

Medicines for the treatment of 2nd stage African trypanosomiasis

Parenteral > General injections > IV: 200 mg per mL in 50 mL bottle (hydrochloride)

### Indications

African trypanosomiasis

## Elbasvir + grazoprevir

### Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

Oral > Solid: 50 mg + 100 mg

### Indications

Chronic hepatitis C

## Empagliflozin

### Section

Oral hypoglycaemic agents

Oral > Solid: 10 mg; 25 mg

### Indications

Type 2 diabetes mellitus

## Emtricitabine

### Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

Oral > Liquid: 10 mg per mL

Oral > Solid: 200 mg

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Emtricitabine + rilpivirine + tenofovir alafenamide

### Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 200 mg + 25 mg + 25 mg

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Emtricitabine + rilpivirine + tenofovir disoproxil fumarate

### Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Emtricitabine + tenofovir

### Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Contact with or exposure to human immunodeficiency virus

## Emtricitabine + tenofovir alafenamide

### Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 200 mg + 10 mg; 200 mg + 25 mg

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Enalapril

### Section

Antihypertensive medicines

Oral > Liquid: 1 mg per mL (as hydrogen maleate)

Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)

Medicines used in heart failure

Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)

### Indications

Essential hypertension

Heart failure

## Encorafenib

### Section

#### Targeted therapies

### Indications

Therapeutic equivalent to [dabrafenib](#) for

Other specified melanoma of skin

## Enoxaparin

### Section

#### Medicines affecting coagulation

Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule

Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 120 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule

### Indications

Acute ischaemic heart disease

Venous thromboembolism

## Entecavir

### Section

#### Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors

Oral > Liquid: 0.05 mg per mL

Oral > Solid: 0.5 mg; 1 mg

### Indications

Chronic hepatitis B

## Enzalutamide

### Section

#### Hormones and antihormones

Oral > Solid: 40 mg

### Indications

Therapeutic equivalent to [abiraterone](#) for

Malignant neoplasms of prostate

Malignant neoplasms of prostate

## Ephedrine

### Section

#### Local anaesthetics

Parenteral > Locoregional injections > Spinal anaesthesia: 30 mg per mL in 1 mL ampoule (ephedrine hydrochloride)

### Indications

Cardiac complications of anaesthesia during labour or delivery

## Epinephrine

### Section

#### Antiarrhythmic medicines

Parenteral > General injections > IV: 100 µg per mL in 10 mL ampoule (as acid tartrate or hydrochloride)

#### Ophthalmological preparations > Mydriatics

Local > Ophthalmological > Solution (eye drops): 2% (as hydrochloride)

#### Antiasthmatic and medicines for chronic obstructive pulmonary disease

Parenteral > General injections > unspecified: 1 mg per mL in ampoule (as hydrochloride or hydrogen tartrate)

#### Antiallergics and medicines used in anaphylaxis

Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (as hydrochloride or hydrogen tartrate)

### Indications

Cardiac arrest

Primary open-angle glaucoma

Asthma

Chronic obstructive pulmonary disease

Anaphylaxis

## Epoetin alfa

### Section

#### Antianaemia medicines

### Indications

Therapeutic equivalent to erythropoiesis-stimulating agents for

Anaemia due to chronic disease

## Epoetin beta

### Section

#### Antianaemia medicines

### Indications

Therapeutic equivalent to erythropoiesis-stimulating agents for

Anaemia due to chronic disease

## Epoetin theta

### Section

#### Antianaemia medicines

### Indications

Therapeutic equivalent to erythropoiesis-stimulating agents for

Anaemia due to chronic disease

## Equine rabies immunoglobulin

### Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies  
Parenteral > Locoregional injections > Intradermal: 150 IU per mL in vial;  
200 IU per mL in vial; 300 IU per mL in vial; 400 IU per mL in vial

### Indications

Rabies

## Eravacycline

### Section

Reserve group antibiotics  
Parenteral > General injections > IV: 50 mg lyophilized powder for  
injection

### Indications

Carbapenem resistant Enterobacterales

## Ergocalciferol

### Section

Vitamins and minerals  
Oral > Liquid: 250 µg per mL (10 000 IU per mL)  
Oral > Solid: 1.25 mg (50 000 IU)

### Indications

Therapeutic equivalent to [colecalfiferol](#) for

Calcium deficiency

Therapeutic equivalent to [colecalfiferol](#) for

Vitamin D deficiency

Vitamin D deficiency

Calcium deficiency

## Ergometrine

### Section

Uterotonics  
Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule  
(hydrogen maleate)

### Indications

Postpartum haemorrhage

## Erlotinib

### Section

Targeted therapies  
Oral > Solid: 100 mg; 150 mg

### Indications

Other specified malignant neoplasms of  
bronchus or lung

## Erythromycin

### Section

#### Watch group antibiotics

Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)

Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)

Oral > Solid: 250 mg (as stearate or ethylsuccinate)

#### Ophthalmological preparations > Anti-infective agents

Local > Ophthalmological > Ointment: 0.5%

### Indications

#### Second choice

Therapeutic equivalent to [clarithromycin](#) for

Acute pharyngitis

#### Other indications

Bacterial infection of unspecified site

Chlamydial conjunctivitis

Gonococcal infection of eye

## Erythropoiesis-stimulating agents

### Section

#### Antianaemia medicines

Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe

### Indications

Anaemia due to chronic disease

## Estradiol

### Section

#### Estrogens

Oral > Solid > tablet: 0.5 mg; 1 mg; 2 mg

### Indications

Hypopituitarism

Gonadotropin deficiency

Turner syndrome

## Estradiol cypionate + medroxyprogesterone acetate

### Section

#### Injectable hormonal contraceptives

Parenteral > General injections > IM: 5 mg + 25 mg

### Indications

Contact with health services for reasons associated with reproduction

## Etanercept

### Section

Immunomodulators for non-malignant disease

Medicines for juvenile joint diseases

### Indications

Therapeutic equivalent to [adalimumab](#) for

[Axial spondyloarthritis](#)

Therapeutic equivalent to [adalimumab](#) for

[Crohn disease site](#)

Therapeutic equivalent to [adalimumab](#) for

[Rheumatoid arthritis](#)

Therapeutic equivalent to [adalimumab](#) for

[Juvenile idiopathic arthritis](#)

## Ethambutol

### Section

Antituberculosis medicines

Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL

Oral > Solid: 100 mg (hydrochloride); 400 mg (hydrochloride); 100 mg tablet (dispersible)

### Indications

[Other specified tuberculosis](#)

[Tuberculosis](#)

## Ethambutol + isoniazid

### Section

Antituberculosis medicines

Oral > Solid: 400 mg + 150 mg tablet

### Indications

[Tuberculosis](#)

## Ethambutol + isoniazid + pyrazinamide + rifampicin

### Section

Antituberculosis medicines

Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet

### Indications

[Tuberculosis](#)

## Ethambutol + isoniazid + rifampicin

### Section

Antituberculosis medicines

Oral > Solid: 275 mg + 75 mg + 150 mg tablet

### Indications

[Tuberculosis](#)

## Ethanol

### Section

#### Antiseptics

Local > Topical > Solution: 70% (denatured)

### Indications

Denatured alcohol

## Ether

### Section

#### General anaesthetics and oxygen > Inhalational medicines

Respiratory > Inhalation > solution:

### Indications

Anaesthetics and therapeutic gases

## Ethinylestradiol + etonogestrel

### Section

#### Intravaginal contraceptives

Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg

### Indications

Contact with health services for contraceptive management

## Ethinylestradiol + levonorgestrel

### Section

#### Oral hormonal contraceptives

Oral > Solid: 50 µg + 250 µg [4]

Oral > Solid: 30 µg + 150 µg

### Indications

Contact with health services for postcoital contraception

Contact with health services for contraceptive management

## Ethinylestradiol + norethisterone

### Section

#### Oral hormonal contraceptives

Oral > Solid: 35 µg + 1 mg

### Indications

Contact with health services for contraceptive management

## Ethionamide

### Section

#### Antituberculosis medicines

Oral > Solid: 250 mg tablet; 125 mg tablet (dispersible)

### Indications

Multi-drug resistant Mycobacterium tuberculosis

Tuberculous meningitis

## Ethosuximide

| Section                                                                         | Indications               |
|---------------------------------------------------------------------------------|---------------------------|
| Antiseizure medicines<br>Oral > Liquid: 250 mg per 5 mL<br>Oral > Solid: 250 mg | Absence seizures, typical |

## Etonogestrel-releasing implant

| Section                                                             | Indications                                                        |
|---------------------------------------------------------------------|--------------------------------------------------------------------|
| Implantable contraceptives<br>Implant > Subdermal: 68 mg single rod | Contact with health services for insertion of contraceptive device |

## Etoposide

| Section                                                                                                                                                                                                                                                                                            | Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Cytotoxic medicines<br>Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule<br>Oral > Solid: 100 mg capsule<br>Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)<br>Oral > Solid: 100 mg capsule; 50 mg capsule | Unspecified malignant neoplasms of ill-defined or unspecified sites<br>Burkitt lymphoma including Burkitt leukaemia<br>Ewing sarcoma of bone and articular cartilage of unspecified sites<br>Lymphoid leukaemia, not elsewhere classified<br>Myeloid leukaemia<br>Other specified malignant neoplasms of the ovary<br>Other specified malignant neoplasms of bronchus or lung<br>Germ cell tumour of testis<br>Malignant trophoblastic neoplasms of placenta<br>Malignant neoplasms of kidney, except renal pelvis<br>Osteosarcoma of bone and articular cartilage of unspecified sites<br>Hodgkin lymphoma<br>Retinoblastoma<br>Anaplastic large cell lymphoma, ALK-negative<br>Anaplastic large cell lymphoma, ALK-positive |

## Everolimus

| Section                                                                                                                                          | Indications                      |
|--------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|
| Targeted therapies<br>Oral > Solid: 2.5 mg; 5 mg; 7.5 mg; 10 mg; 2 mg tablet (dispersible); 3 mg tablet (dispersible); 5 mg tablet (dispersible) | Other specified gliomas of brain |

## Fentanyl

| Section                                                                                                                                                                                                                                                                                   | Indications                                                                           |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
| <b>Opioid analgesics</b><br>Local > Topical > Transdermal patch: 12 µg/hour; 25 µg/hour; 50 µg/hour; 75 µg/hour; 100 µg/hour<br>Oral > Solid: 100 to 800 µg sub-lingual tablet (as citrate); 200 to 1600 µg lozenge (as citrate)<br>Oral > Other: 200 to 1200 µg buccal film (as citrate) | <div>Chronic cancer pain</div> <div>Other specified chronic cancer related pain</div> |

## Ferrous salt

| Section                                                                                                   | Indications                        |
|-----------------------------------------------------------------------------------------------------------|------------------------------------|
| <b>Antianaemia medicines</b><br>Oral > Liquid: 25 mg per mL iron (as sulfate)<br>Oral > Solid: 60 mg iron | <div>Iron deficiency anaemia</div> |

## Ferrous salt + folic acid

| Section                                                                                                                                                         | Indications                                                                                                                                                                            |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Antianaemia medicines</b><br>Oral > Solid: 60 mg iron + 2.8 mg<br>Oral > Solid > tablet: 60 mg elemental iron + 400 µg tablet; 60 mg elemental iron + 2.8 mg | <div>Iron deficiency anaemia</div> <div>Clefts of lip, alveolus or palate</div> <div>Iron deficiency anaemia</div> <div>Anencephaly or similar anomalies</div> <div>Spina bifida</div> |

## Fexinidazole

| Section                                                                                         | Indications                        |
|-------------------------------------------------------------------------------------------------|------------------------------------|
| <b>Medicines for the treatment of 1st stage African trypanosomiasis</b><br>Oral > Solid: 600 mg | <div>African trypanosomiasis</div> |
| <b>Medicines for the treatment of 2nd stage African trypanosomiasis</b><br>Oral > Solid: 600 mg | <div>African trypanosomiasis</div> |

## Fexofenadine

| Section                                                | Indications                                                                                                        |
|--------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|
| <b>Antiallergics and medicines used in anaphylaxis</b> | Therapeutic equivalent to loratadine for<br><div>Allergic or hypersensitivity conditions of unspecified type</div> |

## Fifth generation cephalosporins

### Section

Reserve group antibiotics

### Indications

Other specified bacterial diseases

## Filgrastim

### Section

Immunomodulators

Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial

### Indications

Acquired neutropaenia

## Fingolimod

### Section

Immunomodulators for non-malignant disease

Oral > Solid: 0.25 mg; 0.5 mg

### Indications

Relapsing-remitting multiple sclerosis

## Flomoxef

### Section

Watch group antibiotics

Parenteral > General injections > IV: 0.5 g in vial powder for injection; 1 g in vial powder for injection

### Indications

Other specified other antibiotic resistant Enterobacterales

## Fluconazole

### Section

Antifungal medicines

Parenteral > General injections > IV: 2 mg per mL in vial

Oral > Liquid: 50 mg per 5 mL; 50 mg per 5 mL powder for oral liquid

Oral > Solid > capsule: 50 mg

### Indications

Cryptococcosis

Candidosis

## Flucytosine

### Section

Antifungal medicines

Parenteral > General injections > IV: 2.5 g per 250 mL infusion

Oral > Solid: 250 mg capsule

### Indications

Cryptococcosis

## Fludarabine

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection

Oral > Solid: 10 mg tablet (fludarabine phosphate)

### Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

## Fludrocortisone

### Section

#### Adrenal hormones and synthetic substitutes

Oral > Solid: 100 µg (acetate)

### Indications

Adrenocortical insufficiency

## Flunisolide

### Section

#### Antiasthmatic and medicines for chronic obstructive pulmonary disease

### Indications

Therapeutic equivalent to [budesonide](#) for

Asthma

## Fluorescein

### Section

#### Diagnostic agents > Ophthalmic medicines

Local > Ophthalmological > Solution (eye drops): 1% (sodium salt)

### Indications

Fluorescein

## Fluoride

### Section

#### Dental medicines and preparations

Local > Dental > Gel: 2500 to 12500 ppm fluoride (any type)

Local > Dental > Toothpaste, cream or gel: 1000 to 1500 ppm fluoride (any type)

Local > Dental > Mouthrinse: 230 to 900 ppm fluoride (any type)

Local > Dental > Varnish: 22500 ppm fluoride (any type)

### Indications

Dental caries

## Fluorouracil

### Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Local > Topical > Ointment: 5%

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule

Parenteral > General injections > IV: 50 mg per mL in vial

### Indications

Plantar warts

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant neoplasms of nasopharynx

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of breast

Malignant neoplasms of rectum

Malignant neoplasms of colon

## Fluoxetine

### Section

Medicines for depressive disorders

Oral > Solid: 20 mg (as hydrochloride)

Medicines for anxiety disorders

Oral > Solid: 20 mg (as hydrochloride)

Medicines for other common symptoms in palliative care

Oral > Solid: 20 mg (as hydrochloride)

Medicines for obsessive compulsive disorders

Oral > Solid: 20 mg (as hydrochloride)

### Indications

Depressive disorders

Social anxiety disorder

Generalised anxiety disorder

Panic disorder

Palliative care

Obsessive-compulsive disorder

## Fluphenazine

### Section

Medicines for psychotic disorders

Parenteral > General injections > IM: 25 mg per mL in ampoule (decanoate); 25 mg per mL in ampoule (enanthate)

### Indications

Schizophrenia or other primary psychotic disorders

## Flutamide

### Section

Hormones and antihormones

### Indications

Therapeutic equivalent to bicalutamide for

Malignant neoplasms of prostate

## Fluticasone

### Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

### Indications

Therapeutic equivalent to **budesonide** for

Asthma

## Fluticasone + formoterol

### Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

### Indications

Therapeutic equivalent to **budesonide + formoterol** for

Asthma

## Fluticasone furoate + vilanterol

### Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

### Indications

Therapeutic equivalent to **budesonide + formoterol** for

Asthma

## Fluvastatin

### Section

Lipid-lowering agents

### Indications

Therapeutic equivalent to **simvastatin** for

Mixed hyperlipidaemia

Therapeutic equivalent to **simvastatin** for

Coronary atherosclerosis

## Folic acid

### Section

Antianaemia medicines

Oral > Solid: 1 mg tablet; 5 mg tablet

Oral > Solid: 400 µg

### Indications

Folate deficiency anaemia

Anencephaly or similar anomalies

Spina bifida

Cephalocele

## Fomepizole

### Section

Antidotes and other substances used in poisonings > Specific  
Parenteral > General injections > IV: 5 mg per mL in 20 mL ampoule (sulfate); 1 g per mL in 1.5 mL ampoule (base)

### Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

## Fosfomycin (injection)

### Section

Reserve group antibiotics  
Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection

### Indications

Other specified bacterial diseases

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

## Fourth generation cephalosporins

### Section

Watch group antibiotics  
.

### Indications

Other specified bacterial diseases

## Fresh-frozen plasma

### Section

Blood and blood components  
Parenteral > General injections > IV:

### Indications

Blood transfusion without reported diagnosis

## Fulvestrant

### Section

Hormones and antihormones  
Parenteral > General injections > IV: 250 mg per 5 mL

### Indications

Malignant neoplasms of breast

## Furosemide

### Section

#### Medicines used in heart failure

Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule

Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL

Oral > Solid > tablet: 40 mg; 20 mg

#### Diuretics

Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule

Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL

Oral > Solid > tablet: 40 mg; 20 mg

### Indications

Heart failure

Anuria or oliguria

Oedema

## Gabapentin

### Section

#### Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs)

Oral > Solid: 100 mg; 200 mg; 300 mg; 400 mg; 600 mg; 800 mg

### Indications

Neuropathic pain

## Gallamine

### Section

#### Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

Parenteral > General injections > IV: 40 mg per mL in 2 mL ampoule (gallamine triethiodide)

### Indications

Muscle relaxants

## Gatifloxacin

### Section

#### Antituberculosis medicines

Oral > Solid: 200 mg; 400 mg

### Indications

Multi-drug resistant *Mycobacterium tuberculosis*

## Gefitinib

### Section

#### Targeted therapies

### Indications

Therapeutic equivalent to erlotinib for

Other specified malignant neoplasms of bronchus or lung

## Gemcitabine

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection

### Indications

Other specified carcinomas of ovary

Other specified malignant neoplasms of bronchus or lung

## Gentamicin

### Section

#### Access group antibiotics

Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)

### Indications

#### First choice

Neonatal meningitis

co-prescribed with amoxicillin

Sepsis without septic shock

co-prescribed with amoxicillin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with ampicillin

Peritoneal abscess (mild-moderate)

co-prescribed with ampicillin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with ampicillin

Peritoneal abscess (severe)

co-prescribed with ampicillin

Peritonitis (severe)

co-prescribed with ampicillin

Sepsis without septic shock

co-prescribed with ampicillin

Peritonitis (mild-moderate)

co-prescribed with ampicillin

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescribed with benzylpenicillin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with benzylpenicillin

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescribed with benzylpenicillin

Sepsis without septic shock

#### Second choice

Other specified prophylactic measures

Gonococcal infection

|                                                                                                                                                         |                                         |
|---------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
| <p>Ophthalmological preparations &gt; Anti-infective agents</p> <p>Local &gt; Ophthalmological &gt; Solution (eye drops): 0.3% (gentamicin sulfate)</p> | Other indications                       |
|                                                                                                                                                         | Bacterial infection of unspecified site |
|                                                                                                                                                         | Other specified conjunctivitis          |
|                                                                                                                                                         | Infectious blepharitis                  |

## Glass ionomer cement

| Section                                                                                                                                                                       | Indications   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|
| <p>Dental medicines and preparations</p> <p>Local &gt; Dental &gt; Powder + liquid: Single-use capsules: 0.4 g powder + 0.09 mL liquid; Multi-use bottle: powder + liquid</p> | Dental caries |

## Glatiramer acetate

| Section                                                                                                                                                                                                                                         | Indications                                                             |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| <p>Medicines for multiple sclerosis</p> <p>Parenteral &gt; General injections &gt; SC: 20 mg per mL; 40 mg per mL</p> <p>Parenteral &gt; General injections &gt; SC: 20 mg per mL in pre-filled syringe; 40 mg per mL in pre-filled syringe</p> | <p>Relapsing-remitting multiple sclerosis</p> <p>Multiple sclerosis</p> |

## Glecaprevir + pibrentasvir

| Section                                                                                                                                                       | Indications         |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|
| <p>Medicines for hepatitis C &gt; Pangenotypic direct-acting antiviral combinations</p> <p>Oral &gt; Solid: 100 mg + 40 mg tablet; 50 mg + 20 mg granules</p> | Chronic hepatitis C |

## Glibenclamide

| Section                                                               | Indications              |
|-----------------------------------------------------------------------|--------------------------|
| <p>Oral hypoglycaemic agents</p> <p>Oral &gt; Solid: 5 mg; 2.5 mg</p> | Type 2 diabetes mellitus |

## Gliclazide

| Section                                                                                                                               | Indications              |
|---------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| <p>Oral hypoglycaemic agents</p> <p>Oral &gt; Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release</p> | Type 2 diabetes mellitus |

## Glucagon

### Section

Medicines for hypoglycaemia

Parenteral > General injections > unspecified: 1 mg per mL

### Indications

Hypoglycaemia in the context of diabetes

## Glucose

### Section

Solutions correcting water, electrolyte and acid-base disturbances >

Parenteral

Parenteral > General injections > IV: 5% isotonic; 10% hypertonic

Parenteral > General injections > IV: 50% hypertonic

### Indications

Other specified disorders of fluid, electrolyte or acid-base balance

Hypoglycaemia without associated diabetes

## Glucose + sodium chloride

### Section

Solutions correcting water, electrolyte and acid-base disturbances >

Parenteral

Parenteral > General injections > IV: 4% + 0.18% (equivalent to Na<sup>+</sup> 30 mmol/L and Cl<sup>-</sup> 30 mmol/L; 5% + 0.9% (equivalent to Na<sup>+</sup> 150 mmol/L and Cl<sup>-</sup> 150 mmol/L); 5% + 0.45% (equivalent to Na<sup>+</sup> 75 mmol/L and Cl<sup>-</sup> 75 mmol/L)

### Indications

Other specified disorders of fluid, electrolyte or acid-base balance

## Glutaral

### Section

Disinfectants

Local > Topical > Solution: 2%

### Indications

Glutaral nonmedicinal

## Glyceryl trinitrate

### Section

Antianginal medicines

Oral > Solid: 500 µg sublingual tablet

### Indications

Angina pectoris

## Glycopyrronium

### Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

### Indications

Therapeutic equivalent to tiotropium bromide for

Chronic obstructive pulmonary disease

## Golimumab

### Section

Immunomodulators for non-malignant disease

### Indications

Therapeutic equivalent to [adalimumab](#) for

[Axial spondyloarthritis](#)

Therapeutic equivalent to [adalimumab](#) for

[Crohn disease site](#)

Therapeutic equivalent to [adalimumab](#) for

[Rheumatoid arthritis](#)

Medicines for juvenile joint diseases

Therapeutic equivalent to [adalimumab](#) for

[Juvenile idiopathic arthritis](#)

## Goserelin

### Section

Hormones and antihormones

### Indications

Therapeutic equivalent to [leuporelin](#) for

[Malignant neoplasms of breast](#)

Therapeutic equivalent to [leuporelin](#) for

[Malignant neoplasms of prostate](#)

## Granisetron

### Section

Medicines for other common symptoms in palliative care

### Indications

Therapeutic equivalent to [ondansetron](#) for

[Palliative care](#)

Antiemetic medicines

Therapeutic equivalent to [ondansetron](#) for

[Nausea or vomiting](#)

## Griseofulvin

### Section

Antifungal medicines

Oral > Liquid: 125 mg per 5 mL

Oral > Solid: 125 mg; 250 mg

### Indications

[Dermatophytosis](#)

## Haemophilus influenzae type b vaccine

| Section                                                                                                                                       | Indications                                                    |
|-----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|
| <p>Recommendations for all immunization programmes</p> <p>All vaccines should comply with the WHO requirements for biological substances.</p> | <p>Need for immunization against single bacterial diseases</p> |

## Haloperidol

| Section                                                                                                                                                                                                                               | Indications                                               |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------|
| <p>Medicines for other common symptoms in palliative care</p> <p>Oral &gt; Liquid: 2 mg per mL</p> <p>Oral &gt; Solid: 0.5 mg; 2 mg; 5 mg</p> <p>Parenteral &gt; General injections &gt; unspecified: 5 mg per mL in 1-mL ampoule</p> | <p>Palliative care</p>                                    |
| <p>Medicines for psychotic disorders</p> <p>Parenteral &gt; General injections &gt; IM: 5 mg per mL in ampoule</p> <p>Oral &gt; Solid: 2 mg; 5 mg</p>                                                                                 | <p>Schizophrenia or other primary psychotic disorders</p> |

## Haloperidol decanoate

| Section                                  | Indications                                                                                                 |
|------------------------------------------|-------------------------------------------------------------------------------------------------------------|
| <p>Medicines for psychotic disorders</p> | <p>Therapeutic equivalent to fluphenazine for</p> <p>Schizophrenia or other primary psychotic disorders</p> |

## Halothane

| Section                                                                                                            | Indications                               |
|--------------------------------------------------------------------------------------------------------------------|-------------------------------------------|
| <p>General anaesthetics and oxygen &gt; Inhalational medicines</p> <p>Respiratory &gt; Inhalation &gt; liquid:</p> | <p>Anaesthetics and therapeutic gases</p> |

## Heparin sodium

| Section                                                                                                                                                                                   | Indications                                                                               |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
| <p>Medicines affecting coagulation</p> <p>Parenteral &gt; General injections &gt; IV: 1000 IU per mL in 5 mL ampoule; 20000 IU per mL in 5 mL ampoule; 5000 IU per mL in 5 mL ampoule</p> | <p>Acute ischaemic heart disease</p> <p>Unstable angina</p> <p>Venous thromboembolism</p> |

## Hepatitis a vaccine

### Section

Recommendations for some high-risk populations

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against viral hepatitis

## Hepatitis b vaccine

### Section

Recommendations for all immunization programmes

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against viral hepatitis

## Homatropine

### Section

Ophthalmological preparations > Mydriatics

Local > Ophthalmological > Solution (eye drops): 2% (hydrobromide)

### Indications

Anterior uveitis

Therapeutic equivalent to *atropine* for

Anterior uveitis

## Human papilloma virus (HPV) vaccine

### Section

Recommendations for all immunization programmes

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against certain single viral diseases

## Hydralazine

### Section

Antihypertensive medicines

Parenteral > General injections > IV: 20 mg in ampoule powder for injection (hydrochloride)

Oral > Solid: 50 mg tablet; 25 mg tablet (hydrochloride)

Oral > Solid: 50 mg (hydrochloride); 25 mg (hydrochloride)

### Indications

Essential hypertension

Gestational hypertension

## Hydrochlorothiazide

### Section

#### Antihypertensive medicines

Oral > Liquid: 50 mg per 5 mL

Oral > Solid: 25 mg; 12.5 mg

#### Medicines used in heart failure

Oral > Liquid: 50 mg per 5 mL

Oral > Solid: 25 mg

#### Diuretics

Oral > Solid: 25 mg

### Indications

Essential hypertension

Heart failure

Oedema

## Hydrocortisone

### Section

#### Hormones and antihormones

Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)

#### Adrenal hormones and synthetic substitutes

Oral > Solid: 5 mg; 10 mg; 20 mg

#### Ophthalmological preparations > Anti-inflammatory agents

Local > Ophthalmological > Ointment: 1% (acetate)

#### Antiallergics and medicines used in anaphylaxis

Parenteral > General injections > unspecified: 100 mg in vial powder for injection (as sodium succinate)

#### Anti-inflammatory medicines

Local > Rectal > Suppository: 25 mg (acetate)

Local > Rectal > Retention enema: 100 mg per 60 mL

#### Dermatological medicines > Anti-inflammatory and antipruritic medicines

Local > Topical > Cream: 1% (acetate)

Local > Topical > Ointment: 1% (acetate)

### Indications

Lymphoid leukaemia, not elsewhere classified

Unspecified malignant neoplasms of ill-defined or unspecified sites

Burkitt lymphoma including Burkitt leukaemia

Adrenocortical insufficiency

Scleritis

Anterior uveitis

Anaphylaxis

Crohn disease site

Ulcerative colitis

Dermatitis or eczema

Lichen planus

Pruritus due to skin disorder

Psoriasis of unspecified type

## Hydromorphone

### Section

Opioid analgesics

### Indications

Therapeutic equivalent to [morphine](#) for

Pain

## Hydroxocobalamin

### Section

Antianaemia medicines

Parenteral > General injections > IM: 1 mg per mL in 1 mL ampoule (as acetate); 1 mg per mL in 1 mL ampoule (as hydrochloride); 1 mg per mL in 1 mL ampoule (as sulfate)

### Indications

Megaloblastic anaemia due to vitamin B12 deficiency

## Hydroxycarbamide (hydroxyurea)

### Section

Cytotoxic medicines

Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g

Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg

Other medicines for haemoglobinopathies

Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg

### Indications

Squamous cell carcinoma of oropharynx

Chronic myeloid leukaemia, not elsewhere classified

Other specified sickle cell disorders or other haemoglobinopathies

## Hydroxychloroquine

### Section

Antimalarial medicines > For chemoprevention

Disease-modifying anti-rheumatic drugs (DMARDs)

Oral > Solid: 200 mg (as sulfate)

### Indications

Therapeutic equivalent to [chloroquine](#) for

Malaria due to *Plasmodium falciparum*

Systemic lupus erythematosus

Cutaneous lupus erythematosus of unspecified type

## Hyoscine butylbromide

### Section

Medicines for other common symptoms in palliative care

Parenteral > General injections > unspecified: 20 mg per mL injection

### Indications

Palliative care

## Hyoscine hydrobromide

### Section

Medicines for other common symptoms in palliative care

Local > Topical > Transdermal patch: 1 mg per 72 hours transdermal patch

Parenteral > General injections > unspecified: 400 µg per mL injection; 600 µg per mL injection

### Indications

Palliative care

## Hypochlorous acid

### Section

Antiseptics

Local > Topical > Solution:

### Indications

Disinfectant, not elsewhere classified

## Hypromellose

### Section

Ophthalmological preparations

Local > Ophthalmological > Solution (eye drops): 0.3%

### Indications

Keratoconjunctivitis sicca

## Ibrutinib

### Section

Targeted therapies

Oral > Solid: 140 mg

### Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

## Ibuprofen

### Section

Medicines administered to the neonate [c]

Parenteral > General injections > IV: 5 mg per mL

Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs)

Oral > Liquid: 200 mg per 5 mL; 100 mg per 5 mL

Oral > Solid > tablet: 200 mg; 400 mg; 600 mg

Antimigraine medicines > For treatment of acute attack

Oral > Liquid: 100 mg per 5 mL; 200 mg per 5 mL

Oral > Solid > tablet: 200 mg; 400 mg

### Indications

Patent arterial duct

Pain

Migraine

## Idoxuridine

### Section

Ophthalmological preparations > Anti-infective agents  
Local > Ophthalmological > Solution (eye drops): 0.1%  
Local > Ophthalmological > Ointment: 0.2%

### Indications

Herpes simplex keratitis

## Ifosfamide

### Section

Cytotoxic medicines  
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection  
Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection

### Indications

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Ewing sarcoma of bone and articular cartilage of unspecified sites

Osteosarcoma of bone and articular cartilage of unspecified sites

Rhabdomyosarcoma primary site

Unspecified malignant neoplasms of ill-defined or unspecified sites

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasms of kidney, except renal pelvis

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

## Imatinib

### Section

Targeted therapies  
Oral > Solid: 100 mg; 400 mg

### Indications

B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1

Gastrointestinal stromal tumour of unspecified gastrointestinal sites

Chronic myeloid leukaemia, not elsewhere classified

## Imipenem + cilastatin

### Section

#### Watch group antibiotics

Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection

#### Antituberculosis medicines

### Indications

#### Second choice

Therapeutic equivalent to [meropenem](#) for

Neutropenia (high-risk)

Therapeutic equivalent to [meropenem](#) for

Peritoneal abscess (severe)

Therapeutic equivalent to [meropenem](#) for

Peritonitis (severe)

#### Other indications

Pseudomonas aeruginosa resistant to other antibiotic

Antibiotic resistant Acinetobacter baumannii

Therapeutic equivalent to [meropenem](#) for

Multi-drug resistant Mycobacterium tuberculosis

## Imipenem + cilastatin + relebactam

### Section

#### Reserve group antibiotics

Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection

### Indications

Other specified other antibiotic resistant Enterobacterales

Carbapenem resistant Enterobacterales

Carbapenem-resistant Pseudomonas aeruginosa

## Indapamide

### Section

#### Antihypertensive medicines

Therapeutic equivalent to [hydrochlorothiazide](#) for

Essential hypertension

#### Medicines used in heart failure

Therapeutic equivalent to [hydrochlorothiazide](#) for

Heart failure

## Indinavir

### Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 400 mg (as sulfate)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Indometacin

### Section

Medicines administered to the neonate [c]

### Indications

Therapeutic equivalent to [ibuprofen](#) for

Patent arterial duct

## Infliximab

### Section

Immunomodulators for non-malignant disease

### Indications

Therapeutic equivalent to [adalimumab](#) for

Axial spondyloarthritis

Therapeutic equivalent to [adalimumab](#) for

Crohn disease site

Therapeutic equivalent to [adalimumab](#) for

Rheumatoid arthritis

Medicines for juvenile joint diseases

Therapeutic equivalent to [adalimumab](#) for

Juvenile idiopathic arthritis

## Influenza vaccine (seasonal)

### Section

Recommendations for immunization programmes with certain characteristics

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against influenza

## Insulin

### Section

#### Insulins

Parenteral > General injections > SC: 40 IU per mL in 10 mL vial (soluble); 100 IU per mL in 10 mL vial (soluble); 100 IU per mL in 3 mL cartridge (soluble); 100 IU per mL in 3 mL pre-filled pen (soluble)

Parenteral > General injections > SC: 40 IU per mL in 10 mL vial (soluble); 100 IU per mL in 10 mL vial (soluble); 100 IU per mL in 3 mL cartridge (soluble); 100 IU per mL in 3 mL pre-filled pen

### Indications

Type 2 diabetes mellitus

Type 1 diabetes mellitus

## Insulin analogues

### Section

#### Insulins

Not specified

### Indications

Type 1 diabetes mellitus

Type 2 diabetes mellitus

## Insulin degludec

### Section

#### Insulins

Parenteral > General injections > SC: 100 units per mL

### Indications

Therapeutic equivalent to [insulin glargine](#) for

Type 1 diabetes mellitus

Therapeutic equivalent to [long-acting insulin analogues](#) for

Type 1 diabetes mellitus

Therapeutic equivalent to [long-acting insulin analogues](#) for

Type 2 diabetes mellitus

## Insulin detemir

### Section

#### Insulins

### Indications

Therapeutic equivalent to [insulin glargine](#) for

Type 1 diabetes mellitus

Therapeutic equivalent to [long-acting insulin analogues](#) for

Type 1 diabetes mellitus

Therapeutic equivalent to [long-acting insulin analogues](#) for

Type 2 diabetes mellitus

## Insulin glargine

### Section

#### Insulins

Parenteral > General injections > SC: 100 units per mL

### Indications

Type 1 diabetes mellitus

Therapeutic equivalent to long-acting insulin analogues for

Type 1 diabetes mellitus

Therapeutic equivalent to long-acting insulin analogues for

Type 2 diabetes mellitus

## Intermediate-acting insulin

### Section

#### Insulins

Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL cartridge as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL pre-filled pen as compound insulin zinc suspension or isophane insulin

### Indications

Type 2 diabetes mellitus

## Intraperitoneal dialysis solution

### Section

Peritoneal dialysis solution  
parenteral solution

### Indications

Care involving peritoneal dialysis

## Iodine

### Section

#### Vitamins and minerals

Parenteral > General injections > IM: 0.5 mL (240 mg iodine) iodized oil in ampoule; 1 mL (480 mg iodine) iodized oil in ampoule

Oral > Liquid: 1 mL (480 mg iodine) iodized oil in ampoule; 0.5 mL (240 mg iodine) iodized oil in ampoule; 0.57 mL (308 mg iodine) iodized oil in dispenser bottle

Oral > Solid: 190 mg

#### Antiseptics

### Indications

Iodine deficiency

Therapeutic equivalent to povidone iodine for

Povidone iodine

## Iohexol

### Section

Diagnostic agents > Radiocontrast media

Parenteral > General injections > unspecified: 140 to 350 mg iodine per mL in 5 mL ampoule; 140 to 350 mg iodine per mL in 10 mL ampoule; 140 to 350 mg iodine per mL in 20 mL ampoule

### Indications

X-ray contrast media, iodinated

## Ipecacuanha

### Section

Antidotes and other substances used in poisonings > Non-specific

Oral > Liquid: 0.14% ipecacuanha alkaloids calculated as emetine

### Indications

Unspecified injury, poisoning or certain other consequences of external causes

## Ipratropium bromide

### Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Respiratory > Inhalation > aerosol: 20 µg per dose

### Indications

Asthma

Chronic obstructive pulmonary disease

## Irinotecan

### Section

Cytotoxic medicines

Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial

### Indications

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of kidney, except renal pelvis

Rhabdomyosarcoma primary site

## Isoflurane

### Section

General anaesthetics and oxygen > Inhalational medicines

Respiratory > Inhalation > liquid:

### Indications

Anaesthetics and therapeutic gases

## Isoniazid

### Section

Antituberculosis medicines

Parenteral > General injections > IV: 100 mg per mL

Oral > Solid: 100 mg tablet; 100 mg tablet (dispersible); 300 mg tablet

### Indications

Other specified tuberculosis

Tuberculosis

## Isoniazid + pyrazinamide + rifampicin

### Section

Antituberculosis medicines

Oral > Solid: 50 mg + 150 mg + 75 mg tablet (dispersible)

### Indications

Tuberculosis

## Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim

### Section

Medicines for prevention of HIV-related opportunistic infections

Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)

### Indications

Other specified prophylactic measures

## Isoniazid + rifampicin

### Section

Antituberculosis medicines

Oral > Solid: 50 mg + 75 mg tablet (dispersible); 75 mg + 150 mg tablet; 150 mg + 300 mg tablet

### Indications

Tuberculosis

## Isoniazid + rifapentine

### Section

Antituberculosis medicines

Oral > Solid: 300 mg + 300 mg tablet (scored)

### Indications

Latent tuberculosis

## Isoprenaline

### Section

Antiarrhythmic medicines

Parenteral > General injections > IV: 20 µg per mL in ampoule (hydrochloride)

Oral > Solid: 10 mg (hydrochloride or sulfate); 15 mg (hydrochloride or sulfate)

### Indications

Bradycardia

Cardiogenic shock

## Isosorbide dinitrate

### Section

Antianginal medicines

Oral > Solid: 5 mg sublingual tablet

### Indications

Angina pectoris

## Itraconazole

### Section

Antifungal medicines

Oral > Liquid: 10 mg per mL

Oral > Solid: 100 mg

### Indications

Chronic pulmonary aspergillosis

Chromoblastomycosis

Histoplasmosis

Talaromycosis

Sporotrichosis

Paracoccidioidomycosis

## Ivermectin

### Section

Intestinal anthelmintics

Oral > Solid > tablet: 3 mg

### Indications

Strongyloidiasis

Ascariasis

Trichuriasis

Hookworm diseases

Ancylostomiasis

Antifilarials

Oral > Solid > tablet: 3 mg

Onchocerciasis

Lymphatic filariasis

Medicines for ectoparasitic infections

Oral > Solid > tablet: 3 mg

Scabies

## Kanamycin

### Section

Ophthalmological preparations > Anti-infective agents

### Indications

Therapeutic equivalent to [gentamicin](#) for

Other specified conjunctivitis

Therapeutic equivalent to [gentamicin](#) for

Infectious blepharitis

## Kanamycin (injection)

### Section

Antituberculosis medicines

Parenteral > General injections > IV: 1000 mg powder for injection (vial)

### Indications

Multi-drug resistant *Mycobacterium tuberculosis*

## Ketamine

| Section                                                                                                                                                | Indications                        |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|
| General anaesthetics and oxygen > Injectable medicines<br>Parenteral > General injections > unspecified: 50 mg per mL in 10 mL vial (as hydrochloride) | Anaesthetics and therapeutic gases |

## Ketoconazole

| Section                                                            | Indications      |
|--------------------------------------------------------------------|------------------|
| Medicines for endocrine disorders<br>Oral > Solid > tablet: 200 mg | Cushing syndrome |

## Lactulose

| Section                                                                                                    | Indications     |
|------------------------------------------------------------------------------------------------------------|-----------------|
| Medicines for other common symptoms in palliative care<br>Oral > Liquid: 3.1 to 3.7 g per 5 mL oral liquid | Palliative care |

## Lamivudine

| Section                                                                                                                                  | Indications                                                                                                         |
|------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors<br>Oral > Liquid: 50 mg per 5 mL<br>Oral > Solid: 150 mg tablet | Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified |

## Lamivudine + nevirapine + zidovudine

| Section                                                                                                                   | Indications                                                                                                         |
|---------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| Fixed-dose combinations of antiretrovirals<br>Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg Tablet | Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified |

## Lamivudine + tenofovir

| Section                                    | Indications                                                                                                                                                                                                                                                                                                              |
|--------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Fixed-dose combinations of antiretrovirals | <p>Therapeutic equivalent to emtricitabine + tenofovir for</p> <p>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</p> <p>Therapeutic equivalent to emtricitabine + tenofovir for</p> <p>Contact with or exposure to human immunodeficiency virus</p> |

## Lamivudine + zidovudine

### Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Lamotrigine

### Section

Antiseizure medicines

Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet; 200 mg tablet; 2 mg tablet (chewable, dispersible); 5 mg tablet (chewable, dispersible); 25 mg tablet (chewable, dispersible); 50 mg tablet (chewable, dispersible); 100 mg tablet (chewable, dispersible); 200 mg tablet (chewable, dispersible)

### Indications

Epilepsy or seizures

## Latanoprost

### Section

Ophthalmological preparations > Miotics and antiglaucoma medicines

Local > Ophthalmological > Solution (eye drops): 50 µg per mL eye drops

### Indications

Primary open-angle glaucoma

## Ledipasvir + sofosbuvir

### Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

Oral > Solid: 90 mg + 400 mg tablet

### Indications

Chronic hepatitis C

## Lenalidomide

### Section

Immunomodulators

Oral > Solid: 25 mg

### Indications

Plasma cell myeloma

## Letrozole

### Section

Ovulation inducers

Oral > Solid > dosage form: 2.5 mg

### Indications

Female infertility without specification whether primary or secondary

## Leuprorelin

### Section

Hormones and antihormones

Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe

### Indications

Malignant neoplasms of breast

Malignant neoplasms of prostate

## Levamisole

### Section

Intestinal anthelmintics

Oral > Solid > tablet: 50 mg (as hydrochloride); 150 mg (as hydrochloride)

### Indications

Ascariasis

## Levetiracetam

### Section

Antiseizure medicines

Oral > Liquid: 100 mg per mL

Oral > Solid > tablet: 250 mg; 500 mg; 750 mg; 1000 mg

Parenteral > General injections > IV: 500 mg per 5 mL in 5 mL vial; 5 mg per mL in 100 mL bag; 10 mg per mL in 100 mL bag; 15 mg per mL in 100 mL bag

### Indications

Epilepsy or seizures

Status epilepticus

## Levodopa

### Section

Antiseizure medicines

Oral > Solid: 250 mg

### Indications

Parkinson disease

## Levodopa + benserazide

### Section

Medicines for parkinsonism

### Indications

Therapeutic equivalent to levodopa + carbidopa for

Parkinson disease

## Levodopa + carbidopa

### Section

Medicines for parkinsonism

Oral > Solid: 100 mg + 10 mg tablet; 250 mg + 25 mg tablet; 100 mg + 25 mg tablet

### Indications

Parkinson disease

## Levofloxacin

| Section                                                                                                                     | Indications                                     |
|-----------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|
| <b>Antituberculosis medicines</b><br>Oral > Solid: 250 mg tablet; 500 mg tablet; 750 mg tablet; 100 mg tablet (dispersible) | Multi-drug resistant Mycobacterium tuberculosis |

## Levonorgestrel

| Section                                                                                               | Indications                                                                                                            |
|-------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|
| <b>Oral hormonal contraceptives</b><br>Oral > Solid: 750 µg [2]; 1.5 mg [1]<br>Oral > Solid: 30 µg    | Contact with health services for postcoital contraception<br>Contact with health services for contraceptive management |
| <b>Intrauterine devices</b><br>Intrauterine system with reservoir containing 52 mg of levonorgestrel. | Contact with health services for insertion of contraceptive device                                                     |

## Levonorgestrel-releasing implant

| Section                                                                            | Indications                                                        |
|------------------------------------------------------------------------------------|--------------------------------------------------------------------|
| <b>Implantable contraceptives</b><br>Implant > Subdermal: 75 mg per rod (two-rods) | Contact with health services for insertion of contraceptive device |

## Levothyroxine

| Section                                                                                                                           | Indications    |
|-----------------------------------------------------------------------------------------------------------------------------------|----------------|
| <b>Thyroid hormones and antithyroid medicines</b><br>Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt) | Hypothyroidism |

## Lidocaine

| Section                                                                                                                                                                                                                                                                                                              | Indications                 |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|
| <b>Antiarrhythmic medicines</b><br>Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule (hydrochloride)                                                                                                                                                                                                | Ventricular tachyarrhythmia |
| <b>Local anaesthetics</b><br>Parenteral > Locoregional injections > Spinal anaesthesia: 5% in 2 mL ampoule (hydrochloride) + 7.5% glucose solution<br>Parenteral > Locoregional injections > Other: 1% in vial (hydrochloride); 2% in vial (hydrochloride)<br>Local > Topical > unspecified: 2 to 4% (hydrochloride) | Local anaesthetics          |

## Lidocaine + epinephrine

| Section                                                                                                                                                                                                                                                                                                                                     | Indications                        |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|
| <a href="#">Local anaesthetics</a><br>Parenteral > Locoregional injections > Other: 1% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial; 2% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial<br>Local > Dental > Cartridge: 2% (lidocaine hydrochloride) + 1:80 000 epinephrine | <a href="#">Local anaesthetics</a> |

## Lindane

| Section                                                                                                                                   | Indications             |
|-------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|
| <a href="#">Dermatological medicines &gt; Scabicides and pediculicides</a><br>Local > Topical > Cream: 1%<br>Local > Topical > Lotion: 1% | <a href="#">Scabies</a> |

## Linezolid

| Section                                                                                                                                                                                                                                                                                           | Indications                                                                                                                                                                                                                          |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <a href="#">Reserve group antibiotics</a><br>Parenteral > General injections > IV: 2 mg per mL in 300 mL bag<br>Oral > Liquid: 100 mg per 5 mL powder for oral liquid<br>Oral > Solid: 400 mg tablet; 600 mg tablet<br>Oral > Solid > dispersible tablet: 150 mg<br>Oral > Solid > tablet: 600 mg | <a href="#">Other specified bacterial diseases</a><br><a href="#">Methicillin resistant Staphylococcus aureus</a><br><a href="#">Vancomycin resistant Staphylococcus aureus</a><br><a href="#">Vancomycin resistant Enterococcus</a> |
| <a href="#">Antituberculosis medicines</a><br>Oral > Solid: 600 mg tablet; 150 mg tablet (dispersible)                                                                                                                                                                                            | <a href="#">Multi-drug resistant Mycobacterium tuberculosis</a>                                                                                                                                                                      |

## Liraglutide

| Section                                                                                                                       | Indications             |
|-------------------------------------------------------------------------------------------------------------------------------|-------------------------|
| <a href="#">Medicines for endocrine disorders</a><br>Parenteral > General injections > SC: 6 mg per mL in 3 mL pre-filled pen | <a href="#">Obesity</a> |

## Lisinopril + amlodipine

| Section                                                                                               | Indications                            |
|-------------------------------------------------------------------------------------------------------|----------------------------------------|
| <a href="#">Antihypertensive medicines</a><br>Oral > Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg | <a href="#">Essential hypertension</a> |

## Lisinopril + hydrochlorothiazide

### Section

Antihypertensive medicines

Oral > Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg

### Indications

Essential hypertension

## Lisocabtagene maraleucel

### Section

Antineoplastics and supportive medicines

### Indications

Therapeutic equivalent to axicabtagene ciloleucel for

Diffuse large B-cell lymphomas

## Lithium carbonate

### Section

Medicines for bipolar disorders

Oral > Solid: 300 mg

### Indications

Bipolar or related disorders

## Long-acting insulin analogues

### Section

Insulins

Parenteral > General injections > SC: 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen

### Indications

Type 1 diabetes mellitus

Type 2 diabetes mellitus

## Loperamide

### Section

Medicines for other common symptoms in palliative care

Oral > Solid: 2 mg solid oral dosage form

### Indications

Palliative care

## Lopinavir + ritonavir

### Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable); 40 mg + 10 mg

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Loratadine

### Section

Antiallergics and medicines used in anaphylaxis

Oral > Liquid: 1 mg per mL

Oral > Solid: 10 mg

### Indications

Allergic or hypersensitivity conditions of unspecified type

## Lorazepam

### Section

#### Antiseizure medicines

Parenteral > General injections > IV: 2 mg per mL in 1 mL ampoule; 4 mg per mL in 1 mL ampoule

#### Medicines for anxiety disorders

### Indications

Status epilepticus

Therapeutic equivalent to [diazepam](#) for

Anxiety

## Losartan

### Section

#### Antihypertensive medicines

Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet

#### Medicines used in heart failure

Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet

### Indications

Essential hypertension

Heart failure

## Lovastatin

### Section

#### Lipid-lowering agents

### Indications

Therapeutic equivalent to [simvastatin](#) for

Mixed hyperlipidaemia

Therapeutic equivalent to [simvastatin](#) for

Coronary atherosclerosis

## Lugol's solution

### Section

#### Thyroid hormones and antithyroid medicines

Oral > Liquid: 13% w/v (about 130 mg/mL total iodine)

### Indications

Thyrotoxicosis

## Magnesium sulfate

### Section

#### Antiseizure medicines

Parenteral > General injections > IV: 500 mg per mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% weight/volume)

Parenteral > General injections > IM: 500 mg per mL in 10 mL ampoule (equivalent to 5 g in 10 mL; 50% weight/volume)

### Indications

Severe pre-eclampsia

Eclampsia

## Mannitol

### Section

#### Diuretics

Parenteral > General injections > IV: 10% solution; 20% solution

### Indications

Ocular hypertension

Cerebral oedema

## Measles vaccine

### Section

#### Recommendations for all immunization programmes

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against measles alone

## Mebendazole

### Section

#### Intestinal anthelmintics

Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)

### Indications

Ascariasis

Enterobiasis

Trichuriasis

Hookworm diseases

#### Cysticidal medicines

Oral > Solid > tablet: 500 mg (chewable); 100 mg (chewable)

Other specified echinococcosis

## Medroxyprogesterone acetate

### Section

#### Injectable hormonal contraceptives

Parenteral > General injections > IM: 150 mg per mL in 1 mL vial

Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system

### Indications

Contact with health services for reasons associated with reproduction

#### Progestogens

Oral > Solid: 5 mg

Excessive menstruation with irregular cycle

## Mefloquine

### Section

#### Antimalarial medicines > For curative treatment

Oral > Solid: 250 mg tablet (hydrochloride)

### Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

#### Antimalarial medicines > For chemoprevention

Oral > Solid: 250 mg tablet (hydrochloride)

Malaria due to *Plasmodium falciparum*

## Meglumine antimoniate

### Section

Antileishmaniasis medicines

Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule

### Indications

Visceral leishmaniasis

Mucocutaneous leishmaniasis

Cutaneous leishmaniasis

## Meglumine iotroxate

### Section

Diagnostic agents > Radiocontrast media

Parenteral > General injections > IV: 5 to 8 g iodine (as meglumine) in 100 to 250 mL

### Indications

X-ray contrast media, iodinated

## Melarsoprol

### Section

Medicines for the treatment of 2nd stage African trypanosomiasis

Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound)

### Indications

African trypanosomiasis

## Melphalan

### Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial powder for injection

Oral > Solid: 2 mg

### Indications

Plasma cell myeloma

## Meningococcal meningitis vaccine

### Section

Recommendations for some high-risk populations

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against single bacterial diseases

## Mercaptopurine

### Section

Cytotoxic medicines

Oral > Solid: 50 mg tablet

Oral > Liquid: 20 mg per mL

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Acute myeloid leukaemia with recurrent genetic abnormalities

Lymphoid leukaemia, not elsewhere classified

Langerhans cell histiocytosis

## Meropenem

| Section                                                                                                                                                                          | Indications                                                                                                                                                      |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Watch group antibiotics</b><br>Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection    | <b>Second choice</b><br><div>Neutropenia (high-risk)</div> <div>Peritoneal abscess (severe)</div> <div>Peritonitis (severe)</div> <div>Neonatal meningitis</div> |
| <b>Antituberculosis medicines</b><br>Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection | <div>Multi-drug resistant <i>Mycobacterium tuberculosis</i></div>                                                                                                |

## Meropenem + vaborbactam

| Section                                                                                                                  | Indications                                                                                                                                                                   |
|--------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Reserve group antibiotics</b><br>Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection | <div>Carbapenem-resistant <i>Pseudomonas aeruginosa</i></div> <div>Carbapenem resistant Enterobacterales</div> <div>Carbapenem resistant <i>Acinetobacter baumannii</i></div> |

## Mesalazine

| Section                            | Indications                                                                                                                                                                       |
|------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Anti-inflammatory medicines</b> | <div>Therapeutic equivalent to sulfasalazine for<br/><div>Crohn disease site</div></div> <div>Therapeutic equivalent to sulfasalazine for<br/><div>Ulcerative colitis</div></div> |

## Mesna

| Section                                                                                                                                                            | Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Supportive medicines</b><br>Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule<br>Oral > Solid: 400 mg; 600 mg | <div>Osteosarcoma of bone and articular cartilage of other specified sites</div> <div>Other specified malignant neoplasms of the ovary</div> <div>Germ cell tumour of testis</div> <div>Ewing sarcoma of bone and articular cartilage of unspecified sites</div> <div>Rhabdomyosarcoma primary site</div> <div>Unspecified malignant neoplasms of ill-defined or unspecified sites</div> <div>Burkitt lymphoma including Burkitt leukaemia</div> <div>Malignant neoplasms of kidney, except renal pelvis</div> |

## Metformin

| Section                                                                  | Indications                         |
|--------------------------------------------------------------------------|-------------------------------------|
| <b>Oral hypoglycaemic agents</b><br>Oral > Solid: 500 mg (hydrochloride) | <div>Type 2 diabetes mellitus</div> |

## Methadone

| Section                                                                                                                                                                                                                                                                                                                                              | Indications                    |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|
| <b>Medicines for opioid use disorders</b><br>Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)                                                                 | <div>Opioid dependence</div>   |
| <b>Opioid analgesics</b><br>Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)<br>Oral > Solid: 5 mg (methadone hydrochloride); 10 mg (methadone hydrochloride) | <div>Chronic cancer pain</div> |

## Methimazole

| Section                                                                               | Indications               |
|---------------------------------------------------------------------------------------|---------------------------|
| <b>Thyroid hormones and antithyroid medicines</b><br>Oral > Solid: 5 mg; 10 mg; 20 mg | <div>Thyrotoxicosis</div> |

## Methionine

### Section

Antidotes and other substances used in poisonings > Specific  
Oral > Solid: 250 mg (DL)

### Indications

Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs

## Methotrexate

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial (as sodium salt)

Oral > Solid: 2.5 mg (as sodium salt)

Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Lymphoid leukaemia, not elsewhere classified

Acute myeloid leukaemia with recurrent genetic abnormalities

Malignant trophoblastic neoplasms of placenta

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasms of breast

Osteosarcoma of bone and articular cartilage of unspecified sites

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Langerhans cell histiocytosis

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Oral > Solid > tablet: 2.5 mg (as sodium salt); 10 mg (as sodium salt)

Psoriasis of unspecified type

#### Disease-modifying anti-rheumatic drugs (DMARDs)

Oral > Solid > tablet: 2.5 mg (as sodium salt)

Rheumatoid arthritis, serology unspecified

#### Immunomodulators for non-malignant disease

Parenteral > General injections > SC: pre-filled syringe in multiple strengths

Crohn disease site

Psoriatic arthritis

#### Medicines for juvenile joint diseases

Oral > Solid > tablet: 2.5 mg (as sodium salt)

Juvenile idiopathic arthritis

## Methoxy polyethylene glycol-epoetin beta

### Section

#### Antianaemia medicines

### Indications

Therapeutic equivalent to erythropoiesis-stimulating agents for

Anaemia due to chronic disease

## Methyldopa

### Section

Antihypertensive medicines

Oral > Solid: 250 mg

### Indications

Essential hypertension

Gestational hypertension

## Methylergometrine

### Section

Uterotonics

### Indications

Therapeutic equivalent to [ergometrine](#) for

Postpartum haemorrhage

## Methylphenidate

### Section

Medicines for mental and behavioural disorders

Multiple formulations and strengths.

### Indications

Attention deficit hyperactivity disorder

## Methylprednisolone

### Section

Hormones and antihormones

Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate); 40 mg per mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per mL in 1 mL single-dose vial (as sodium succinate)

### Indications

Lymphoid leukaemia, not elsewhere classified

Burkitt lymphoma including Burkitt leukaemia

## Methylthioninium chloride

### Section

Antidotes and other substances used in poisonings > Specific

Parenteral > General injections > IV: 10 mg per mL in 10 mL ampoule

### Indications

Acquired methaemoglobinaemia

## Metoclopramide

| Section                                                                                                                                                                                                                                                    | Indications               |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|
| <p>Medicines for other common symptoms in palliative care</p> <p>Oral &gt; Liquid: 5 mg per 5 mL</p> <p>Oral &gt; Solid: 10 mg (hydrochloride)</p> <p>Parenteral &gt; General injections &gt; unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)</p> | <p>Palliative care</p>    |
| <p>Antiemetic medicines</p> <p>Oral &gt; Liquid: 5 mg per 5 mL</p> <p>Oral &gt; Solid: 10 mg (hydrochloride)</p> <p>Parenteral &gt; General injections &gt; unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)</p>                                   | <p>Nausea or vomiting</p> |

## Metoprolol

| Section                                | Indications                                                                                   |
|----------------------------------------|-----------------------------------------------------------------------------------------------|
| <p>Antianginal medicines</p>           | <p>Therapeutic equivalent to <a href="#">bisoprolol</a> for</p> <p>Angina pectoris</p>        |
| <p>Medicines used in heart failure</p> | <p>Therapeutic equivalent to <a href="#">bisoprolol</a> for</p> <p>Heart failure</p>          |
| <p>Antihypertensive medicines</p>      | <p>Therapeutic equivalent to <a href="#">bisoprolol</a> for</p> <p>Essential hypertension</p> |
| <p>Antiarrhythmic medicines</p>        | <p>Therapeutic equivalent to <a href="#">bisoprolol</a> for</p> <p>Cardiac arrhythmia</p>     |

## Metronidazole

### Section

#### Access group antibiotics

Oral > Liquid: 200 mg per 5 mL (as benzoate)

Oral > Solid: 200 to 500 mg tablet

Parenteral > General injections > unspecified: 500 mg per 100 mL in vial

Injection

Local > Rectal > Suppository: 500 mg suppository; 1 g suppository

#### Antiamoebic and anti giardiasis medicines

Oral > Liquid: 200 mg per 5 mL (as benzoate)

Parenteral > General injections > unspecified: 500 mg in 100 mL vial

Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg

### Indications

#### First choice

co-prescribed with [cefazolin](#)

Other specified prophylactic measures

co-prescribed with [cefotaxime](#)

Peritoneal abscess (severe)

co-prescribed with [cefotaxime](#)

Peritonitis (severe)

co-prescribed with [cefotaxime](#)

Peritonitis (mild-moderate)

co-prescribed with [cefotaxime](#)

Peritoneal abscess (mild-moderate)

co-prescribed with [ceftriaxone](#)

Peritoneal abscess (severe)

co-prescribed with [ceftriaxone](#)

Peritoneal abscess (mild-moderate)

co-prescribed with [ceftriaxone](#)

Peritonitis (severe)

co-prescribed with [ceftriaxone](#)

Peritonitis (mild-moderate)

#### Second choice

co-prescribed with [ciprofloxacin](#)

Peritoneal abscess (mild-moderate)

co-prescribed with [ciprofloxacin](#)

Peritonitis (mild-moderate)

#### Other indications

Bacterial infection of unspecified site

Amoebiasis

## Micafungin

### Section

#### Antifungal medicines

Parenteral > General injections > IV: 50 mg in vial (as sodium) powder for injection; 100 mg in vial (as sodium) powder for injection

### Indications

Systemic or invasive candidosis

## Miconazole

### Section

[Dermatological medicines](#) > [Antifungal medicines](#)

Local > Topical > Cream: 2% (nitrate)

Local > Topical > Ointment: 2% (nitrate)

### Indications

Fungal infection of the skin

## Midazolam

### Section

[Medicines for other common symptoms in palliative care](#)

Oral > Liquid: 2 mg per mL oral liquid

Oral > Solid: 7.5 mg solid oral dosage form; 15 mg solid oral dosage form

Parenteral > General injections > unspecified: 1 mg per mL injection; 5 mg per mL injection

[Antiseizure medicines](#)

Parenteral > General injections > unspecified: 1 mg per mL in 5 mL vial (for buccal administration); 5 mg per mL in 1 mL vial (for buccal administration); 5 mg per mL in 3 mL vial (for buccal administration)

Local > Buccal > Solution: 5 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.75 mL pre-filled syringe; 10 mg per mL in 1 mL pre-filled syringe (for oromucosal administration)

[Preoperative medication and sedation for short-term procedures](#)

Parenteral > General injections > IV: 1 mg per mL

Oral > Liquid: 2 mg per mL

Oral > Solid: 15 mg tablet; 7.5 mg tablet

### Indications

Palliative care

Therapeutic equivalent to [lorazepam](#) for

Status epilepticus

Status epilepticus

Sedative-hypnotic and anxiolytic drugs

## Mifepristone - misoprostol

### Section

[Uterotonics](#)

Oral > Solid: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package

### Indications

Induced abortion

Unspecified time of fetal death, cause not specified

## Miltefosine

### Section

Antileishmaniasis medicines

Oral > Solid: 10 mg; 50 mg

### Indications

Visceral leishmaniasis

Mucocutaneous leishmaniasis

Cutaneous leishmaniasis

## Misoprostol

### Section

Uterotonics

Oral > Solid: 200 µg

Local > Vaginal > tablet: 25 µg

### Indications

Spontaneous abortion, incomplete, without complication

Unspecified obstetric condition

Postpartum haemorrhage

## Mometasone

### Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

### Indications

Therapeutic equivalent to [budesonide](#) for

Asthma

## Mometasone + formoterol

### Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

### Indications

Therapeutic equivalent to [budesonide + formoterol](#) for

Asthma

## Morphine

| Section                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Indications                                                                            |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| <p>Preoperative medication and sedation for short-term procedures</p> <p>Parenteral &gt; General injections &gt; IV: 10 mg in 1 mL ampoule (sulfate OR hydrochloride)</p> <p>Opioid analgesics</p> <p>Oral &gt; Liquid: 10 mg per 5 mL (morphine hydrochloride or morphine sulfate)</p> <p>Oral &gt; Solid: 10 mg immediate release (morphine sulfate); 10 to 200 mg slow release (morphine hydrochloride or morphine sulfate)</p> <p>Oral &gt; Other: 20 to 200 mg slow release granules to mix with water (morphine sulfate)</p> <p>Parenteral &gt; General injections &gt; unspecified: 10 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate)</p> | <p>Opioids or related analgesics and agents affecting opioid receptors</p> <p>Pain</p> |

## Moxifloxacin

| Section                                                                                                                                    | Indications                                                                |
|--------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|
| <p>Antituberculosis medicines</p> <p>Oral &gt; Solid: 400 mg tablet; 100 mg tablet (dispersible)</p> <p>Oral &gt; Solid: 400 mg tablet</p> | <p>Multi-drug resistant Mycobacterium tuberculosis</p> <p>Tuberculosis</p> |

## Multiple micronutrient powder

| Section                                              | Indications                    |
|------------------------------------------------------|--------------------------------|
| <p>Vitamins and minerals</p> <p>Oral &gt; Other:</p> | <p>Iron deficiency anaemia</p> |

## Multiple micronutrient supplement

| Section                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Indications                                                                            |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| <p>Other medicines administered to the mother</p> <p>Tablet containing:</p> <p>Vit A: 800 mcg retinol activity equivalent</p> <p>Vit C: 70 mg</p> <p>Vit D: 5 mcg (200 IU)</p> <p>Vit E: 10 mg alpha tocopherol equivalent</p> <p>Vit B1: 1.4 mg</p> <p>Vit B2: 1.4 mg</p> <p>Vit B3: 18 mg niacin equivalent</p> <p>Vit B6: 1.9 mg</p> <p>Folic acid: 400 mcg</p> <p>Vit B12: 2.6 mcg</p> <p>Iron: 30 mg</p> <p>Iodine: 150 mcg</p> <p>Zinc: 15 mg</p> <p>Selenium: 65 mcg</p> <p>Copper: 2 mg</p> | <p>Maternal care for other specified conditions predominantly related to pregnancy</p> |

## Mumps vaccine

| Section                                                                                                                                                                | Indications                                      |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|
| <p>Recommendations for immunization programmes with certain characteristics</p> <p>All vaccines should comply with the WHO requirements for biological substances.</p> | <p>Need for immunization against mumps alone</p> |

## Mupirocin

| Section                                                                                                                                                                   | Indications                                               |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------|
| <p>Dermatological medicines &gt; Anti-infective medicines</p> <p>Local &gt; Topical &gt; Cream: 2% (as mupirocin calcium)</p> <p>Local &gt; Topical &gt; Ointment: 2%</p> | <p>Superficial bacterial folliculitis</p> <p>Impetigo</p> |

## Nadroparin

### Section

Medicines affecting coagulation

### Indications

Therapeutic equivalent to enoxaparin for

Acute ischaemic heart disease

Therapeutic equivalent to enoxaparin for

Venous thromboembolism

## Nalidixic acid

### Section

Anti-infective medicines

Oral > Solid: 250 mg; 500 mg

### Indications

Shigella resistant to unspecified antibiotic

## Naloxone

### Section

Antidotes and other substances used in poisonings > Specific  
Parenteral > General injections > unspecified: 400 µg per 1 mL in ampoule  
(naloxone hydrochloride)

### Indications

Unintentional exposure to or harmful effects of  
opioids or related analgesics

## Naltrexone

### Section

Medicines for alcohol use disorders  
Parenteral > General injections > IM: 380 mg in vial (extended-release)  
Oral > Solid > tablet: 50 mg

### Indications

Disorders due to use of alcohol

## Natamycin

### Section

Ophthalmological preparations > Anti-infective agents  
Local > Ophthalmological > Suspension: 5% eye drops

### Indications

Infectious keratitis

## Nelfinavir

### Section

Antiretrovirals > Protease inhibitors  
Oral > Solid: 250 mg (as mesilate)  
Oral > Other: 50 mg per g oral powder

### Indications

Human immunodeficiency virus disease  
without mention of associated disease or  
condition, clinical stage unspecified

## Neostigmine

### Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

Oral > Solid: 15 mg (neostigmine bromide)

Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)

### Indications

Myasthenia gravis

Anticholinesterase reversible

## Netilmicin

### Section

Ophthalmological preparations > Anti-infective agents

### Indications

Therapeutic equivalent to [gentamicin](#) for

Other specified conjunctivitis

Therapeutic equivalent to [gentamicin](#) for

Infectious blepharitis

## Nevirapine

### Section

Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors

Oral > Liquid: 50 mg per 5 mL oral solution

Oral > Solid: 200 mg tablet; 50 mg tablet (dispersible)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Niclosamide

### Section

Intestinal anthelmintics

Oral > Solid: 500 mg tablet (chewable)

### Indications

Hymenolepiasis

Diphyllobothriasis

Taeniasis due to *Taenia saginata*

Taeniasis due to *Taenia solium*

## Nicotinamide

### Section

Vitamins and minerals

Oral > Solid: 50 mg

### Indications

Pellagra

## Nicotine replacement therapy

| Section                                                                                                                                                                                                                                           | Indications                |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|
| <b>Medicines for nicotine use disorders</b><br>Oral > Other: 2 mg chewing gum; 4 mg chewing gum; 2 mg lozenge; 4 mg lozenge; 1 mg per actuation oral spray<br>Local > Topical > Transdermal patch: 5 to 30 mg per 16 hour; 7 to 21 mg per 24 hour | <b>Nicotine dependence</b> |

## Nifedipine

| Section                                                                                         | Indications                            |
|-------------------------------------------------------------------------------------------------|----------------------------------------|
| <b>Antioxytocics (tocolytics)</b><br>Oral > Solid: 10 mg (immediate-release)                    | <b>Preterm labour without delivery</b> |
| <b>Antianginal medicines</b><br>Oral > Solid: 10 mg                                             | <b>Angina pectoris</b>                 |
| <b>Antihypertensive medicines</b><br>Oral > Solid: 10 mg tablet; sustained-release formulations | <b>Essential hypertension</b>          |

## Nifurtimox

| Section                                                                                                                           | Indications                    |
|-----------------------------------------------------------------------------------------------------------------------------------|--------------------------------|
| <b>Medicines for the treatment of 2nd stage African trypanosomiasis</b><br>Oral > Solid > tablet: 120 mg (scored); 30 mg (scored) | <b>African trypanosomiasis</b> |
| <b>American trypanosomiasis</b><br>Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)                                         | <b>Chagas disease</b>          |

## Nilotinib

| Section                                                                   | Indications                                                |
|---------------------------------------------------------------------------|------------------------------------------------------------|
| <b>Targeted therapies</b><br>Oral > Solid: 150 mg capsule; 200 mg capsule | <b>Chronic myeloid leukaemia, not elsewhere classified</b> |

## Nilutamide

| Section                          | Indications                                                                                 |
|----------------------------------|---------------------------------------------------------------------------------------------|
| <b>Hormones and antihormones</b> | Therapeutic equivalent to <b>bicalutamide</b> for<br><b>Malignant neoplasms of prostate</b> |

## Nitrofurantoin

### Section

Access group antibiotics

Oral > Liquid: 25 mg per 5 mL oral liquid

Oral > Solid > dosage form: 100 mg; 50 mg

### Indications

#### First choice

Infectious cystitis

## Nitrous oxide

### Section

General anaesthetics and oxygen > Inhalational medicines

Respiratory > Inhalation:

### Indications

Anaesthetics and therapeutic gases

## Nivolumab

### Section

Immunomodulators

Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion

### Indications

Other specified malignant neoplasms of bronchus or lung

Melanoma of skin

## Norethisterone

### Section

Oral hormonal contraceptives

Oral > Solid: 350 µg

Progestogens

Oral > Solid: 5 mg

### Indications

Contact with health services for contraceptive management

Excessive menstruation with irregular cycle

Therapeutic equivalent to medroxyprogesterone acetate for

Excessive menstruation with irregular cycle

## Norethisterone enantate

### Section

Injectable hormonal contraceptives

Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution

### Indications

Contact with health services for reasons associated with reproduction

## Normal immunoglobulin

### Section

#### Human immunoglobulins

Parenteral > General injections > IV: 5% protein solution; 10% protein solution

Parenteral > General injections > IM: 16% protein solution

Parenteral > General injections > SC: 15% protein solution; 16% protein solution

### Indications

Primary immunodeficiencies

Mucocutaneous lymph node syndrome

Langerhans cell histiocytosis

## Nystatin

### Section

#### Antifungal medicines

Oral > Liquid: 100000 IU per mL

Local > Topical > Other: 100000 IU pessary

Oral > Solid > dosage form: 500000 IU

Oral > Solid > lozenge: 100000 IU

### Indications

Candidosis

## Ocrelizumab

### Section

#### Medicines for multiple sclerosis

Parenteral > General injections > IV: 30 mg per mL in 10 vial concentrate for solution

Parenteral > General injections > IV: 30 mg per mL in 10 mL vial

### Indications

Multiple sclerosis

Relapsing-remitting multiple sclerosis

## Octreotide

### Section

#### Medicines for disorders of the pituitary hormone system

Parenteral > General injections > IM: 20 mg in vial (modified-release, as acetate) plus diluent

Parenteral > General injections > SC: 0.05 mg per mL in 1 mL vial (immediate-release, as acetate); 0.1 mg per mL in 1 mL vial (immediate-release, as acetate); 0.5 mg per mL in 1 mL vial (immediate-release, as acetate)

### Indications

Acromegaly or pituitary gigantism

## Ofloxacin

| Section                                                                                                        | Indications                                                                        |
|----------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
| Antituberculosis medicines<br>Oral > Solid: 200 mg; 400 mg                                                     | Multi-drug resistant Mycobacterium tuberculosis                                    |
| Ear, nose and throat medicines [c]                                                                             | Therapeutic equivalent to ciprofloxacin for<br>Infectious diseases of external ear |
| Ophthalmological preparations > Anti-infective agents<br>Local > Ophthalmological > Solution (eye drops): 0.3% | Other specified conjunctivitis<br>Infectious keratitis                             |

## Olanzapine

| Section                                                                                                       | Indications                                                                                                                                           |
|---------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
| Medicines for psychotic disorders<br>Parenteral > General injections > IM: 10 mg in vial powder for injection | Therapeutic equivalent to risperidone for<br>Schizophrenia or other primary psychotic disorders<br>Schizophrenia or other primary psychotic disorders |

## Omadacycline

| Section                                                                                                                            | Indications                                 |
|------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|
| Reserve group antibiotics<br>Parenteral > General injections > IV: 100 mg lyophilized powder for injection<br>Oral > Solid: 300 mg | Methicillin resistant Staphylococcus aureus |

## Ombitasvir + paritaprevir + ritonavir

| Section                                                                                                                           | Indications         |
|-----------------------------------------------------------------------------------------------------------------------------------|---------------------|
| Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations<br>Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet | Chronic hepatitis C |

## Omeprazole

| Section                                                                                                                                                                                      | Indications                                                                                      |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| Antiulcer medicines<br>Oral > Liquid: 20 mg powder for oral liquid; 40 mg powder for oral liquid<br>Oral > Solid: 10 mg; 20 mg; 40 mg<br>Parenteral > General injections > IV: 40 mg in vial | Peptic ulcer, site unspecified<br>Gastro-oesophageal reflux disease<br>Gastrointestinal bleeding |

## Ondansetron

### Section

#### Medicines for other common symptoms in palliative care

Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (ondansetron base, as hydrochloride)

Oral > Liquid: 4 mg per 5 mL (ondansetron base)

Oral > Solid: 4 mg (ondansetron base); 8 mg (ondansetron base)

#### Antiemetic medicines

Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (ondansetron base, as hydrochloride)

Oral > Liquid: 4 mg per 5 mL (ondansetron base)

Oral > Solid: 4 mg (ondansetron base); 8 mg (ondansetron base); 24 mg (ondansetron base)

### Indications

Palliative care

Nausea or vomiting

## Oral rehydration salts

| Section                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Indications                                                                                                                                 |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Oral rehydration</b><br>Powder for dilution in 200 mL, 500 mL, 1 L: <ul style="list-style-type: none"><li>- glucose 75 mEq</li><li>- sodium 75 mEq or mmol/L</li><li>- chloride 65 mEq or mmol/L</li><li>- potassium 20 mEq or mmol/L</li><li>- citrate 10 mmol/L</li><li>- osmolarity 245 mOsm/L</li><li>- glucose 13.5 g/L</li><li>- sodium chloride 2.6 g/L</li><li>- potassium chloride 1.5 g/L</li><li>- trisodium citrate dihydrate 2.9 g/L</li></ul><br><b>Solutions correcting water, electrolyte and acid-base disturbances &gt; Oral</b><br>Powder for dilution in 200 mL, 500 mL, 1 L: <ul style="list-style-type: none"><li>- glucose 75 mEq</li><li>- sodium 75 mEq or mmol/L</li><li>- chloride 65 mEq or mmol/L</li><li>- potassium 20 mEq or mmol/L</li><li>- citrate 10 mmol/L</li><li>- osmolarity 245 mOsm/L</li><li>- glucose 13.5 g/L</li><li>- sodium chloride 2.6 g/L</li><li>- potassium chloride 1.5 g/L</li><li>- trisodium citrate dihydrate 2.9 g/L</li></ul> | <div>Diarrhoea</div><br><br><br><br><br><br><br><br><br><br><div>Other specified disorders of fluid, electrolyte or acid-base balance</div> |

## Oral rehydration salts - zinc sulfate

| Section                                                                                                                                 | Indications          |
|-----------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| <b>Medicines used in diarrhoea</b><br>Oral > Other: ORS powder for dilution and zinc sulfate solid oral dosage form 20 mg (co-packaged) | <div>Diarrhoea</div> |

## Oseltamivir

| Section                                                                                                                           | Indications                                                     |
|-----------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|
| <b>Other antivirals</b><br>Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate) | <div>Influenza due to identified seasonal influenza virus</div> |

## Osimertinib

### Section

#### Targeted therapies

Oral > Solid: 40 mg (as mesylate); 80 mg (as mesylate)

### Indications

Other specified malignant neoplasms of bronchus or lung

## Oxaliplatin

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial

### Indications

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of colon

## Oxamniquine

### Section

#### Antischistosomes and other antitremitode medicines

Oral > Liquid: 250 mg per 5 mL

Oral > Solid: 250 mg capsule

### Indications

Schistosomiasis due to *Schistosoma mansoni*

## Oxazolindinones

### Section

#### Reserve group antibiotics

.

### Indications

Other specified bacterial diseases

## Oxycodone

### Section

#### Opioid analgesics

### Indications

Therapeutic equivalent to [morphine](#) for

Pain

## Oxygen

### Section

#### General anaesthetics and oxygen > Inhalational medicines

Respiratory > Inhalation: (medical gas)

#### Medical gases

Respiratory > Inhalation:

### Indications

Anaesthetics and therapeutic gases

Respiratory failure as acute or chronic

## Oxytetracycline

### Section

Ophthalmological preparations > Anti-infective agents

### Indications

Therapeutic equivalent to tetracycline for

Other specified conjunctivitis

Therapeutic equivalent to tetracycline for

Infectious keratitis

Therapeutic equivalent to tetracycline for

Infectious blepharitis

Therapeutic equivalent to tetracycline for

Trachoma

## Oxytocin

### Section

Uterotonics

Parenteral > General injections > unspecified: 10 IU per mL

### Indications

Postpartum haemorrhage

## P-aminosalicylate sodium

### Section

Antituberculosis medicines

Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid)

### Indications

Multi-drug resistant Mycobacterium tuberculosis

## P-aminosalicylic acid

### Section

Antituberculosis medicines

Oral > Solid: 4 g granules in sachet

### Indications

Multi-drug resistant Mycobacterium tuberculosis

## Paclitaxel

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 6 mg per mL

### Indications

Other specified malignant neoplasms of the ovary

Other specified malignant neoplasms of bronchus or lung

Malignant neoplasms of nasopharynx

Kaposi sarcoma of unspecified primary site

Other specified malignant neoplasms of breast

Other specified carcinomas of ovary

Malignant neoplasms of breast

Malignant neoplasms of cervix uteri

## Palbociclib

### Section

#### Targeted therapies

Oral > Solid: 75 mg; 100 mg; 125 mg

### Indications

Other specified malignant neoplasms of breast

## Paliperidone

### Section

#### Medicines for psychotic disorders

Parenteral > General injections > IM: 25 mg in pre-filled syringe (as palmitate); 50 mg in pre-filled syringe (as palmitate); 75 mg in pre-filled syringe (as palmitate); 100 mg in pre-filled syringe (as palmitate); 150 mg in pre-filled syringe (as palmitate)

### Indications

Therapeutic equivalent to risperidone for

Schizophrenia or other primary psychotic disorders

Schizophrenia or other primary psychotic disorders

## Palonosetron

### Section

#### Medicines for other common symptoms in palliative care

#### Antiemetic medicines

### Indications

Therapeutic equivalent to ondansetron for

Palliative care

Therapeutic equivalent to ondansetron for

Nausea or vomiting

## Pancreatic enzymes

### Section

#### Pancreatic enzymes

Oral > Solid: Age-appropriate formulations and doses including lipase, protease and amylase.

### Indications

Enzyme intestinal

## Paracetamol (acetaminophen)

### Section

#### Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs)

Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL

Local > Rectal > Suppository: 100 mg; 250 mg

Oral > Solid > dispersible tablet: 100 mg; 250 mg

Oral > Solid > tablet: 250 mg; 325 mg; 500 mg

#### Antimigraine medicines > For treatment of acute attack

Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL

Local > Rectal > Suppository: 250 mg

Oral > Solid > dispersible tablet: 100 mg; 250 mg

Oral > Solid > tablet: 250 mg; 325 mg; 500 mg

### Indications

Pain

Migraine

## Paromomycin

### Section

#### Antileishmaniasis medicines

Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)

#### Antiamoebic and anti-giardiasis medicines

Oral > Liquid: 125 mg per 5 mL as sulfate

Oral > Solid: 250 mg as sulfate

### Indications

Visceral leishmaniasis

Amoebiasis

## Pegaspargase

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection

### Indications

Lymphoid leukaemia, not elsewhere classified

## Pegfilgrastim

### Section

#### Immunomodulators

Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe

### Indications

Acquired neutropaenia

## Pegylated interferon alfa (2a)

### Section

Medicines for hepatitis C > Other antivirals for hepatitis C

Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe

### Indications

Chronic hepatitis C

## Pegylated interferon alfa (2b)

### Section

Medicines for hepatitis C > Other antivirals for hepatitis C

Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe

### Indications

Chronic hepatitis C

## Pembrolizumab

### Section

Immunomodulators

Parenteral > General injections > IV: 50 mg powder for injection

### Indications

Therapeutic equivalent to nivolumab for

Melanoma of skin

Other specified malignant neoplasms of bronchus or lung

## Penicillamine

### Section

Antidotes and other substances used in poisonings > Specific

Oral > Solid: 250 mg

Disease-modifying anti-rheumatic drugs (DMARDs)

Oral > Solid: 250 mg

### Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Rheumatoid arthritis, serology unspecified

## Pentamidine

### Section

Antileishmaniasis medicines

Parenteral > General injections > IM: 200 mg (as isetionate); 300 mg (as isetionate)

Antipneumocystosis and antitoxoplasmosis medicines

Oral > Solid: 200 mg tablet; 300 mg tablet

Medicines for the treatment of 1st stage African trypanosomiasis

Parenteral > General injections > IM: 300 mg in vial (as isetionate) powder for injection

### Indications

Visceral leishmaniasis

Pneumocystosis

African trypanosomiasis

## Permethrin

### Section

[Dermatological medicines > Scabicides and pediculicides](#)

Local > Topical > Lotion: 1%

Local > Topical > Cream: 5%

### Indications

[Pediculosis corporis](#)

[Pediculosis capitis](#)

[Scabies](#)

## Pertussis vaccine

### Section

[Recommendations for all immunization programmes](#)

All vaccines should comply with the WHO requirements for biological substances.

### Indications

[Need for immunization against pertussis alone](#)

## Pertuzumab

### Section

[Targeted therapies](#)

Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution

### Indications

[Carcinoma of breast, specialised type](#)

## Phenelzine

### Section

[Medicines for depressive disorders](#)

Oral > Solid > dosage form: 15 mg (as sulfate)

### Indications

[Other specified depressive disorders](#)

## Phenobarbital

### Section

[Antiseizure medicines](#)

Oral > Liquid: 15 mg per 5 mL

Oral > Solid: 15 to 100 mg

Parenteral > General injections > IV: 200 mg per mL (phenobarbital sodium); 30 mg per mL (phenobarbital sodium); 60 mg per mL (phenobarbital sodium)

### Indications

[Epilepsy or seizures](#)

[Status epilepticus](#)

## Phenoxymethylpenicillin

| Section                                                                                                                                                                                                                                 | Indications                                                                                                                                                                                                                                                        |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Access group antibiotics</b><br>Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid<br>Oral > Solid: 250 mg (as potassium salt) tablet<br>Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt) | <b>First choice</b><br><div>Acute pharyngitis</div> <div>Periapical abscess without sinus</div> <div>Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)</div><br><b>Other indications</b><br><div>Bacterial infection of unspecified site</div> |

## Phenytoin

| Section                                                                                                                                                                                                                                                                                                                                 | Indications                     |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|
| <b>Antiseizure medicines</b><br>Oral > Liquid: 30 mg per 5 mL (phenytoin)<br>Parenteral > General injections > unspecified: 50 mg per mL in vial (phenytoin sodium)<br>Oral > Solid > tablet: 50 mg (phenytoin) (chewable)<br>Oral > Solid > dosage form: 50 mg (phenytoin sodium); 25 mg (phenytoin sodium); 100 mg (phenytoin sodium) | <div>Epilepsy or seizures</div> |

## Phosphorus

| Section                                                                                                                                                                                                                                         | Indications                          |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|
| <b>Medicines for endocrine disorders</b><br>Oral > Other: 500 mg in sachet (elemental phosphorus) granules<br>Oral > Solid > tablet: 250 mg (elemental phosphorus); 500 mg (elemental phosphorus); 500 mg (elemental phosphorus) (effervescent) | <div>Hypophosphataemic rickets</div> |

## Phytomenadione

| Section                                                                                                                                                       | Indications                                                                                                                                                |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Medicines affecting coagulation</b><br>Parenteral > General injections > IV: 10 mg per mL in ampoule; 1 mg per mL in ampoule<br>Oral > Solid: 10 mg tablet | <div>Haemorrhagic disorder due to other specified circulating anticoagulants</div> <div>Haemorrhagic or haematological disorders of fetus or newborn</div> |

## Pilocarpine

### Section

Ophthalmological preparations > Miotics and antiglaucoma medicines  
Local > Ophthalmological > Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate)

### Indications

Acute angle closure with pupillary block

Ocular hypertension

Primary open-angle glaucoma

## Piperacillin + tazobactam

### Section

#### Watch group antibiotics

Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection

### Indications

#### First choice

Peritoneal abscess (severe)

Other specified pneumonia (Hospital-acquired pneumonia)

Neutropenia (high-risk)

Peritonitis (severe)

co-prescribed with clindamycin

Necrotising fasciitis

## Platelets

### Section

Blood and blood components  
Parenteral > General injections > IV:

### Indications

Blood transfusion without reported diagnosis

## Plazomicin

### Section

#### Reserve group antibiotics

Parenteral > General injections > IV: 500 mg per 10 mL (Injection)

### Indications

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

## Pneumococcal vaccine

### Section

Recommendations for all immunization programmes  
All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against single bacterial diseases

## Podophyllotoxin

### Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

### Indications

Therapeutic equivalent to [podophyllum resin](#) for

Anogenital warts

Therapeutic equivalent to [podophyllum resin](#) for

Plantar warts

## Podophyllum resin

### Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Local > Topical > Solution: 10 to 25%

### Indications

Anogenital warts

Plantar warts

## Poliomyelitis vaccine

### Section

Recommendations for all immunization programmes

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against poliomyelitis

## Polygeline

### Section

Plasma substitutes

Parenteral > General injections > IV: 3.5% injectable solution

Parenteral > General injections > IV: 3.5% in solution

### Indications

Therapeutic equivalent to [dextran 70](#) for

Hypovolaemia

Hypovolaemia

## Polymyxin B (injection)

### Section

Reserve group antibiotics

Parenteral > General injections > unspecified: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)

### Indications

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

## Polymyxins

### Section

Reserve group antibiotics

### Indications

Other specified bacterial diseases

## Potassium chloride

| Section                                                                                                                                                                                                                                                                                                                                                                                                                         | Indications  |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| Solutions correcting water, electrolyte and acid-base disturbances > Oral<br>Oral > Liquid: powder for solution                                                                                                                                                                                                                                                                                                                 | Hypokalaemia |
| Solutions correcting water, electrolyte and acid-base disturbances > Parenteral<br>Parenteral > General injections > IV: 11.2% in 20 mL ampoule (equivalent to K <sup>+</sup> 1.5 mmol/mL and Cl <sup>-</sup> 1.5 mmol/mL); 7.5% solution for dilution (equivalent to K <sup>+</sup> 1 mmol/mL and Cl <sup>-</sup> 2 mmol/mL); 15% solution for dilution (equivalent to K <sup>+</sup> 2 mmol/mL and Cl <sup>-</sup> 2 mmol/mL) | Hypokalaemia |

## Potassium ferric hexacyanoferrate

| Section                                                                                                      | Indications                                                                                                       |
|--------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|
| Antidotes and other substances used in poisonings > Specific<br>Oral > Solid: Powder for oral administration | Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified |

## Potassium iodide

| Section                                                                | Indications    |
|------------------------------------------------------------------------|----------------|
| Antifungal medicines<br>Local > Topical > Solution: Saturated solution | Sporotrichosis |
| Thyroid hormones and antithyroid medicines<br>Oral > Solid: 60 mg      | Thyrotoxicosis |

## Potassium permanganate

| Section                                                                                                       | Indications                                                                  |
|---------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Dermatological medicines > Anti-infective medicines<br>Local > Topical > Solution: aqueous solution: 1:10 000 | Tropical phagedaenic ulcer                                                   |
|                                                                                                               | Pemphigus                                                                    |
|                                                                                                               | Other specified pyogenic bacterial infection of skin and subcutaneous tissue |
|                                                                                                               | Impetigo                                                                     |

## Povidone iodine

| Section                                                                            | Indications     |
|------------------------------------------------------------------------------------|-----------------|
| Antiseptics<br>Local > Topical > Solution: 10% (equivalent to 1% available iodine) | Povidone iodine |

## Pralidoxime

### Section

Antidotes and other substances used in poisonings > Specific

### Indications

Exposure to or harmful effects of undetermined intent of pesticides

## Pramipexole

### Section

Antiseizure medicines

Oral > Solid: 125 µg immediate-release; 250 mg immediate-release; 500 µg immediate-release; 750 µg immediate-release; 1 mg immediate-release; 1.5 mg immediate-release; 375 µg extended-release; 750 µg extended-release; 1.5 mg extended-release; 2.25 mg extended-release; 3 mg extended-release; 3.75 mg extended-release; 4.5 extended-release

### Indications

Parkinson disease

## Pravastatin

### Section

Lipid-lowering agents

### Indications

Therapeutic equivalent to [simvastatin](#) for

Mixed hyperlipidaemia

Therapeutic equivalent to [simvastatin](#) for

Coronary atherosclerosis

## Praziquantel

### Section

Antischistosomes and other antitremitode medicines

Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

### Indications

Paragonimiasis

Clonorchiasis

Opisthorchiasis

Schistosomiasis

Intestinal anthelminthics

Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

Taeniasis due to *Taenia saginata*

Taeniasis due to *Taenia solium*

Diphyllobothriasis

Hymenolepiasis

Cysticidal medicines

Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

Cysticercosis of central nervous system

## Precipitated sulfur

### Section

[Dermatological medicines](#) > [Scabicides and pediculicides](#)

Local > Topical > Ointment:

### Indications

Therapeutic equivalent to [benzyl benzoate](#) for

Pthiriasis

Therapeutic equivalent to [benzyl benzoate](#) for

Pediculosis corporis

Therapeutic equivalent to [benzyl benzoate](#) for

Pediculosis capitis

Therapeutic equivalent to [benzyl benzoate](#) for

Scabies

## Prednisolone

### Section

#### Hormones and antihormones

Oral > Liquid: 5 mg per mL

Oral > Solid: 5 mg; 25 mg

#### Anti-inflammatory medicines

Local > Rectal > Retention enema:

Local > Rectal > Retention enema: 20 mg per 100 mL (as sodium phosphate)

#### Antiallergics and medicines used in anaphylaxis

Oral > Liquid: 5 mg per mL

Oral > Solid: 5 mg; 25 mg

#### Ophthalmological preparations > Anti-inflammatory agents

Local > Ophthalmological > Solution (eye drops): 0.5% (sodium phosphate)

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Plasma cell myeloma

Follicular lymphoma

Lymphoid leukaemia, not elsewhere classified

Malignant neoplasms of prostate

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Hodgkin lymphoma

Diffuse large B-cell lymphomas

Burkitt lymphoma including Burkitt leukaemia

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Langerhans cell histiocytosis

Therapeutic equivalent to hydrocortisone for

Crohn disease site

Crohn disease site

Ulcerative colitis

Allergic or hypersensitivity conditions of unspecified type

Scleritis

Anterior uveitis

## Prednisone

### Section

Hormones and antihormones

### Indications

Therapeutic equivalent to prednisolone for

Plasma cell myeloma

Therapeutic equivalent to prednisolone for

Follicular lymphoma

Therapeutic equivalent to prednisolone for

Lymphoid leukaemia, not elsewhere classified

Therapeutic equivalent to prednisolone for

Malignant neoplasms of prostate

Therapeutic equivalent to prednisolone for

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Therapeutic equivalent to prednisolone for

Hodgkin lymphoma

Therapeutic equivalent to prednisolone for

Diffuse large B-cell lymphomas

Therapeutic equivalent to prednisolone for

Anaplastic large cell lymphoma, ALK-negative

Therapeutic equivalent to prednisolone for

Anaplastic large cell lymphoma, ALK-positive

Therapeutic equivalent to prednisolone for

Langerhans cell histiocytosis

Antiallergics and medicines used in anaphylaxis

Therapeutic equivalent to prednisolone for

Allergic or hypersensitivity conditions of unspecified type

## Pretomanid

### Section

Antituberculosis medicines

Oral > Solid > tablet: 200 mg

### Indications

Multi-drug resistant Mycobacterium tuberculosis

## Primaquine

### Section

Antimalarial medicines > For curative treatment

Oral > Solid: 7.5 mg tablet (as phosphate); 15 mg tablet (as phosphate)

### Indications

Malaria due to Plasmodium ovale

Malaria due to Plasmodium vivax

## Probenecid

### Section

Medicines used to treat gout

Oral > Solid: 500 mg

### Indications

Gout

## Procainamide

### Section

Antiarrhythmic medicines

Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule (hydrochloride)

Oral > Solid: 500 mg (hydrochloride); 250 mg (hydrochloride)

### Indications

Cardiac arrhythmia

## Procaine benzylpenicillin

### Section

Access group antibiotics

Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection

### Indications

#### First choice

Congenital syphilis [children]

#### Second choice

Syphilis

## Procarbazine

### Section

Cytotoxic medicines

Oral > Solid: 50 mg (as hydrochloride)

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Hodgkin lymphoma

## Progesterone vaginal ring

### Section

Intravaginal contraceptives

Local > Vaginal > vaginal ring: 2.074 g micronized progesterone

### Indications

Contact with health services for contraceptive management

## Proguanil

### Section

Antimalarial medicines > For chemoprevention

Oral > Solid: 100 mg tablet (hydrochloride)

### Indications

Malaria due to Plasmodium falciparum

## Promethazine

| Section                                                                                                                                                                                                                           | Indications                        |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|
| <a href="#">Antiemetic medicines</a><br>Oral > Liquid: 5 mg per 5 mL (hydrochloride)<br>Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)<br>Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule | <a href="#">Nausea or vomiting</a> |

## Propanol

| Section                     | Indications                                                                                |
|-----------------------------|--------------------------------------------------------------------------------------------|
| <a href="#">Antiseptics</a> | Therapeutic equivalent to <a href="#">ethanol</a> for<br><a href="#">Denatured alcohol</a> |

## Propofol

| Section                                                                                                                                       | Indications                                        |
|-----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|
| <a href="#">General anaesthetics and oxygen &gt; Injectable medicines</a><br>Parenteral > General injections > IV: 10 mg per mL; 20 mg per mL | <a href="#">Anaesthetics and therapeutic gases</a> |

## Propranolol

| Section                                                                                                                                                                                            | Indications                            |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|
| <a href="#">Antihypertensive medicines</a><br>Oral > Solid: 80 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)                                                                             | <a href="#">Essential hypertension</a> |
| <a href="#">Antianginal medicines</a><br>Parenteral > General injections > IV: 1 mg in 1 mL ampoule (hydrochloride)<br>Oral > Solid: 10 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)    | <a href="#">Angina pectoris</a>        |
| <a href="#">Antiarrhythmic medicines</a><br>Parenteral > General injections > IV: 1 mg in 1 mL ampoule (hydrochloride)<br>Oral > Solid: 10 mg tablet (hydrochloride); 40 mg tablet (hydrochloride) | <a href="#">Cardiac arrhythmia</a>     |
| <a href="#">Antimigraine medicines &gt; For prophylaxis</a><br>Oral > Solid: 40 mg tablet (hydrochloride); 20 mg tablet (hydrochloride)                                                            | <a href="#">Migraine</a>               |

## Propylthiouracil

| Section                                                                           | Indications                    |
|-----------------------------------------------------------------------------------|--------------------------------|
| <a href="#">Thyroid hormones and antithyroid medicines</a><br>Oral > Solid: 50 mg | <a href="#">Thyrotoxicosis</a> |

## Prostaglandin E1

### Section

Medicines administered to the neonate [c]

Parenteral > General injections > IV: 0.5 mg per mL in alcohol

### Indications

Other specified congenital anomaly of great arteries including arterial duct

## Prostaglandin E2

### Section

Medicines administered to the neonate [c]

Parenteral > General injections > IV: 1 mg per mL

### Indications

Therapeutic equivalent to [prostaglandin E1](#) for

Other specified congenital anomaly of great arteries including arterial duct

Other specified congenital anomaly of great arteries including arterial duct

## Protamine sulfate

### Section

Medicines affecting coagulation

Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule

### Indications

Haemorrhagic disorder due to other specified circulating anticoagulants

## Protionamide

### Section

Antituberculosis medicines

### Indications

Therapeutic equivalent to [ethionamide](#) for

Multi-drug resistant *Mycobacterium tuberculosis*

## Pyrantel

### Section

Intestinal anthelmintics

Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)

### Indications

Ascariasis

Enterobiasis

Trichuriasis

Hookworm diseases

## Pyrazinamide

### Section

Antituberculosis medicines

Oral > Solid: 400 mg; 150 mg tablet (dispersible); 500 mg

### Indications

Tuberculosis

## Pyridostigmine

### Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

Parenteral > General injections > IV: 1 mg in 1 mL ampoule  
(pyridostigmine bromide)

Oral > Solid: 60 mg (pyridostigmine bromide)

### Indications

Myasthenia gravis

## Pyridoxine

### Section

Vitamins and minerals

Oral > Solid: 25 mg (hydrochloride)

### Indications

Vitamin B6 deficiency

Sideroblastic anaemia

Other specified polyneuropathy

## Pyrimethamine

### Section

Antipneumocystosis and antitoxoplasmosis medicines

Oral > Solid: 25 mg

### Indications

Toxoplasmosis

## Quetiapine

### Section

Medicines for psychotic disorders

Medicines for bipolar disorders

Oral > Solid > tablet: 25 mg (immediate-release); 100 mg (immediate-release); 150 mg (immediate-release); 200 mg (immediate-release); 300 mg (immediate-release); 50 mg (modified-release); 150 mg (modified-release); 200 mg (modified-release); 300 mg (modified-release); 400 mg (modified-release)

### Indications

Therapeutic equivalent to risperidone for

Schizophrenia or other primary psychotic disorders

Bipolar or related disorders

## Quinidine

### Section

Antiarrhythmic medicines

Oral > Solid: 200 mg (sulfate)

### Indications

Cardiac arrhythmia

## Quinine

### Section

Antimalarial medicines > For curative treatment

Parenteral > General injections > IV: 300 mg per mL in 2 mL ampoule (quinine hydrochloride)

Oral > Solid: 300 mg (quinine sulfate or quinine bisulfate)

### Indications

Malaria due to *Plasmodium falciparum*

## Rabies vaccine

### Section

Recommendations for some high-risk populations

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against rabies

## Raltegravir

### Section

Antiretrovirals > Integrase inhibitors

Oral > Liquid: 100 mg granules for oral suspension

Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Ranibizumab

### Section

Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations

.

### Indications

Retinal venous occlusions

Diabetic macular oedema

Degenerative high myopia

Age related macular degeneration

## Ranitidine

### Section

Antiulcer medicines

Oral > Liquid: 75 mg per 5 mL (as hydrochloride)

Oral > Solid: 150 mg (as hydrochloride)

Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (as hydrochloride)

### Indications

Gastro-oesophageal reflux disease

Peptic ulcer, site unspecified

## Rasburicase

| Section                                                                                                                                                      | Indications           |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| Supportive medicines<br>Parenteral > General injections > IV: 1.5 mg in vial powder and solvent for solution; 7.5 mg in vial powder and solvent for solution | Tumour lysis syndrome |

## Ravidasvir

| Section                                                                                                        | Indications         |
|----------------------------------------------------------------------------------------------------------------|---------------------|
| Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations<br>Oral > Solid > tablet: 200 mg | Chronic hepatitis C |

## Ready to use therapeutic food

| Section                                                                                                                                                                                                    | Indications                                            |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Therapeutic foods<br>Biscuit or paste of nutritional composition as determined by the UN joint statement on the community-based management of severe acute malnutrition and Codex alimentarius guidelines. | Acute malnutrition in infants, children or adolescents |

## Realgar-indigo naturalis formulation

| Section                                                                                    | Indications                                                  |
|--------------------------------------------------------------------------------------------|--------------------------------------------------------------|
| Cytotoxic medicines<br>Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg) | Acute myeloid leukaemia with recurrent genetic abnormalities |

## Red blood cells

| Section                                                             | Indications                                  |
|---------------------------------------------------------------------|----------------------------------------------|
| Blood and blood components<br>Parenteral > General injections > IV: | Blood transfusion without reported diagnosis |

## Resin-based composite (high-viscosity)

| Section                                                                                               | Indications   |
|-------------------------------------------------------------------------------------------------------|---------------|
| Dental medicines and preparations<br>Local > Topical > Other: Single-use capsule or multi-use syringe | Dental caries |

## Resin-based composite (low-viscosity)

| Section                                                                                                 | Indications   |
|---------------------------------------------------------------------------------------------------------|---------------|
| Dental medicines and preparations<br>Local > Topical > Other: Single-use applicator or multi-use bottle | Dental caries |

## Retinol

| Section                                                                                                                                                                                                                                                                                                                                                                                                       | Indications                 |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|
| <b>Vitamins and minerals</b><br>Parenteral > General injections > IM: 100000 IU in 2 mL ampoule (as palmitate) water-miscible injection<br><br>Oral > Liquid: 100000 IU per mL (as palmitate) oral oily solution in multidose dispenser<br><br>Oral > Solid: 10000 IU (as palmitate) sugar-coated tablet; 200000 IU (as palmitate) capsule; 50000 IU (as palmitate) capsule; 100000 IU (as palmitate) capsule | <b>Vitamin A deficiency</b> |

## Ribavirin

| Section                                                                                                                                                                                                                                             | Indications                                               |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------|
| <b>Other antivirals</b><br>Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution<br><br>Oral > Solid: 200 mg; 400 mg; 600 mg                                                | <b>Viral haemorrhagic fever, not elsewhere classified</b> |
| <b>Medicines for hepatitis C &gt; Other antivirals for hepatitis C</b><br>Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution<br><br>Oral > Solid: 200 mg; 400 mg; 600 mg | <b>Chronic hepatitis C</b>                                |

## Ribociclib

| Section                   | Indications                                                                                              |
|---------------------------|----------------------------------------------------------------------------------------------------------|
| <b>Targeted therapies</b> | Therapeutic equivalent to <b>palbociclib</b> for<br><b>Other specified malignant neoplasms of breast</b> |

## Riboflavin

| Section                                            | Indications                  |
|----------------------------------------------------|------------------------------|
| <b>Vitamins and minerals</b><br>Oral > Solid: 5 mg | <b>Vitamin B2 deficiency</b> |

## Rifabutin

| Section                                                   | Indications         |
|-----------------------------------------------------------|---------------------|
| <b>Antituberculosis medicines</b><br>Oral > Solid: 150 mg | <b>Tuberculosis</b> |

## Rifampicin

### Section

#### Antituberculosis medicines

Oral > Liquid: 20 mg per mL

Oral > Solid: 150 mg; 300 mg

Parenteral > General injections > IV: 600 mg in vial powder for injection

#### Antileprosy medicines

Oral > Liquid: 20 mg per mL

Oral > Solid: 150 mg; 300 mg

### Indications

Tuberculosis

Other specified tuberculosis

Leprosy

## Rifapentine

### Section

#### Antituberculosis medicines

Oral > Solid: 150 mg tablet; 300 mg tablet

### Indications

Tuberculosis

Latent tuberculosis

## Risdiplam

### Section

#### Medicines for diseases of the nervous system

Oral > Liquid: 0.75 mg per mL powder for oral liquid

### Indications

Spinal muscular atrophy

## Risperidone

### Section

#### Medicines for psychotic disorders

Oral > Solid: 0.25 mg; 0.5 mg; 1 mg; 2 mg; 3 mg; 4 mg; 6 mg

Parenteral > General injections > IM:

### Indications

Schizophrenia or other primary psychotic disorders

Therapeutic equivalent to paliperidone for

Schizophrenia or other primary psychotic disorders

## Ritonavir

### Section

#### Antiretrovirals > Protease inhibitors

Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Rituximab

| Section                                                                                                                           | Indications                                                                                                                                                                                             |
|-----------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Targeted therapies</b><br>Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial | <div>Follicular lymphoma</div> <div>Chronic lymphocytic leukaemia or small lymphocytic lymphoma</div> <div>Diffuse large B-cell lymphomas</div> <div>Burkitt lymphoma including Burkitt leukaemia</div> |
| <b>Medicines for multiple sclerosis</b><br>Parenteral > General injections > IV: 500 mg per 50 mL in 50 mL vial                   | <div>Multiple sclerosis</div>                                                                                                                                                                           |

## Rivaroxaban

| Section                                | Indications                                                                                                                                                                              |
|----------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Medicines affecting coagulation</b> | <div>Therapeutic equivalent to dabigatran for</div> <div>Venous thromboembolism</div> <div>Therapeutic equivalent to dabigatran for</div> <div>Other specified atrial fibrillation</div> |

## Ropinirole

| Section                                                                                                                                                                                                                                                                                                                                    | Indications                  |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|
| <b>Antiseizure medicines</b><br>Oral > Solid: 0.25 mg immediate-release; 0.5 mg immediate-release; 1 mg immediate-release; 2 immediate-release; 3 mg immediate-release; 4 mg immediate-release; 5 mg immediate-release; 2 mg extended-release; 4 mg extended-release; 6 mg extended-release; 8 mg extended-release; 12 mg extended-release | <div>Parkinson disease</div> |

## Rotavirus vaccine

| Section                                                                                                                                   | Indications                                                            |
|-------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|
| <b>Recommendations for all immunization programmes</b><br>All vaccines should comply with the WHO requirements for biological substances. | <div>Need for immunization against certain single viral diseases</div> |

## Rubella vaccine

| Section                                                                                                                                   | Indications                                            |
|-------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Recommendations for all immunization programmes</b><br>All vaccines should comply with the WHO requirements for biological substances. | <div>Need for immunization against rubella alone</div> |

## Salbutamol

### Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Parenteral > General injections > IV: 50 µg per mL in 5 mL ampoule (as sulfate)

Respiratory > Inhalation > aerosol: 100 µg per dose (as sulfate); 100 µg per dose (as sulfate) metered-dose inhaler

Respiratory > Inhalation > solution: 5 mg per mL (as sulfate) for use in nebulizers

### Indications

Chronic obstructive pulmonary disease

Asthma

## Salicylic acid

### Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Local > Topical > Solution: 5%

### Indications

Seborrhoeic dermatitis

Psoriasis of unspecified type

Ichthyoses

## Saquinavir

### Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 200 mg; 500 mg

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Selenium sulfide

### Section

Dermatological medicines > Antifungal medicines

Local > Topical > Suspension: 2% detergent-based

### Indications

Seborrhoeic dermatitis

Pityriasis versicolor

## Senna

### Section

Medicines for other common symptoms in palliative care

Oral > Liquid: 7.5 mg per 5 mL oral liquid

Laxatives

Oral > Solid: 7.5 mg (sennosides) (or traditional dosage forms)

### Indications

Palliative care

Constipation

## Sevoflurane

### Section

General anaesthetics and oxygen > Inhalational medicines  
Respiratory > Inhalation > liquid:

### Indications

Anaesthetics and therapeutic gases

## Silver diamine fluoride

### Section

Dental medicines and preparations  
Local > Dental > Solution: 38% w/v

### Indications

Dental caries

## Silver nitrate

### Section

Ophthalmological preparations > Anti-infective agents  
Local > Ophthalmological > Solution (eye drops): 1%

### Indications

Neonatal conjunctivitis or dacryocystitis

## Silver sulfadiazine

### Section

Dermatological medicines > Anti-infective medicines  
Local > Topical > Cream: 1%

### Indications

Burns

## Simeprevir

### Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations  
Oral > Solid: 150 mg

### Indications

Chronic hepatitis C

## Simvastatin

### Section

Lipid-lowering agents  
Oral > Solid: 5 mg; 10 mg; 20 mg; 40 mg

### Indications

Mixed hyperlipidaemia

Coronary atherosclerosis

Medicines for endocrine disorders  
Oral > Solid: 20 mg

Polycystic ovary syndrome

## Smallpox vaccine

### Section

Recommendations for all immunization programmes  
All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against certain single viral diseases

## Snake antivenom

### Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies  
.

### Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

## Sodium calcium edetate

### Section

Antidotes and other substances used in poisonings > Specific  
Parenteral > General injections > IV: 200 mg per mL in 5 mL ampoule

### Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

## Sodium chloride

### Section

Solutions correcting water, electrolyte and acid-base disturbances >  
Parenteral  
Parenteral > General injections > IV: 0.9% isotonic (equivalent to Na<sup>+</sup> 154 mmol/L and Cl<sup>-</sup> 154 mmol/L)

### Indications

Other specified disorders of fluid, electrolyte or acid-base balance

## Sodium hyaluronate

### Section

Ophthalmological preparations

### Indications

Therapeutic equivalent to hypromellose for

Keratoconjunctivitis sicca

## Sodium hydrogen carbonate

### Section

Solutions correcting water, electrolyte and acid-base disturbances >  
Parenteral  
Parenteral > General injections > IV: 1.4% isotonic (equivalent to Na<sup>+</sup> 167 mmol/L and HCO<sub>3</sub><sup>-</sup> 167 mmol/L); 8.4% in 10 mL ampoule (equivalent to Na<sup>+</sup> 1000 mmol/L and HCO<sub>3</sub><sup>-</sup> 1000 mmol/L)

### Indications

Acidosis

## Sodium nitrite

### Section

Antidotes and other substances used in poisonings > Specific  
Parenteral > General injections > IV: 30 mg per mL in 10 mL ampoule

### Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

## Sodium nitroprusside

### Section

Antihypertensive medicines  
Parenteral > General injections > IV: 50 mg in ampoule powder for infusion

### Indications

Hypertensive crisis

## Sodium stibogluconate

### Section

Antileishmaniasis medicines  
Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial

### Indications

Visceral leishmaniasis

Mucocutaneous leishmaniasis

Cutaneous leishmaniasis

## Sodium thiosulfate

### Section

Dermatological medicines > Antifungal medicines  
Local > Topical > Solution: 15%

Antidotes and other substances used in poisonings > Specific  
Parenteral > General injections > IV: 250 mg per mL in 50 mL ampoule

### Indications

Pityriasis versicolor

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

## Sofosbuvir

### Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations  
Oral > Solid: 400 mg; 200 mg

### Indications

Chronic hepatitis C

## Sofosbuvir + velpatasvir

### Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations  
Oral > Solid: 400 mg + 100 mg tablet; 200 mg + 50 mg tablet

### Indications

Chronic hepatitis C

## Somatropin

### Section

Medicines for endocrine disorders

Parenteral > General injections > SC: 5 mg in cartridge powder for injection; 5 mg per mL in 2 mL cartridge

### Indications

Hypoglycaemia without associated diabetes

## Spectinomycin

### Section

Access group antibiotics

Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection

### Indications

#### Second choice

Gonococcal infection

#### Other indications

Bacterial infection of unspecified site

## Spironolactone

### Section

Medicines used in heart failure

Oral > Solid: 25 mg

Diuretics

Oral > Liquid: 10 mg per 5 mL; 25 mg per 5 mL; 5 mg per 5 mL

Oral > Solid: 25 mg

### Indications

Heart failure

Oedema

Ascites

## Stavudine

### Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

Oral > Liquid: 5 mg per 5 mL powder for oral solution

Oral > Solid: 15 mg; 20 mg; 30 mg

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Streptokinase

### Section

Thrombolytic medicines

Parenteral > General injections > IV: 1.5 million IU in vial powder for injection

### Indications

Acute myocardial infarction

## Streptomycin (injection)

### Section

Antituberculosis medicines

Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial

### Indications

Multi-drug resistant Mycobacterium tuberculosis

## Succimer

### Section

Antidotes and other substances used in poisonings > Specific

Oral > Solid: 100 mg

### Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

## Sulfacetamide

### Section

Ophthalmological preparations > Anti-infective agents

Local > Ophthalmological > Ointment: 10% (sodium salt)

### Indications

Other specified conjunctivitis

## Sulfadiazine

### Section

Antipneumocystosis and antitoxoplasmosis medicines

Oral > Solid: 500 mg

Anti-infective medicines

Oral > Solid: 500 mg

Parenteral > General injections > unspecified: 250 mg in 4 mL ampoule (sodium salt)

### Indications

Toxoplasmosis

Bacterial infection of unspecified site

## Sulfadimidine

### Section

Anti-infective medicines

Oral > Liquid: 500 mg per 5 mL

Oral > Solid: 500 mg

Parenteral > General injections > unspecified: 1 g in 3 mL ampoule (sodium salt)

### Indications

Bacterial infection of unspecified site

## Sulfadoxine + pyrimethamine

| Section                                                                                                                                         | Indications                                                                                             |
|-------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| <a href="#">Antimalarial medicines &gt; For curative treatment</a><br>Oral > Solid: 500 mg + 25 mg tablet                                       | <a href="#">Malaria due to Plasmodium falciparum</a><br><a href="#">Malaria due to Plasmodium vivax</a> |
| <a href="#">Antimalarial medicines &gt; For chemoprevention</a><br>Oral > Solid: 500 mg + 25 mg tablet<br>Oral > Solid: 250 mg + 12.5 mg tablet | <a href="#">Malaria due to Plasmodium falciparum</a><br><a href="#">Malaria</a>                         |

## Sulfamethoxazole + trimethoprim

| Section                                                                                                                                                                                                                                                                                                                                                                                  | Indications                                                                                                                                                                           |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <a href="#">Access group antibiotics</a><br>Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule<br>Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid<br>Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet<br>Oral > Solid > dispersible tablet: 100 mg + 20 mg                           | <b>First choice</b><br><a href="#">Infectious cystitis</a><br><b>Second choice</b><br><a href="#">Infectious gastroenteritis or colitis without specification of infectious agent</a> |
| <a href="#">Antipneumocystosis and antitoxoplasmosis medicines</a><br>Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule<br>Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid<br>Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet<br>Oral > Solid > dispersible tablet: 100 mg + 20 mg | <b>Other indications</b><br><a href="#">Bacterial infection of unspecified site</a><br><a href="#">Pneumocystosis</a>                                                                 |

## Sulfasalazine

| Section                                                                                                                                          | Indications                                                              |
|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|
| <a href="#">Disease-modifying anti-rheumatic drugs (DMARDs)</a><br>Oral > Solid: 500 mg                                                          | <a href="#">Rheumatoid arthritis, serology unspecified</a>               |
| <a href="#">Anti-inflammatory medicines</a><br>Oral > Solid: 500 mg<br>Local > Rectal > Suppository: 500 mg<br>Local > Rectal > Retention enema: | <a href="#">Crohn disease site</a><br><a href="#">Ulcerative colitis</a> |

## Sumatriptan

### Section

Antimigraine medicines > For treatment of acute attack  
Oral > Solid: 50 mg

### Indications

Migraine

## Sunscreen (broad-spectrum)

### Section

Dermatological medicines  
Topical cream, lotion, gel, ointment, spray with sun protection factor  $\geq$  50.

### Indications

Albinism or other specified genetically-determined hypomelanotic disorders

Xeroderma pigmentosum

## Suramin sodium

### Section

Antifilarials  
Parenteral > General injections > IV: 1 g in vial  
  
Medicines for the treatment of 1st stage African trypanosomiasis  
Parenteral > General injections > IV: 1 g in vial

### Indications

Filariasis

African trypanosomiasis

## Surfactant

### Section

Medicines administered to the neonate [c]  
Respiratory > Suspension: 80 mg per mL for intratracheal instillation; 25 mg per mL for intratracheal instillation

### Indications

Respiratory distress syndrome of newborn

## Suxamethonium

### Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors  
Parenteral > General injections > IV: 50 mg per mL in 2 mL ampoule (suxamethonium chloride); powder for injection (suxamethonium chloride) in vial

### Indications

Muscle relaxants

## Tacalcitol

### Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

### Indications

Therapeutic equivalent to calcipotriol for

Psoriasis of unspecified type

## Tacrolimus

### Section

Immunomodulators for non-malignant disease

Parenteral > General injections > IV: 5 mg per mL in 1 mL vial

Oral > Liquid: 0.2 mg granules for oral suspension; 1 mg granules for oral suspension

Oral > Solid: 0.5 mg (immediate-release); 0.75 mg (immediate-release); 1 mg (immediate-release); 2 mg (immediate-release); 5 mg (immediate-release)

### Indications

Failure or rejection of transplanted organs or tissues

## Tamoxifen

### Section

Hormones and antihormones

Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)

### Indications

Other specified malignant neoplasms of breast

Malignant neoplasms of breast

## Tedizolid

### Section

Reserve group antibiotics

### Indications

Therapeutic equivalent to *linezolid* for

Methicillin resistant *Staphylococcus aureus*

Therapeutic equivalent to *linezolid* for

Vancomycin resistant *Staphylococcus aureus*

Therapeutic equivalent to *linezolid* for

Vancomycin resistant *Enterococcus*

## Telmisartan + amlodipine

### Section

Antihypertensive medicines

Oral > Solid: 40 mg + 5 mg; 80 mg + 5 mg; 80 mg + 10 mg

### Indications

Essential hypertension

## Telmisartan + hydrochlorothiazide

### Section

Antihypertensive medicines

Oral > Solid: 40 mg + 12.5 mg; 80 mg + 12.5 mg; 80 mg + 25 mg

### Indications

Essential hypertension

## Tenofovir alafenamide

### Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors  
Oral > Solid: 25 mg

### Indications

Chronic hepatitis B

## Tenofovir disoproxil fumarate

### Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors  
Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Contact with or exposure to human immunodeficiency virus

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors

Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

Chronic hepatitis B

## Terbinafine

### Section

Dermatological medicines > Antifungal medicines  
Local > Topical > Cream: 1% terbinafine hydrochloride  
Local > Topical > Ointment: 1% terbinafine hydrochloride

### Indications

Fungal infection of the skin

## Terbutaline

### Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

### Indications

Therapeutic equivalent to salbutamol for

Chronic obstructive pulmonary disease

Therapeutic equivalent to salbutamol for

Asthma

## Terizidone

### Section

Antituberculosis medicines

### Indications

Therapeutic equivalent to cycloserine for

Multi-drug resistant Mycobacterium tuberculosis

## Testosterone

| Section                                                                                     | Indications                                              |
|---------------------------------------------------------------------------------------------|----------------------------------------------------------|
| Androgens<br>Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule (enantate) | Testicular dysfunction or testosterone-related disorders |

## Tetanus antitoxin

| Section                                                                                                                    | Indications |
|----------------------------------------------------------------------------------------------------------------------------|-------------|
| Immunologicals > Sera, immunoglobulins and monoclonal antibodies<br>Parenteral > General injections > IM: 50000 IU in vial | Tetanus     |

## Tetanus vaccine

| Section                                                                                                                            | Indications                                 |
|------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|
| Recommendations for all immunization programmes<br>All vaccines should comply with the WHO requirements for biological substances. | Need for immunization against tetanus alone |

## Tetracaine

| Section                                                                                                                     | Indications        |
|-----------------------------------------------------------------------------------------------------------------------------|--------------------|
| Ophthalmological preparations > Local anaesthetics<br>Local > Ophthalmological > Solution (eye drops): 0.5% (hydrochloride) | Local anaesthetics |

## Tetracycline

| Section                                                                                                                       | Indications                               |
|-------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|
| Access group antibiotics<br>Oral > Solid: 250 mg (hydrochloride)                                                              | Bacterial infection of unspecified site   |
| Ophthalmological preparations > Anti-infective agents<br>Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride) | Neonatal conjunctivitis or dacryocystitis |
|                                                                                                                               | Other specified conjunctivitis            |
|                                                                                                                               | Infectious keratitis                      |
|                                                                                                                               | Infectious blepharitis                    |
|                                                                                                                               | Trachoma                                  |

## Thalidomide

| Section                                 | Indications         |
|-----------------------------------------|---------------------|
| Immunomodulators<br>Oral > Solid: 50 mg | Plasma cell myeloma |

## Thiamine

### Section

Vitamins and minerals

Oral > Solid: 50 mg (hydrochloride)

### Indications

Vitamin B1 deficiency

## Thiopental

### Section

General anaesthetics and oxygen > Injectable medicines

### Indications

Therapeutic equivalent to propofol for

Anaesthetics and therapeutic gases

## Ticagrelor

### Section

Anti-platelet medicines

Oral > Solid > tablet: 60 mg; 90 mg

### Indications

Acute ischaemic heart disease

Presence of coronary angioplasty implant or graft

## Tick-borne encephalitis vaccine

### Section

Recommendations for certain regions

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against arthropod-borne viral encephalitis

## Tigecycline

### Section

Reserve group antibiotics

Parenteral > General injections > IV: 50 mg in vial powder for injection

### Indications

Other specified bacterial diseases

## Timolol

### Section

Ophthalmological preparations > Miotics and antiglaucoma medicines

Local > Ophthalmological > Solution (eye drops): 0.25% (hydrogen maleate); 0.5% (hydrogen maleate)

### Indications

Primary open-angle glaucoma

Ocular hypertension

## Tinidazole

### Section

Antiamoebic and anti giardiasis medicines

### Indications

Therapeutic equivalent to metronidazole for

Amoebiasis

## Tioguanine

### Section

Cytotoxic medicines

Oral > Solid: 40 mg

### Indications

Lymphoid leukaemia, not elsewhere classified

## Tiotropium bromide

### Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Respiratory > Inhalation > dry powder: 18 µg capsule

Respiratory > Inhalation > solution: 1.25 µg per actuation; 2.5 µg per actuation

### Indications

Chronic obstructive pulmonary disease

## Tisagenlecleucel

### Section

Antineoplastics and supportive medicines

### Indications

Therapeutic equivalent to axicabtagene ciloleucel for

Diffuse large B-cell lymphomas

## Tislelizumab

### Section

Immunomodulators

Parenteral > General injections > IV: 100 mg per 10 mL

### Indications

Malignant neoplasms of urinary tract

Hodgkin lymphoma

Other specified malignant neoplasms of bronchus or lung

## Tobramycin

### Section

Ophthalmological preparations > Anti-infective agents

### Indications

Therapeutic equivalent to gentamicin for

Other specified conjunctivitis

Therapeutic equivalent to gentamicin for

Infectious blepharitis

## Tocilizumab

### Section

Medicines for juvenile joint diseases

Parenteral > General injections > IV: 80 mg per 4 mL in vial; 200 mg per 10 mL in vial; 400 mg per 20 mL in vial

Parenteral > General injections > SC: 162 mg per 0.9 mL in pre-filled syringe

### Indications

Juvenile systemic arthritis

## Tolbutamide

### Section

Oral hypoglycaemic agents

Oral > Solid: 500 mg

### Indications

Type 2 diabetes mellitus

## Torsemide

### Section

Medicines used in heart failure

Diuretics

### Indications

Therapeutic equivalent to furosemide for

Heart failure

Therapeutic equivalent to furosemide for

Anuria or oliguria

Therapeutic equivalent to furosemide for

Oedema

## Toripalimab

### Section

Immunomodulators

Parenteral > General injections > IV: 240 mg per 6 mL in vial

### Indications

Malignant neoplasms of nasopharynx

Malignant neoplasms of oesophagus

## Tramadol

| Section                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Indications                         |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|
| <a href="#">Opioid analgesics</a><br>Oral > Liquid: 100 mg per mL (hydrochloride)<br>Oral > Solid: 50 mg (hydrochloride) immediate release; 50 mg (hydrochloride) controlled release; 100 mg (hydrochloride) controlled release; 150 mg (hydrochloride) controlled release; 200 mg (hydrochloride) controlled release; 300 mg (hydrochloride) controlled release; 400 mg (hydrochloride) controlled release<br>Parenteral > General injections > unspecified: 50 mg per mL in 2 mL ampoule (hydrochloride) | <a href="#">Chronic cancer pain</a> |

## Trametinib

| Section                                                          | Indications                                      |
|------------------------------------------------------------------|--------------------------------------------------|
| <a href="#">Targeted therapies</a><br>Oral > Solid: 0.5 mg; 2 mg | <a href="#">Other specified melanoma of skin</a> |

## Tranexamic acid

| Section                                                                                                                            | Indications                                           |
|------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|
| <a href="#">Medicines affecting coagulation</a><br>Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule            | <a href="#">Haemorrhage, not elsewhere classified</a> |
| <a href="#">Other medicines administered to the mother</a><br>Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule | <a href="#">Postpartum haemorrhage</a>                |

## Trastuzumab

| Section                                                                                                                                                                                  | Indications                                           |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|
| <a href="#">Targeted therapies</a><br>Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection | <a href="#">Carcinoma of breast, specialised type</a> |

## Trastuzumab emtansine

| Section                                                                                                                                              | Indications                                           |
|------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|
| <a href="#">Targeted therapies</a><br>Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection | <a href="#">Carcinoma of breast, specialised type</a> |

## Triamcinolone hexacetonide

### Section

Medicines for juvenile joint diseases

Parenteral > Locoregional injections > Intra-articular: 20 mg per mL in vial

### Indications

Juvenile idiopathic arthritis

## Triclabendazole

### Section

Antischistosomes and other antitremitode medicines

Oral > Solid > tablet: 250 mg (scored)

### Indications

Fascioliasis

Paragonimiasis

## Trihexyphenidyl

### Section

Antiseizure medicines

Oral > Solid: 2 mg (hydrochloride); 5 mg (hydrochloride)

Medicines for parkinsonism

### Indications

Parkinson disease

Therapeutic equivalent to biperiden for

Parkinson disease

## Trimethoprim

### Section

Access group antibiotics

Oral > Liquid: 50 mg per mL

Oral > Solid: 100 mg; 200 mg

### Indications

First choice

Infectious cystitis

## Triptorelin

### Section

Hormones and antihormones

### Indications

Therapeutic equivalent to leuporelin for

Malignant neoplasms of breast

Therapeutic equivalent to leuporelin for

Malignant neoplasms of prostate

## Tropicamide

### Section

Diagnostic agents > Ophthalmic medicines

Local > Ophthalmological > Solution (eye drops): 0.5%

### Indications

Cycloplegic drug

## Tropisetron

| Section                                                | Indications                                                                                     |
|--------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| Medicines for other common symptoms in palliative care | Therapeutic equivalent to <a href="#">ondansetron</a> for<br><a href="#">Palliative care</a>    |
| Antiemetic medicines                                   | Therapeutic equivalent to <a href="#">ondansetron</a> for<br><a href="#">Nausea or vomiting</a> |

## Tuberculin, purified protein derivative

| Section                                                                                   | Indications                            |
|-------------------------------------------------------------------------------------------|----------------------------------------|
| Immunologicals > Diagnostic agents<br>Parenteral > Locoregional injections > Intradermal: | <a href="#">Mycobacterial diseases</a> |

## Tubocurarine

| Section                                                                                                                                                              | Indications                      |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|
| Muscle relaxants (peripherally-acting) and cholinesterase inhibitors<br>Parenteral > General injections > IV: 10 mg per mL in 1.5 mL ampoule (tubocurarine chloride) | <a href="#">Muscle relaxants</a> |

## Typhoid vaccine

| Section                                                                                                                           | Indications                                                             |
|-----------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| Recommendations for some high-risk populations<br>All vaccines should comply with the WHO requirements for biological substances. | <a href="#">Need for immunization against typhoid-paratyphoid alone</a> |

## Ulipristal

| Section                                                                         | Indications                                                               |
|---------------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Oral hormonal contraceptives<br>Oral > Solid: 30 mg tablet (ulipristal acetate) | <a href="#">Contact with health services for postcoital contraception</a> |

## Umeclidinium

| Section                                                               | Indications                                                                                                               |
|-----------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|
| Antiasthmatic and medicines for chronic obstructive pulmonary disease | Therapeutic equivalent to <a href="#">tiotropium bromide</a> for<br><a href="#">Chronic obstructive pulmonary disease</a> |

## Urea

### Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Local > Topical > Cream: 10%; 5%

Local > Topical > Ointment: 10%; 5%

### Indications

Xerosis cutis or asteatosis

## Ustekinumab

### Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Parenteral > General injections > SC: 45 mg per 0.5 mL in vial; 90 mg per mL in pre-filled syringe

### Indications

Psoriasis of unspecified type

## Valaciclovir

### Section

Antiherpes medicines

### Indications

Therapeutic equivalent to [aciclovir](#) for

Zoster

Therapeutic equivalent to [aciclovir](#) for

Varicella

Therapeutic equivalent to [aciclovir](#) for

Herpes simplex infections

## Valganciclovir

### Section

Other antivirals

Oral > Liquid: 50 mg per mL powder for oral solution

Oral > Solid: 450 mg Tablet

### Indications

Cytomegaloviral retinitis

## Valproic acid (sodium valproate)

### Section

#### Antiseizure medicines

Oral > Liquid: 200 mg per 5 mL

Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated); 100 mg tablet (crushable)

Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 3 mL ampoule

#### Medicines for bipolar disorders

Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated)

### Indications

Epilepsy or seizures

Status epilepticus

Bipolar or related disorders

## Vancomycin

### Section

#### Watch group antibiotics

Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection

Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection

### Indications

#### First choice

Necrotising fasciitis

co-prescribed with [ceftazidime](#)

Endophthalmitis

co-prescribed with [ceftriaxone](#)

Endophthalmitis

#### Second choice

Neutropenia (high-risk)

#### Other indications

Methicillin resistant *Staphylococcus aureus*

## Varenicline

### Section

#### Medicines for nicotine use disorders

Oral > Solid: 0.5 mg; 1 mg

### Indications

Nicotine dependence

## Varicella vaccine

### Section

#### Recommendations for immunization programmes with certain characteristics

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against certain single viral diseases

## Vecuronium

### Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors  
Parenteral > General injections > IV: 10 mg in vial powder for injection (vecuronium bromide)

### Indications

Muscle relaxants

## Vemurafenib

### Section

Targeted therapies

### Indications

Therapeutic equivalent to [dabrafenib](#) for

Other specified melanoma of skin

## Verapamil

### Section

Antiarrhythmic medicines

Parenteral > General injections > IV: 2.5 mg per mL in 2 mL ampoule (hydrochloride)

Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)

Antianginal medicines

Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)

### Indications

Supraventricular tachyarrhythmia

Angina pectoris

## Vinblastine

### Section

Cytotoxic medicines

Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)

Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified gliomas of brain

Kaposi sarcoma of unspecified primary site

Hodgkin lymphoma

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Langerhans cell histiocytosis

## Vincristine

| Section                                                                                                                                                                                                                                                                                                                                            | Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Cytotoxic medicines</b><br>Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)<br>Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate) | <div>Unspecified malignant neoplasms of ill-defined or unspecified sites</div> <div>Other specified gliomas of brain</div> <div>Malignant trophoblastic neoplasms of placenta</div> <div>Follicular lymphoma</div> <div>Kaposi sarcoma of unspecified primary site</div> <div>Rhabdomyosarcoma primary site</div> <div>Hodgkin lymphoma</div> <div>Diffuse large B-cell lymphomas</div> <div>Retinoblastoma</div> <div>Burkitt lymphoma including Burkitt leukaemia</div> <div>Malignant neoplasms of kidney, except renal pelvis</div> <div>Ewing sarcoma of bone and articular cartilage of unspecified sites</div> <div>Lymphoid leukaemia, not elsewhere classified</div> <div>Langerhans cell histiocytosis</div> |

## Vinorelbine

| Section                                                                                                                                                                                                                                                       | Indications                                                                                                                                                          |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Cytotoxic medicines</b><br>Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 50 mg per 5 mL in 5 mL vial<br>Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial<br>Oral > Solid: 20 mg; 30 mg; 80 mg | <div>Other specified malignant neoplasms of bronchus or lung</div> <div>Other specified malignant neoplasms of breast</div> <div>Rhabdomyosarcoma primary site</div> |

## Voriconazole

| Section                                                                                                                                                                                                     | Indications                                                                  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| <b>Antifungal medicines</b><br>Parenteral > General injections > IV: 200 mg in vial powder for injection<br>Oral > Liquid: 40 mg per mL powder for oral liquid<br>Oral > Solid: 50 mg tablet; 200 mg tablet | <div>Chronic pulmonary aspergillosis</div> <div>Invasive aspergillosis</div> |

## Warfarin

| Section                                                                                                                           | Indications                                                                                                                                                                                  |
|-----------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Medicines affecting coagulation<br>Oral > Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt); 0.5 mg (sodium salt) | <div>Other specified diseases of arteries or arterioles</div> <div>Cerebral ischaemic stroke due to embolic occlusion</div> <div>Venous thromboembolism</div> <div>Atrial fibrillation</div> |

## Water for injection

| Section                                                                                                                                                                        | Indications                                                                               |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
| Solutions correcting water, electrolyte and acid-base disturbances > Miscellaneous<br>Parenteral > General injections > unspecified: 2 mL ampoule; 5 mL ampoule; 10 mL ampoule | <div>Unspecified appropriateness of dosing or administration without injury or harm</div> |

## Whole blood

| Section                                                             | Indications                                             |
|---------------------------------------------------------------------|---------------------------------------------------------|
| Blood and blood components<br>Parenteral > General injections > IV: | <div>Blood transfusion without reported diagnosis</div> |

## Xylometazoline

| Section                                                                                            | Indications                 |
|----------------------------------------------------------------------------------------------------|-----------------------------|
| Ear, nose and throat medicines [c]<br>Local > Nasal > Spray: 0.05% w/v equivalent to 0.5 mg per mL | <div>Nasal congestion</div> |

## Yellow fever vaccine

| Section                                                                                                                | Indications                                                            |
|------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|
| Recommendations for certain regions<br>All vaccines should comply with the WHO requirements for biological substances. | <div>Need for immunization against certain single viral diseases</div> |

## Zanubrutinib

| Section                                   | Indications                                                                                            |
|-------------------------------------------|--------------------------------------------------------------------------------------------------------|
| Targeted therapies<br>Oral > Solid: 80 mg | <div>Mantle cell lymphoma</div> <div>Chronic lymphocytic leukaemia or small lymphocytic lymphoma</div> |

## Zidovudine

### Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors  
Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion injection  
Oral > Liquid: 50 mg per 5 mL  
Oral > Solid: 250 mg capsule; 300 mg tablet

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Zinc sulfate

### Section

Medicines for diarrhoea  
Oral > Solid: 20 mg

### Indications

Diarrhoea

## Zoledronic acid

### Section

Supportive medicines  
Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle  
Medicines for endocrine disorders  
Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle

### Indications

Malignant neoplasm metastasis in bone or bone marrow

Osteogenesis imperfecta

## Zuclopenthixol decanoate

### Section

Medicines for psychotic disorders

### Indications

Therapeutic equivalent to fluphenazine for

Schizophrenia or other primary psychotic disorders